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Resistance to antimalarial drugs continues to be a major obstacle in controlling 
and eradicating malaria.  The identification of genetic markers of resistance is vital 
for disease management but they can be difficult to predict before resistance arises in 
the field.  This thesis describes an alternative approach to gene identification, 
combining an in vivo experimental evolution model, Linkage Group Selection (LGS) 
and Solexa genome re-sequencing.  Here this model was used to resolve the genetic 
basis of chloroquine and artemisinin resistance in the rodent malaria parasite 
Plasmodium chabaudi.  
AS-30CQ is a parasite with high resistance to chloroquine and resistance to 
artemisinin.  It was crossed with the genetically different drug-sensitive strain AJ.  
The resulting progeny were selected with drugs and backcrossed to the sensitive 
parent.  Both crosses were treated with increasing concentrations of chloroquine and 
artemisinin.  The frequency of markers from the sensitive parasite were analysed in 
order to characterize the signatures of drug selection.  Three loci involved 
progressively in chloroquine resistance were identified on chromosomes 11, 3 and 2.  
One main locus on chromosome 2 was identified with artemisinin selection. 
The Solexa platform was used to re-sequence the genomes of both AS-30CQ 
and its sensitive progenitor, AS-sens.  The differences between the two genomes 
were integrated with the LGS data to identify: 1) a strong candidate for the main CQ-
resistance determinant - a putative amino acid transporter on chromosome 11 (aat1) 
2) two candidates for high level chloroquine resistance on chromosome 3. and 3) a 
mutation in ubp1 gene on chromosome 2 that is likely to contribute to the highest 
level of chloroquine resistance and be main determinant of the artemisinin resistance 
phenotype.  
In addition the last section of this thesis describes two otherwise isogenic 
clones showing low- and high levels of chloroquine resistance were grown 
competitively to evaluate the effect of these mutations on parasite fitness.  The 
highly resistant strain demonstrated a loss of fitness in relation to its more sensitive 





1.1.1. The burden of malaria 
Malaria is one of the oldest diseases known to mankind.  First reports about the 
so-called “swamp disease” come from ancient China 2
nd
 century BC, although 
malaria would have been around for much longer and probably is as old as human 
species (Hughes and Verra, 2010).  Today, it still remains one of the most deadly 
tropical diseases, taking each year ~1 million lives and causing ~250 million 
infections (WHO, 2008)  Currently ~50% of the world’s population lives in areas of 
potential malaria transmission.  It is widespread throughout of the tropics (Fig 1.1):  
however most infections, morbidity and mortality occur in sub-Saharan Africa.  The 
most susceptible persons are young children and travellers from malaria-free areas 
that visit the tropics. 
 
Figure 1.1 The distribution of malaria worldwide.  




1.1.2. The parasite, vector and life cycle 
Malaria is caused by protozoan parasites from the genus Plasmodium that 
infect and destroy the host’s red blood cells (RBCs).  Today four species of human 
parasites are known; P.falciparum, P.vivax, P.ovale and P.malariae.  However, there 
is growing recognition that P.knowlesi – a simian parasite that can cause human 
infection – should be added to this list (Cox-Singh et al., 2008).  Also, it is now 
proposed that P.ovale also represents two distinct species (Sutherland et al., 2010).  
Most malaria research concentrates on P.falciparum because it is responsible for    
80 % of malaria cases and almost 90% of deaths (WHO, 2008) although there is a 
growing awareness of importance of P.vivax, whose contribution to malaria 
morbidity was previously somewhat neglected (Price et al., 2007; Galinski and 
Barnwell, 2008). 
Parasites are transmitted by the female Anopheles mosquitoes.  Various 
mosquito species are found to be dominant vectors in different countries, depending 
on the region and environment.  Three African species (Anopheles gambiae, 
Anopheles arabiensis and Anopheles funestus) are responsible for the bulk of the 
transmission, around 30 additional ones are highly competent vectors and many 
others are able to transmit malaria given the opportunity (Kiszewski et al., 2004). 
Plasmodium parasites are characterized by a complicated developmental cycle 
involving many different stages in mosquito and in human host (Fig. 1.2).   
After an infectious mosquito bite, the haploid sporozoites (infectious parasite 
forms) migrate to the liver where they infect hepatocytes and undergo asexual 
reproduction (Prudencio et al., 2006).  After an incubation period (which usually 
lasts about 10 days in P.falciparum) they destroy the hepatocytes and emerge from 
the liver as merozoites – a free stage able to infect the RBC.   
Inside the red cells, a merozoite transforms into a ring stage, characterized by 
small size and low metabolic activity.  Later a ring becomes a trophozoite - a 
metabolically active parasite which digests the host cell protein (consisting mainly of 
haemoglobin (Rosenthal and Meshnick, 1996)).  The trophozoite grows and starts to 
undergo multiple nuclear division and segmentation to produce a schizont.  Finally 
the schizont bursts destroying the red blood cell and giving rise to the new 
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merozoites, which are free to invade uninfected erythrocytes.  These regular, 
synchronized cycles of asexual replication repeats itself every 48 or 72 hours 
(depending on the parasites species) until successful intervention of the immune 
system or the death of the host, and is responsible for most of the symptoms 
associated with P. falciparum malaria.   
During this asexual erythrocytic cycle, a small number of ring parasites will 
transform into sexual forms – male and female gametocytes (Talman et al., 2004).  
When these are taken up by a mosquito in a blood meal, the gametes emerge from 
the red cells and fertilize to form diploid zygotes which undergo meiotic division 
forming new tetraploid cells.  They develop into motile forms called ookinetes and 
penetrate the mosquito gut forming oocysts on the outer surface of the gut wall 
(Boete, 2005).  There, in the process of multiple nuclear divisions, large numbers of 
haploid sporozoites are produced.  After several days, the oocyst ruptures, releasing 
sporozoites to migrate to the salivary glands.  There, the parasites become ready to 
infect another human host when mosquito takes next takes a blood meal, thus closing 
the developmental cycle.  
 
Figure 1.2 The life cycle of P.falciparum.  
Blue arrows represent the part of the cycle in the human host , red one in the mosquito vector.  The 




In P.vivax and P.ovale an additional stage is observed.  After the hepatocyte 
infection some parasites do not develop into merozoites but into the dormant form 
called hypnozoites.  They remain in the liver for years and are responsible for new 
attacks of the disease when reactivated (Cogswell, 1992).   
1.1.3. Clinical picture of disease 
The manifestations of infection vary from one patient to another depending on 
parasite strain, age of host, host immunity, general health condition etc.  In some 
cases (for example, in older, partially immune individuals in areas of high 
transmission) the infection may be completely asymptomatic.  Otherwise malaria 
may manifest itself by headache, chills, joint pains and fever.  Periodic chills and 
fever are characteristic, recurring at intervals of 2-3 days depending on the species of 
parasite (they are caused by the cyclic bursting of erythrocytes freeing merozoites).   
In some cases severe malaria occurs.  In addition to typical malaria symptoms 
one or more of the following can be observed: hyperanaemia, renal failure, metabolic 
acidosis, pulmonary oedema or hypoglycaemia (Trampuz et al., 2003).  Cerebral 
malaria is the most serious sub-class of severe disease and is characterized by 
changes in mental status followed by coma. All cases of severe malaria require 
prompt treatment as the untreated mortality rates are high (untreated, cerebral 
malaria is fatal in 90% of the cases (WHO, 2006). 
Malaria can be easily misdiagnosed if the symptoms vary from the classical 
picture (Kallander et al., 2004).  The reverse is also true – in areas of high 
transmission every fever tends to be interpreted as malaria, leading to possible over-
diagnosis (Reyburn et al., 2004; Gwer et al., 2007).  Both confer serious health 
consequences, as they result in a: lack of appropriate treatment for the underlying 
fever cause and over-use of antimalarials, encouraging the development of the 




1.1.4. Disease control strategies 
Today many different strategies are used in order to prevent morbidity and 
mortality due to malaria. 
1.1.4.1.Prevention of infection 
Simple means like encouraging protective clothing and closing the windows 
overnight can reduce the availability of humans to mosquitoes.  As the mosquito’s 
attack takes place mainly during the night, sleeping under bed nets is a particularly 
efficient way of protecting the local population (Lengeler and Snow, 1996). 
1.1.4.2.Vector control 
As the parasite is absolutely dependent on its vector, mosquito control is an 
essential part of malaria management programs.  So far, two strategies were 
employed on a massive scale; indoor residual spraying (the walls of dwellings are 
covered with diluted insecticide that kills or repels the insects) and insecticide treated 
bed nets.  Both achieved high success rates in reducing Plasmodium transmission 
(Beier et al., 2008; Enayati and Hemingway, 2010).  However, insecticides may put 
evolutionary pressure on mosquitoes to develop resistance to the insecticide used 
(Sina and Aultman, 2001).  For example the resistance to DDT – the most widely 
used insecticide – is currently widespread among the malaria vectors (Ranson et al., 
2000).   
Recently new methods of vector control have been suggested, that aim to 
manipulate the Anopheles population (so that it is less likely to transmit malaria) 
without eliminating mosquitoes from the environment.  For instance, malaria 
resistant mosquitoes may be released into the wild to breed with the local 
populations, spreading the genes that cause them to be refractory towards malaria 
parasites (Marshall and Taylor, 2009).  An alternative approach is to use methods 
that either selectively target the older mosquitoes or cause delayed death days after 
exposure.  As mosquitoes need only 2-4 days to lay eggs after each blood feed and 
10-14 days to become infectious after contracting malaria parasites, a window exists 
in which killing the mosquito would have only moderate effect on its reproductive 
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success but would stop malaria transmission (Read et al., 2009).  The use of fungal 
biopesticides (Blanford et al., 2005), genetically engineered Wolbachia bacteria 
(Read and Thomas, 2009) and densoviruses were proposed.  
1.1.4.3.Vaccines 
Unfortunately, despite huge investment, no fully effective vaccine for malaria 
has been developed so far, although there is a pipeline of candidates currently 
entering or undergoing the various stages required for clinical testing (Girard et al., 
2007).  Previous attempts have resulted in limited success, possibly because of 
incomplete understanding of critical targets, variation in parasite antigens, poor 
development of natural lifelong immunity even after repeated exposure (suggesting 
that immune memory is not stimulated well) or parasite evasion of the immune 
system.  Therefore new and innovative methods may be needed to elicit the 
appropriate immune response (Pierce and Miller, 2009; Vanderberg, 2009). 
1.1.4.4.Chemotherapy 
In practice, much of the control of disease involves the use of chemotherapy – 
either treatment of infected patients, or prophylaxis.  It is described in detail in the 





1.2.  Malaria chemotherapy 
Chemotherapy remains the key tool for malaria control reducing mortality and 
morbidity as well as decreasing the parasite transmission worldwide.  A variety of 
antimalarials exists.  Some are derived from natural herbal remedies (like the bark of 
the cinchona tree in South America and sweet wormwood plant in China); others are 
the results of de novo synthesis or modification of existing compounds.  
Unfortunately, use of these compounds has often resulted in the evolution of drug 
resistance, eventually leading to reduced clinical effectiveness. 
This section reviews some of the most important classes of antimalarials, with 
particular focus on chloroquine and artemisinins that are the subject of this thesis.  
Section 3 focuses on different aspects of resistance to antimalarials. 
1.2.1. Antifolates 
Antifolates are drugs that affect the synthesis and utilization of folate.  A 
supply of tetrahydrofolate is required for the synthesis of DNA and some amino 
acids.  It is particularly important in metabolically active, rapidly dividing cells such 
as malaria parasites during their asexual cycle.  In Plasmodium folate may come 
principally from de novo synthesis because parasites may not be very efficient in 
salvaging the host folates (Hyde, 2005).  The folate pathway appears to be a good 
target for antimalarial drugs: its successful inhibition leads to the cell cycle arrest and 
death. 
The antifolates used in malaria treatments are divided into two groups, often 
called class I and class II antifolates, depending on their target (Nzila, 2006).  The 
class II antifolates inhibit dihydrofolate reductase (dhfr) - an enzyme catalysing one 
of the final steps of folate pathway.  The most popular drugs in this group are 
pyrimethamine (currently discarded in many places because of resistance), proguanil 
(often used for prophylaxis), and chlorproguanil.  The drugs from the second group 
(class I antifolates) are inhibiting dihydropteroate synthase (dhps) an enzyme further 
upstream in the pathway.  Sulfadoxine and dapsone are the most common examples.  
The class II antifolates are rarely used alone.  In malaria treatment the class I and II 
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antifolates are often combined for better effect.  The most common combinations 
include pyrimethamine/sulfadoxine (Fansidar), pyrimethamine/sulfalene 
(Metakelfin), proguanil/dapsone and chlorproguanil/dapsone (Lapdap).   
1.2.2. Aminoquinolines and chloroquine (CQ) 
This wide group of antimalarials includes a number of very effective 
commonly used drugs as well as some historically important ones.  They are 
characterized by an aromatic quinoline skeleton with a modified amino group 
attached to it.  They are divided into two main subgroups based on the chemical 
structure of the compounds.  The 4-aminoquinolines (e.g. chloroquine, 
amodiaquine), are powerful blood schizontocides, killing mainly the parasite stages 
carrying out haemoglobin digestion.  8-aminoquinolines (primaquine, pamaquine) 
are also effective against the pre-erythrocytic liver stages which makes them a useful 
tool for prophylactic treatment (as they target the early infection stages) and against 
non-falciparum malaria (P.vivax and P.ovale) in which the dormant liver stages may 
be the source of reinfection (relapses) in not eradicated properly.   
Chloroquine is the most important and well-studied drug from this group  
1.2.2.1.Chloroquine 
Chloroquine (Fig. 1.3a) was first synthesised in 1934 in response to the general 
demand for a cheaper replacement for cinchona bark.  Interestingly, initial animal 
tests and a small-scale clinical trial performed in 1935 suggested that it was “too 
toxic to be used for humans” (Coatney, 1963).  However, when during the 2nd World 
War the leading antimalarial treatment (cinchona bark) became unavailable in 
Europe due the socioeconomic reasons; chloroquine (this time in different 
formulation) was revisited and, as the results of the repeated tests very encouraging, 
officially introduced on the marked in 1944.  It turned out to be a perfect drug for use 
in tropics: very effective, cheap, easy to administer orally, stable at room temperature 
and safe (even during pregnancy).  Unsurprisingly it quickly became the first line of 
antimalarial treatment worldwide for over 20 years.  However, resistance began to 
develop in Southeast Asia and South America, spreading to Africa by 1978.  By 
2002 the WHO officially recommended the withdrawal of chloroquine due to 
widespread resistance and in most countries it is currently replaced with alternative 
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therapies.  However, it is still used (mostly in Africa), due to its low price and lack of 
access to the other therapies. 
1.2.2.2.The mechanism of action 
Similarly to other 4- aminoquinolines chloroquine is a schizontoid targeting 
the asexual blood stage of malaria and it does not affect liver stages (Belnoue et al., 
2004) or gametocytes (Chevalley et al., 2010).  Chloroquine acts in the parasite 
digestive vacuole – the lysosomal-like compartment characterised by a very low pH 
in which host protein is digested by proteolytic enzymes (Saliba et al., 1998).  Here, 
host haemoglobin is digested by proteases releasing amino-acids and the porphyrin 
ring with co-ordinated iron in the centre – hem (Goldberg and Slater, 1992).  In its 
free form hem is a highly active compound, capable of generating a cascade of free 
radicals and thus is toxic to the parasite.  Therefore in the digestive vacuole hem is 
polymerised into the crystals of inactive hemozoin (Slater et al., 1991).  The 
interference with this mechanism is universally considered to be a main pathway of 
CQ action (Slater and Cerami, 1992). 
Chloroquine is a weak base that diffuses freely into the digestive vacuole (Fig. 
1.3a) where it gets diprotonated and, as the vacuolar membrane is impermeable to 
charged compounds, trapped within the compartment.  There it binds to 
ferriprotoporphyrin IX (FPIX, oxidised hem derivate) (Jearnpipatkul et al., 1980) 
disturbing the formation of hemozoin and keeping FPIX in its active form. This 
results in the accumulation of free FPIX and/or CQ-FPIX complexes, which damage 
the parasites, possibly by oxidative stress (radical oxygen species), ultimately leading 
to its death (Fig. 1.3b). 
The mechanism described above is considered to be the main pathway of 
chloroquine action.  However some other reports suggest that the drug is effective 
also against the parasite stages (like young rings and schizonts) that are not involved 
in hem metabolism and do not possess (in the case of ring stages) a fully formed 
digestive vacuole (Gligorijevic et al., 2008; Sharrock et al., 2008).  Moreover CQ 
may also decrease multiplicity in nuclear divisions observed in schizonts (suggesting 
interference with DNA replication) and cause a delayed death syndrome 
(characteristic for some antibiotics interfering with apicoplast function (Dahl and 
 11 
Rosenthal, 2007)) (Gligorijevic et al., 2008).  These data suggest the possible 















Figure 1.3  The chemical structure of CQ and the putative mechanism of its action. 
a) the chemical structure of CQ,  b) the putative mechanism of CQ action. The drug is diffusing into 
the digestive vacuole (1) when it gets protonated and binds to hem (2), inhibiting the formation of 










Very similar to the previous group, the 4-methanolquinolines are characterised 
by the same aromatic skeleton, this time however the amino group is replaced with 
the methanol one.  The two important drugs from this group are quinine – a naturally 
occurring alkaloid isolated from the cinchona tree bark, one of the earliest malaria 
remedies - and mefloquine, a long acting synthetic antimalarial, now more widely 
used as part of combination therapies.  The mechanisms of action of 4-
methanolquinolines is not known although some physiological effects of these drugs 
suggests that they also intervene with some stage of haemoglobin catabolism (Famin 
and Ginsburg, 2002).  
1.2.4. Artemisinins 
The antimalarial properties of Artemisia annua or Sweet Wormwood, a 
common plant across central Asia, have been known since ancient times in Chinese 
medicine.  In 1972 an active antimalarial compound - artemisinin - was isolated and 
derivates with better pharmaceutical proprieties were soon synthesised.  All 
artemisinins are sesquiterpene lactones containing an endoperoxide bridge in their 
structure.  They are all very short lived (no greater than about 2 hours half-life) and 
very effective not only against blood stages (Adjuik et al., 2004) but also against the 
young gametocytes (thus interrupting the parasite transmission) (Pukrittayakamee et 
al., 2004).   
1.2.4.1.Artemisinin combination therapy (ACT) 
Currently artemisinins (mainly dihydroartemisinin, artesunate and artemether) 
are recommended as the first line of treatment worldwide.  As WHO strongly 
discourages the use of artemisinins as monotherapy (in order to delay the appearance 
of resistance (White and Olliaro, 1996)), they are usually recommended to be 
combined with other drugs, usually long-lasting ones, and with a different 
mechanism of action .  The most common partner drugs are mefloquine (Lariam
®
), 
lumefantrine, amodiaquine, piperaquine and antifolates.  ACTs are the only form of 
therapy with universal efficiency towards drug resistant strains. 
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1.2.4.2. The mechanism of action 
The mechanisms of action of artemisinins are less understood than those of 
chloroquine.  The general mechanism of molecule activation is known - all 
artemisinins contain a peroxide bridge which, when cleaved (probably in the 
presence of iron Fe2+), generates a cascade of free radicals within the cell (Meshnick 
et al., 1996a).  However, the object of this attack remains to be identified.  The 
proposed targets included hem (Hong et al., 1994; Meshnick, 1994), PfATP6 
(sarco/endoplasmic reticulum membrane calcium ATP-ase) (Eckstein-Ludwig et al., 
2003; Jung et al., 2005), alkylation of specific proteins (Yang et al., 1993; Meshnick, 
1994) and, recently, the mitochondrial oxidative chain (Li et al., 2005; Wang et al., 
2010).  Most likely, as in the case of chloroquine, it is a complex interplay between 
multiple pathways that ultimately leads to parasite death.  
1.2.5. Atovaquone 
Atovaquone is a synthetic drug that is effective against a range of different 
protozoan parasites.  It is found to target the cytochrome bc1 complex, disrupting 
mitochondrial electron transport and thus interfering with ATP synthesis (Mather et 
al., 2005).  In malaria treatment it is used in combination (Malarone
®
) with proguanil 
with which it seems to be sharing some synergistic effects (Srivastava and Vaidya, 
1999).  
1.2.6. Antibiotics 
Tetracycline, doxycycline, clindamycin and azithromycin can all be used 
(usually as part of ACT) for malaria treatment (WHO, 2006; Noedl, 2009).  The 
broad spectrum of action of antibiotics can be useful as they can also treat the 
additional infections often accompanying malaria, or (in cases of misdiagnosis) the 
true cause of the symptoms interpreted as malaria.  However for the same reason 
they are not very suitable for prophylaxis and self-treatment and are more often used 
as the second- line treatment for infections that don’t respond well to traditional 
antimalarials (WHO, 2006). 
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1.3. Drug resistance in malaria 
In the second half of 20th century the growing efficiency of insecticides and 
antimalarials and improved standards of medical care prompted the WHO to predict 
that malaria would be eradicated by the end of the century (Jeffery, 1976).  Today 
malaria seems far from eradication and its mortality is still high.  The increasing 
frequency of drug resistant parasites is considered one of the major factors 
contributing to this situation.  Currently, parasite strains resistant to all major classes 
of drugs are present in the field and resistance to some of them so widespread that 
they have been withdrawn from use.  
1.3.1. Assessing resistance 
How do we know that resistance to a given drug has appeared in a population?  
Today local monitoring networks in many countries concentrate on monitoring the 
resistance status of local parasite populations.  Three different approaches can be 
used: field studies, in vitro testing and verification of molecular markers of 
resistance. 
1.3.1.1. In vivo – field studies 
During field studies the reaction of patients to a treatment is recorded and 
resistance is suspected if increased rates of treatment failure are observed.  To this 
end, treatment failure is defined as incapability to clear parasitaemia (parasitological 
failure) and/or resolve clinical symptoms (clinical failure) despite the administration 
of the drug (WHO, 2009).  A treatment failure, however, does not always imply 
resistance - it can be caused by inadequate drug absorption, poor adherence to the 
treatment etc.  The reverse is also true - the adequate clinical response can be 
observed with the resistant strain if the individual is semi-immune.  Therefore field 
data may need to be confirmed by laboratory testing of culture adapted parasites. 
1.3.1.2. In vitro - laboratory testing 
Compared to field studies, laboratory tests are more accurate in defining and 
quantifying parasite-determined resistance.  In laboratory conditions cultured 
parasites can be exposed to precisely known concentrations of drug and the degree of 
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growth inhibition can be accurately recorded.  The resistance is usually defined as a 
shift in dose response curve resulting in change of IC50 (a concentration of the drug 
required to kill 50% of parasites) or more rarely IC90 (see Fig. 1.4).  The in vitro test 
are not used for routine surveillance, however they can be useful to resolve many 
aspects of drug resistance.  It includes the validation of molecular markers, detection 
of cross resistance patterns and monitoring the resistance to drugs used in 
combination therapy (when the treatment failure would require the simultaneous 
resistance to both of them).  
 
Figure 1.4 Resistance observed in vitro 
The difference in dose response curve between the sensitive (a) and resistant (b,c) parasites. The 
resistance is achieved either by the shift of the response curve (b) or change of its shape (c,). Figure 
according to (White, 2002). 
 
1.3.1.3. Use of molecular markers 
Once the molecular markers of resistance are identified, they can be used to 
monitor the resistance in field.  They can detect even the small prevalence of a 
resistant strain present in a population, which is useful, especially when mixed 
infections are common and a resistant strain can be easily masked by the sensitive 
population. Moreover they tend to be quicker and more reliable than other tests.  Due 
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replacing in vitro tests in many specific uses including monitoring for the first signs 
of emerging resistance in a given population, following-up of the fate of a resistant 
allele once the drug has been withdrawn, monitoring resistance to one of the 
compounds in a combination therapy etc. 
1.3.2. Evolution of resistance 
1.3.2.1.Appearance and spread and resistance - how easy it is for parasite? 
From an evolutionary point of view, the rise and spread of resistant parasites in 
a population will depend on two factors – the probability of an initial mutational 
event and the reproductive advantage it confers to the parasite.  In theory both of 
those should be very high.  On the one hand the sheer numbers of parasites ensure 
the constant generation of large number of mutations.  An infected adult can easily 
carry 10
12
 parasites (which corresponds to ~3% of parasitaemia) and the new 
generation appears with each round of asexual replication.  Combined with the 
mutation rate (~10
-9
/base/generation (Conway, 2007)) it means that, if the resistance 
is conferred by single SNP mutation, ~10
3
 resistant parasites will arise within each 
patient.  On the other hand a drug intervention constitutes a very strong selection 
pressure and current massive drug use ensures that thousands of infections are 
exposed to the treatment every day.  Therefore the resistance would appear fairly 
often and we should observe multiple origins of resistance mutations. 
The field data however suggests that resistance arises from few mutational 
events that spread throughout populations rather than from many multiple, 
independent origins.  This is true for three of the most widely spread resistances: 
chloroquine (Wootton et al., 2002), sulfadoxine-pyrimethamine (Nair et al., 2003) 
and (to a lesser extent) mefloquine (Nair et al., 2007). 
This may be explained by an initial bottleneck in the infection.  Once a 
resistant parasite appears, it has to successfully compete with other parasites present 
in the same host, achieve a significant proportion of infection and produce 
gametocytes that are going to be ingested by mosquitoes and transmitted to another 
patient.  Then the whole cycle is repeated.  The probability of all these events is very 
low and is fairly independent of the selective advantage conferred by resistance - 
even very fit genotypes can appear late in the infection and fail to produce 
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gametocytes before a mosquito bite or end up in a partially immune host that is going 
to clear the infection regardless of its resistant status.  Only after passing this crucial 
stage does resistance spread according to the reproductive advantage that it confers 
to the resistant parasite.  If we compare it with the other potential obstacles (necessity 
of competing with other genetically different strains in mixed infections, potential 
fitness cost of resistance (see section 3.3), var gene switching etc.) we obtain actual 
mutation rates that may be many orders of magnitudes lower (Hastings, 2004).  It 
helps explain why we observe so few origins of mutations. 
The initial obstacles may also explain why the resistance to many antimalarials 
seems to arise in the same geographical regions – the resistance “hot-spots” 
characterized by low transmission and low level of immunity in the population (like 
South-east Asia (most notably Thai-Cambodian border) and equatorial South 
America).  In that setting the majority of infections are treated (asymptomatic 
malaria is rare in a non-immune host) and the mixed infections in which parasites 
will have to compete against a different sensitive strain (possibly without drug 
treatment) are less frequent.  Therefore a resistant allele is less likely to be eliminated 
before reaching the critical frequency allowing the subsequent spread. 
1.3.2.2.Use of combination therapy to slow the development of resistance 
The use of combination therapy is an example of how the evolutionary forces 
responsible for the development and spread of the resistance can be used in order to 
extend the useful lifespan of a drug.  It was successfully used in tuberculosis and 
HIV treatment and now it is applied to malaria.  The concept is simple - in order to 
slow the evolution of resistance and extend the useful lifetime of drugs, two or more 
antimalarials are paired together.  If resistance to one drug is hard to develop the 
probability of acquiring resistance to two drugs simultaneously is very low (possibly 
next to 0) (White and Olliaro, 1996).  
Currently used ACT are usually composed from a short acting artemisinin 
(ART) derivative paired with a long lasting compound of different mechanism of 
action (e.g. mefloquine, amadioquine, antifolates).  This combination has some 
advantages.  ART compound is a powerful schizonticide, quickly reducing most of 
the parasite burden.  The second drug instead, remains in the patient blood long after, 
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killing the remaining parasites and protecting from re-infection, thus reducing the 
frequency of survival of parasites exposed to subcurative concentration of ART, 
(which encourages resistance).  Some argue however that this mismatch in the half-
lives of the drugs is not ideal as it encourages the spread of the resistance to the long 
–acting drug as, in the absence of ART, it functions as it would in monotherapy.   
Moreover, some of the partner drugs were previously used as monotherapy and 
resistance to them is already at least partly established.  In that case ACT would lead 
to further spread of resistance to partner drugs (although it would still delay the 
emergence of resistance to artemisinin compared to monotherapy).  Therefore the 
half-lives of two ACT components should be similar, to slow down development of 
the resistance towards both compounds. 
1.3.3. Fitness cost of drug resistance 
Already Charles Darwin in “The origin of species” suggested that the 
development of one trait in the population may come at the expense of another 
(Darwin, 1859).  The trait that is an advantage in one environment can be a burden to 
another.  The same applies to drug resistance - the mutations that allow the organism 
to tolerate the higher level of curative agent are likely to reduce its performance in 
the drug free environment (Fig. 1.5).  This phenomenon called “fitness cost” has 
been observed in such different organisms as Mycobacterium tuberculosis  (Burgos 
et al., 2003), Human immunodeficiency virus (HIV) (Borman et al., 1996) and 
Staphylococcus areus  (Besier et al., 2008).  Now an accumulating body of evidence 
suggests that it may also apply to the resistance to antimalarials. 
1.3.3.1. Evidence from field 
If a fitness cost of resistance exists, after the withdrawal of the drug pressure, 
the decline in frequency of resistant alleles in the population should be observed 
because of their gradual replacement with fitter, more sensitive alleles.  Several field 
studies reported such decreases following the withdrawal of pyrimethamine (Clyde 
and Shute, 1959; Zhou et al., 2008)) or chloroquine (Thaithong et al., 1988; Mita et 
al., 2003; Temu et al., 2006).  The most spectacular example comes from Malawi.  
After replacing chloroquine with alternative therapy, the frequency of resistant allele 
decreased from 85% in 1992 to 13% in 2000 (Kublin et al., 2003; Mita et al., 2003; 
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Laufer et al., 2006) and a recently performed clinical trial shown that CQ is again 




















Figure 1.5 Fitness cost of drug resistance.   
The green and red circles represent sensitive and resistant parasites respectively and   sign 
represents the drug action.  The sensitive mutant (a) is inhibited by the drug but grows poorly in drug 
free conditions.  The resistant mutant (b ) can survive the drug treatment but its growth is 
handicapped.  Therefore in mixed infection the resistant parasite will dominate but under lack of 
treatment the sensitive parasite is going to outgrow the mutant 
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Additionally, in some countries, characterised by variable transmission rates 
between the wet and dry season, seasonal variation in the frequency of resistant 
alleles was observed. During the wet season (when transmission is high and more 
infections are symptomatic and treated) the frequency of resistant allele was 
increasing but during the dry season (when the parasite persists mainly in 
asymptomatic untreated infections) this frequency decreased (Abdel-Muhsin et al., 
2004; Babiker et al., 2005; Ord et al., 2007).  These studies also suggest the existence 
of fitness costs associated with resistance (Babiker et al., 2009) 
1.3.3.2. Evidence from laboratory studies 
In the laboratory two strains of different levels of resistance can be competed 
in controlled conditions.  Ideally the two isogenic strains: resistant and sensitive one 
are used.  This can be achieved by genetic modification that replaces a resistant allele 
with a sensitive one or vice versa, or by laboratory selection of a resistant strain and 
its comparison with its sensitive progenitor.  So far, two such experiments were 
performed in P.falciparum.  They were studying the impact of pfmdr1 alleles 
associated with resistance to aminoquinolines (Hayward et al., 2005) and the 
mutations in cytochrome c conferring atovaquone resistance (Peters et al., 2002).  
Both experiments suggested the existence of fitness cost.  
Alternatively the rodent model was used when a laboratory selected resistant 
strain can be compared with its sensitive progenitor.  For example the analysis of 
parasites cloned out of the mixture of resistant and sensitive strains at various points 
of the infection revealed that pyrimethamine resistant P.chabaudi (Rosario et al., 
1978; Peters et al., 2002; Walliker et al., 2005) has reduced growth when competed 
with its sensitive progenitors.  Moreover the analysis of the cross between the Pyr-
resistant and sensitive parasites revealed that the causative mutation in dhfr gene 
conferring the resistance is gradually eliminated from the population, providing the 
conclusive evidence that the fitness cost is due to the locus of pyrimethamine 
resistance (Rosario et al., 1978).  However, it has to be added that in P.chabaudi 
pyrimethamine resistant parasites, a fitness cost was observed only initially: after 
further passage a clone had recovered its original fitness, possibly because of the 
appearance of supplementary, compensatory mutations (Walliker et al., 2005).   
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P.chabaudi was also used in order to investigate chloroquine resistance.  Again 
the parasites cloned at various time point from the mixed infection were analysed, 
however in this case no evidence of fitness cost was discovered (Rosario et al., 
1978).  
 
1.3.3.3. Consequences  
What impact can the fitness cost have on the spread of resistant alleles in the 
population? 
First of all it can slow down the spread of the resistance.  If the competition of 
resistant and sensitive strain in untreated hosts results in the domination of sensitive 
alleles, the likelihood of an accidental elimination of resistance mutations during the 
initial stages of resistance development, described in section 3.2 is greater.  
Secondly, the fitness cost can potentially increase the success of combination therapy 
– if the presence of second drug decreases the evolutionary advantages of resistance 
in a treated infection and the fitness cost decreases its survival of resistant parasites 
in an untreated one, the net result can lead to elimination of the resistance allele 
(Hastings and Donnelly, 2005).   
Finally, once the drug is withdrawn, the fitness cost may cause the elimination 
of resistant alleles from population making possible at least temporary re-
introduction of the drug.  However this process would most likely take a long time 
and, as resistant alleles would probably still be present in very low frequency, the 
resistance would probably re-emerge rapidly after the drug reintroduction.  It remains 
to be investigated whether some strategies (like using multiple treatments regimes or 





1.4. Chloroquine (CQ) resistance 
1.4.1.  Appearance and spread of CQ resistance 
Chloroquine resistance appeared after almost 20 years of heavy use of the 
drug.  The first reports of treatment failures arrived simultaneously from South 
America (Moore and Lanier, 1961) and Southeast Asia (Harinasuta et al., 1965).  
From there the resistance spread across those continents before reaching Africa in the 
1970’s -  the first cases of chloroquine resistant P.falciparum were reported in 
Tanzania in 1979 (Campbell et al., 1979).  After that the resistant parasite spread 
across Africa.  Soon it was estimated that  80% of world parasite population 
exhibited some level of CQ resistance (Ginsburg, 2005) and in many countries it 
reached fixation.   
The rise and spread of CQ resistance is considered to be one of the  important 
factors contributing to increase of malaria deaths in Africa in the last 30 years of the 
20th century (Grech et al., 2002). 
 
1.4.2. Genetics of CQ resistance 
The phenotyping of progeny of the cross between CQ-resistant and CQ-
sensitive strains of rodent malaria parasite P.chabaudi revealed that CQ resistance 
was inherited as a simple Mendelian trait and therefore was likely to have a genetic 
basis (Rosario, 1976).  However, the main determinants of the resistance remained 
elusive and the lack of necessary tools (like the in vitro culture system or polymerase 
chain reaction) made the investigation very difficult.  Only in the 1990’s the isolation 
of a CQ-resistant clone (~Dd2) and advances in molecular biology techniques made 
possible the genetic analysis that revealed the main resistance determinants in the 
major human parasite P.falciparum. 
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1.4.2.1. Pfcrt   
In 1990 the cross between two P.falciparum clones: chloroquine-sensitive 
(HB3) and resistant (Dd2) was performed (Wellems et al., 1990).  The genetic 
analysis of progeny from this cross indicated a locus on chromosome 7 as the main 
determinant of the resistance (Wellems et al., 1991).  Later the analysis of the 
additional progeny has narrowed this locus to 38 kb fragment containing only 10 
genes (Su et al., 1997).  After ruling out cg2 gene (initially the prime candidate), 
resistance was mapped to the highly polymorphic ~3.1 kb gene composed from 13 
exons (Fidock et al., 2000).  It encoded a 424 amino acid long 48.6 kDa protein, 
forming 10 transmembrane domains situated in the parasite digestive vacuole (Fig. 
1.6).  Due to the transporter-like features of its secondary structure the new protein 
was called P.falciparum chloroquine resistance transporter - PFCRT.  Its original 
function is unknown, however bioinformatic analysis (Martin and Kirk, 2004; Tran 
and Saier, 2004) revealed that it is a part of drug-metabolite transporter superfamily 
and Martin and Kirk suggest that in its native state pfcrt is a transporter of small 
cellular metabolites from the parasite vacuole, possibly peptides or amino acids 
resulting from haemoglobin digestion. 
The sequencing of pfcrt in isolates from different parts of the world indicated 
the strong correlation between the mutations within this gene and CQ resistance 
(Fidock et al., 2000; Chen et al., 2003; Nagesha et al., 2003; Durrand et al., 2004). 
Moreover microsatellite analysis across the P.falciparum genome revealed a 
selective sweep around pfcrt (Wootton et al., 2002) (A selective sweep is a decrease 
in genetic variation in the particular region, usually caused by recent intensive 
evolutionary pressure (in this particular case - the massive CQ use)).  The final proof 
for the connection between pfcrt mutations and CQ resistance came from a series of 
genetic modification (transfection) experiments.  The introduction of a resistant pfcrt 
allele into the sensitive parasite resulted in the significant increase of IC50 for 
chloroquine (Fidock et al., 2000; Sidhu et al., 2002) thus establishing pfcrt as a 
genetic marker of resistance.   
So far, 15 different mutations have been discovered in resistant alleles of pfcrt. (see 
Fig.1.6 for the exact locations).  The most important of those - the K76T substitution 
appears to be crucial and present in all resistant strains.  The allelic exchange 
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experiments proved that the removal of this mutation is sufficient to convert the CQ 
resistant allele into sensitive one (Lakshmanan et al., 2005).  Interestingly, the K76T 
mutation was never observed alone; all identified resistant pfcrt alleles contain 3-9 
additional substitutions.  The pattern of these additional mutations is characteristic 
for geographic region (Fidock et al., 2000).  For example the sequence of residues 
72-76 (CVMNK in sensitive parasite) is mutated into CVIET in most of African and 
south-east Asian resistant strains.  In South American ones, instead, the SVMNT 
haplotype is prevalent.   
The further analysis revealed that the K76T mutation appeared independently 
only around six times worldwide and each time was connected with slightly different 
set of secondary/pre-existing mutations (Mita et al., 2009).  These additional 
mutations do not seem to confer in themselves CQ resistance – parasites containing 
the “resistant” pfcrt allele without K76T mutation were found to be fully sensitive.  
However their presence seem to be necessary to obtain a fully functional pfcrt allele: 
no parasite carrying K76T mutation alone was identified in field and the attempts to 
generate such parasite in laboratory failed because of extremely low replication rate 
of the obtained clone (Lakshmanan et al., 2005).  Therefore it is possible that main 
role of the additional mutations is to compensate for deleterious effects of K76T 
change (Valderramos and Fidock, 2006). 
 
Figure 1.6 Pfcrt – the main determinant of CQ resistance in P.falciparum 
The structure of PFCRT protein.  The crucial K76T mutation is marked in red; other residues  mutated 
in CQ-resistant alleles are marked in black.  The illustration is taken from (Bray et al., 2005). 





Before the discovery of pfcrt as the principle determinant of CQ resistance, it 
was shown that CQ resistant P. falciparum shares some similarities with drug 
resistant mammalian tumor cells; including the reduced accumulation of drug in 
intracellular compartment and reversal of resistance by the calcium channel blocker 
verapamil (Krogstad et al., 1987).  In tumor cells these features are mediated by a 
membrane transporter called P-glycoprotein encoded by mdr1 gene (Juliano and 
Ling, 1976).  The search for its homologue in malaria parasite revealed pfmdr1 – 
Plasmodium falciparum multidrug resistance gene (Foote et al., 1990).  Pfmdr1 is 
situated on chromosome 5 of Plasmodium falciparum and encodes a 162 kDa trans-
membrane protein with 12 transmembrane domains organised in two symmetrical 
units (Fig. 1.7).  The PFMDR1 protein is a member of the ABC (ATP binding 
cassette) transporter superfamily and (similarly to PFCRT) it is localised within the 
digestive vacuole membrane (Cowman et al., 1991).  It is thought to transport solutes 





Figure 1.7 PFMDR1 – a multidrug resistance protein 
The structure of PFMDR1 protein. Mutations associated with high CQ resistance marked in red. 
NBD- nucleotide binding domain.  Illustration taken from (Valderramos and Fidock, 2006). 
 
Valderramos and Fidock Trends 
Pharmacol Sci. 2006 
Nov;27(11):594-601 
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The sequencing of the pfmdr1 gene in CQ-resistant and CQ-sensitive isolates 
revealed five polymorphisms: N86Y Y184F, S1034C, N1042D and D1246Y (Foote 
et al., 1990) potentially involved in CQ responses.  The N86Y mutation showed 
statistically significant correlation with the high CQ resistance in many field studies 
(von Seidlein et al., 1997; Babiker et al., 2001; Nagesha et al., 2001).  However it 
could not be classified as its main determinant.  There were no associations with the 
other polymorphisms.  
The role of pfmdr1 was further elucidated in laboratory experiments.  The 
genetic cross between the resistant and sensitive strain showed a lack of association 
between this gene and CQ responses of the progeny, which disqualified pfmdr1 as 
the universal resistant determinant (Wellems et al., 1990).  Later a series of allelic 
exchange experiments (Reed et al., 2000; Sidhu et al., 2005) revealed that the 
introduction of triple mutation (S1034C, N1042D and D1246Y) into pfmdr1 allele of 
the sensitive strain does not confer in itself CQ resistance.  Instead it increases the 
level of resistance in some parasites strains already carrying the pfcrt K76T mutation. 
This effect was however highly strain-dependent.   
In summary, evidence suggests that pfmdr1 has an epistatic role (i.e. its 
influence on the phenotype is dependent on the genetic background it is found on) 
and can increase the level of resistance in resistant 76T pfcrt strains.  It also explains 
a non-random association between the pfcrt K76T and pfmdr1 N86Y alleles observed 
in many endemic regions (Duraisingh et al., 2000; Adagu and Warhurst, 2001; 
Babiker et al., 2001; Mita et al., 2006). 
Initially it has been also considered that the amplification of pfmdr1 gene and 
the resulting overexpression of the protein (encountered in some of the resistant 
isolates) can increase the level of resistance to CQ (Foote et al., 1989).  However, 
further investigations did not support this conclusion.  In fact the prolonged exposure 
to high concentration of chloroquine resulted in de-amplification of this gene in a 
mefloquine-selected laboratory strain W2-mef, suggesting that mdr1 amplification 
leads to reduced CQ resistance (Barnes et al., 1992).   
Associations between pfmdr1 mutations and duplication and the responses to 
other antimalarial drugs, including mefloquine , halofantrine, quinine and artemisinin 
 27 
has also been found (Duraisingh and Cowman, 2005; Sidhu et al., 2005), suggesting 
that its action is general rather than CQ-specific. 
1.4.2.3. Unresolved questions concerning genetics of chloroquine resistance 
Although a strong correlation was found between CQ resistance and the pfcrt 
and pfmdr1 mutations, other proteins are likely to be involved.  The phenotyping of 
field isolates (Djimde et al., 2001; Durand et al., 2001; Chen et al., 2002) as well as 
allelic exchange experiments (Valderramos et al., 2010) has shown that even 
parasites with the same allelic variants of pfcrt and pfmdr1 exhibit a wide range of 
possible chloroquine responses, suggesting that other genes may modulate the 
response of parasites to CQ.  Additionally, the crucial K76T substitution is found in 
all of the resistant strains; however it has been also identified in some isolates with 
an apparently effective chloroquine response.  Therefore the mutated pfcrt may not 
always lead to CQ resistance.  
Most importantly however, the other major human parasite -P.vivax, whose 
contribution to malaria mortality and mortality is often underestimated (Mendis et 
al., 2001; Price et al., 2007; Galinski and Barnwell, 2008), can also develop CQ 
resistance.  The reports of chloroquine-resistant P.vivax come mainly from South –
East Asia (Phan et al., 2002; Srivastava et al., 2008) and Indonesia (Sumawinata et 
al., 2003; Ratcliff et al., 2007) but it can be also observed in South America (Soto et 
al., 2001; Ruebush et al., 2003).  Both pfcrt and pfmdr1 homologues in P.vivax were 
investigated for their connection with CQ resistance.  However, although a number 
of polymorphisms were discovered, there was no strong connection between any of 
them and the treatment outcome in field level of resistance (Nomura et al., 2001; 
Suwanarusk et al., 2007; Barnadas et al., 2008; Orjuela-Sanchez et al., 2009). 
Therefore the genetic basis of CQ resistance in P.vivax must be different.   
P.vivax is not an exception.  Rodent malaria parasites either naturally express 
(P.yoelii) or can be selected (P.chabaudi, P.berghei) for CQ resistance without the 
mutations in pfcrt or pfmdr1. The case of P.chabaudi is described in detail in section 
1.7.2. 
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1.4.3. Molecular mechanisms of CQ resistance 
Ever since the discovery of pfcrt it was speculated how exactly the mutations 
within that protein translate into the CQ-resistant phenotype.  The involvement of a 
putative transporter, the reduced accumulation of drug by CQ-resistant parasite 
(Sanchez et al., 1997) and the reversal of resistance by calcium channel blocker 
(verapamil) (Martin et al., 1987) suggest that the altered CQ transport is the source of 
resistance.  However, for a long time there was no consensus whether pfcrt transports 
chloroquine directly (either as an active efflux pump or as a channel allowing the 
passive leak out of vacuole) or indirectly (by modification of physiology of digestive 
vacuole).  Today it seems that both of these may be true. 
1.4.3.1. Pfcrt – a CQ transporter  
The idea that pfcrt is a chloroquine transporter appeared as soon as it was 
discovered (Fidock et al., 2000).  The series of experiments following the kinetics of 
labelled CQ accumulation in sensitive and resistant parasites indicated the presence 
of energy–dependent, saturable CQ efflux in resistant parasites that was dependent 
on the PFCRT K76T mutation (Sanchez et al., 2004; Sanchez et al., 2005; Sanchez et 
al., 2007a).  Moreover both mutated and wild –type pfcrt forms expressed in yeast 
specifically bound CQ (Zhang et al., 2002; Zhang et al., 2004).  Finally very recently 
it was demonstrated that PFCRT 76T (but not PFCRT 76K) protein introduced into 
the Xenopus laevis system can transport CQ across the oocyte membrane, supplying 
the direct evidence that altered CQ transport by pfcrt is a major factor contributing to 
the resistance (Martin et al., 2009) (Fig 1.8a).  
Although initially it was suggested that pfcrt is an active transporter using 
energy to pump the drug from vacuole (Naude et al., 2005; Sanchez et al., 2007b) 
currently the accumulating body of evidence suggests that it is rather a gated channel 
allowing the passive leak of the protonated CQ along the concentration gradient(Bray 
et al., 2006; Cabrera et al., 2009a; Paguio et al., 2009) (Fig 1.8b).   
What is the relationship between pfcrt mutations and chloroquine transport?  
The analysis of pfcrt structure indicates that the crucial K76T mutation is in the part 
of the protein responsible for substrate recognition in the potential channel (Martin 
and Kirk, 2004).  It is therefore possible that a wild-type version of pfcrt would 
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remain impermeable for the drug mainly because of the basic K76 residue situated at 
the entrance of the channel having a refractory role towards also positively charged 
CQ forms (Warhurst, 2003).  The replacement of K76 with T would remove this 
obstacle and chloroquine would freely leak from the vacuole.  It would also explain 
the role of verapamil (a channel blocker) in the resistance reversal.  It would inhibit 
the function of this carrier, thus restoring its impermeability to CQ and retaining the 
high concentration of drug in the vacuole.  Recently the transporter hypothesis was 
further supported by the fact that the introduction of an alternative basic residue into 
the entrance of the channel (S163R substitution) is also reversing the effect of K76T 
mutation (Johnson et al., 2004).  
1.4.3.2. PFCRT - an alternative mechanism of resistance? 
The transporter role of pfcrt is certainly one of the main components of CQ 
resistance.  However it seems that a supplementary mechanism may be involved.  It 
has been suggested that the reduced CQ accumulation cannot explain all of the CQ 
resistance – even with the similar intracellular CQ concentration the resistant 
parasites are still less sensitive to CQ than the sensitive ones (Cabrera et al., 2009b).  
Moreover the mutant pfcrt seems to alter the physiology of a digestive vacuole 
(Gligorijevic et al., 2006) and increase its acidity (Bennett et al., 2004).  It was 
speculated that these changes can also have an impact on CQ resistance, by altering 
the bioavailability of its substrate (Roepe, 2009).   
Finally, the studies of the reaction of resistant and sensitive parasites on the 
bolus CQ dose served at the different stages of synchronised culture did show that 
CQ-resistant parasites have pfcrt-related, decreased sensitivity to chloroquine not 
only in the trophozoite stage but also as a schizont or rings (that don’t possess a fully 
formed digestive vacuole) (Gligorijevic et al., 2008).  How pfcrt confers the CQ 





















Figure 1.8 The possible role of PFCRT in CQ resistance 
The protein interferes with CQ action by allowing the leak of charged drug out of the vacuole (a).  It is 
caused by replacement of positively charged residue by the entrance of the channel with a neutral one 
(b) allowing the CQ transport. The calcium channel blocker reverses this process by blocking the 








1.5. Artemisinin resistance 
1.5.1. The resistance to artemisinins – an incoming threat 
Soon after artemisinins were introduced, the general optimistic approach was 
that resistance to these drugs might not evolve.  Its short half-life (most of the 
derivates are metabolised within ~ 2 h (Meshnick et al., 1996b)) gives parasite very 
little time of exposure on suboptimal concentration of drug, which is necessary for 
development of the resistance (Stepniewska and White, 2008).  Moreover 
artemisinins are generally used in combination with the other partner drugs which, in 
theory, should delay the resistance as described in section 3.2.1.  Partly as a result of 
this optimistic prediction, the pipeline of development of new antimalarials was 
somewhat neglected and current drugs portfolio relies heavily on different versions 
of ACT (Olliaro and Wells, 2009).  Although three different artemisinin derivates are 
used, they are structurally similar and a significant level of cross-resistance is to be 
expected between them.  Therefore we are currently relying on one drug and its loss 
would deal a major blow to malaria control programs.   
This is particularly concerning in view of the recent reports of ART resistance 
selected in vitro and observed in the field, suggesting that the development of full-
blown resistance is likely to be a matter of time.  
1.5.2. The emerging artesunate resistance in central Asia 
A few years ago initial reports of the reduced effectiveness of ACTs in western 
Cambodia started to accumulate (Denis et al., 2006; Alker et al., 2007), but their 
interpretation was complicated by the degree to which these data reflected pre-
existing resistance to non-artemisinin components such as mefloquine.  More 
recently however, well-controlled studies have been performed, monitoring in vivo 
and in vitro responses to artesunate and reporting treatment failures and reduced 
parasite clearance rates in patients with adequate plasma drug concentration 
(Dondorp et al., 2009; Noedl et al., 2009) thus confirming the presence of resistant 
strains in the population.  Although currently the level of resistance seems to be low 
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and limited to a small region, even with proposed countermeasures (Dondorp et al., 
2010) it is very likely to spread and increase its levels. 
Moreover after years of unsuccessful attempts, an artemisinin resistant 
P.falciparum strain was generated under laboratory conditions (Chavchich et al., 
2010).  Three strains of slightly different resistance profiles were selected confirming 
the possibility of the rise and spread of ART resistance. 
1.5.3. Genetics of ART resistance 
Because ART-resistant strains were observed only recently, our knowledge of 
the genetics of this phenomenon is limited.  The initial investigations performed 
using field isolates from the Thai-Cambodian border, revealed a high heritability of 
ART responses, suggesting the existence a strong genetic component of this trait 
(Anderson et al., 2010).  However, there are no generally agreed resistance markers 
although a number of gene candidates have been proposed.   
1.5.3.1. Pfmdr1 
The studies of the influence of previously known resistance genes on the 
response to artemisinins have shown that the amplification of pfmdr1 gene is 
connected with decreased ART sensitivity in vitro (Sidhu et al., 2006) and with the 
failure of artesunate-mefloquine combination in vivo (Alker et al., 2007) (although 
the latter could be due to the mefloquine component (Price et al., 2004)).  The 
increase of pfmdr1 copy number was observed also in two out of three ART resistant 
strains selected in laboratory conditions (Chavchich et al., 2010).  The analysis of 
resistant strains isolated from the Thai Cambodia border however seem to exclude 
this gene as the main determinant of resistance in that setting (Dondorp et al., 2009; 
Imwong et al., 2010).  In summary, like in the case of chloroquine, pfmdr1 seems to 
influence artemisinin responses to some extent; its action however, is likely to be 
highly dependent on the other genetic factors. 
1.5.3.2. PfATP6 
PfATP6 (sarco/endoplasmic reticulum membrane calcium ATP-ase) was 
proposed as another candidate, as it was discovered to be a main target of ART 
action in Xenopus oocysts (Eckstein-Ludwig et al., 2003) and the introduction of a 
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single L263E mutation within this gene is sufficient to obtain resistance in this model 
system (Uhlemann et al., 2005).  Additionally an association between a 
polymorphism in this gene (S769N) and the artemether responses in vitro was also 
suggested in isolates from French Guiana.(Jambou et al., 2005)  However again no 
obvious association between this gene and ART responses was found in Southeast 
Asia (Dondorp et al., 2009; Imwong et al., 2010) and recent allelic exchange 
experiment introducing the PfATP6 L263E mutation into various sensitive parasites 
failed to produce a significant change in ART responses.  Therefore, PfATP6 can be 
rejected as universal resistance determinant (although it cannot be excluded that it 
does influence the ART responses on some genetic backgrounds).   
1.5.3.3. ubp1  
A genetic cross between ART –resistant and sensitive P.chabaudi parasites 
indicated the possible involvement of locus on chromosome 2 and a gene encoding a 
deubiquitinating enzyme was found to be mutated in between the resistant and 
sensitive parasite (Hunt et al., 2007).  The causative association between this gene 
and ART resistance was however uncertain, as the said mutations did appear before 
the exposure to artemisinin and no further genes within the implicated region were 
investigated so far.  Additionally no mutations witin this gene were found in any 
field or laboratory selected artemisinin-resistant P.falciparum parasites (Chavchich et 
al., 2010; Imwong et al., 2010).   
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1.6. Identification of genetic markers of resistance 
1.6.1. Why are we interested in resistance markers? 
Genetic markers of drug resistance are valuable tools for malaria control.  From 
a practical point of view they allow a quick and easy assessment of the resistant 
status of laboratory and field isolates (see section 1.3.1.3).  This information can be 
used for both more effective case management and for continuous monitoring of 
levels of resistance in the field.  Moreover their identity can provide useful 
information concerning the mechanism of drug action, parasite biology, resistance 
evolution etc. that may lead to improved treatment policies or new drug discovery 
avenues etc.  Therefore the rapid identification of resistance markers is of utmost 
importance for malaria research. 
1.6.2. Methods of marker identification. 
1.6.2.1. Candidate gene approaches. 
In some cases, there may be pre-existing evidence suggesting the involvement 
of specific candidate genes or pathways.  In such cases, the influence of these genes 
may be validated both in the field and in the laboratory.  For example molecular 
targets of antifolates were known from studies of bacteria in 1930’s and -40’s (Hyde 
et al., 2008).  Therefore the genes encoding these proteins were natural candidates 
and their investigation led to a discovery of the associations between mutations in 
dhfr and dhps genes and antifolates resistance  
Today in the era of advanced molecular techniques (e.g. transfection) the 
verification of the influence of a specific gene on a resistance phenotype is relatively 
easily confirmed (e.g. involvement of pfmdr1 in CQ resistance (Foote et al., 1990)) 
or rejected (like in case of ART resistance candidates (Imwong et al., 2010)).  This 
method is however heavily dependent on pre-existing knowledge of gene candidates.  
In practice it is limited to drugs of either known mechanisms of action (like 
antifolates) or the similarities to other already studied resistance system (like 
pfmdr1).  Moreover it concentrates on one particular gene at the time, which in the 
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case of multigenic traits may be very limiting.  In cases such as these, other methods 
of mapping the genes conferring the resistance phenotypes are required, as described 
below. 
1.6.2.2. Experimental linkage analysis 
Classical genetic linkage analysis characterises the phenotype and genotype of 
individually cloned recombinant progeny of a genetic cross between genetically 
different resistant and sensitive parasite clones, and seeks genetic markers which are 
consistently inherited along with the resistance phenotype.   
Three crosses of P.falciparum have been performed (Walliker et al., 1987; 
Wellems et al., 1991; Hayton et al., 2008).  Each of them has provided valuable data 
concerning the genetic basis of drug resistance.  For example, the first was used to 
confirm that the pyrimethamine resistance is caused by the mutations in dhfr gene 
(Peterson et al., 1988) and that mdr1 modulates responses to many drugs (Duraisingh 
and Cowman, 2005). The second identified pfcrt as the determinant of CQ resistance 
(Fidock et al., 2000).  Finally the third is being used to investigate the genetic basis 
of quinine resistance. 
Linkage analysis does not require any prior knowledge of the mechanism of 
resistance and the fact that all the progeny are carrying the combinations of just two 
genotypes allows us to eliminate the excessive genetic noise observed with 
genetically diverse isolates from the field (Hayton and Su, 2008).  However in the 
case of P. falciparum technical and ethical constraints are making the generation of 
the crosses difficult.  Another issue is that clearly characterised resistant and 
sensitive strains are needed for this analysis and sometimes (as is the case of 
artemisinin) stable genetic resistance may be difficult to obtain under laboratory 
conditions (Nzila and Mwai, 2009).  Moreover, the results are very variable, largely 
depending on the number of isolated recombinants, quality of the cross, the 
frequency of genetic recombination in proximity of resistance locus etc.  
1.6.2.3. Mapping determinants of drug resistance in field isolates 
In some circumstances, the genetic determinants of drug resistance may leave a 
selection signature in the genomes of populations of parasites.  For instance, where a 
particular (resistance) genotype spreads through a population under the influence of 
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drug use, genetic diversity will be reduced in resistant parasite populations relative to 
sensitive parasites (Anderson, 2004).  Although genetic recombination may 
progressively introduce genetic diversity into the resistant population, there will be 
persistent reductions of diversity and areas of linkage disequilibrium in genes linked 
to those conferring the resistance phenotype.  Such ‘selective sweeps’ have been 
observed for CQ and crt (Wootton et al., 2002) dhfr and antifolates (Nair et al., 2003) 
and pfmdr1 (Nair et al., 2007) for mefloquine.  Recently the combination of the  
above and the development of large-scale genotyping technologies resulted in the 
application of malaria genome-wide association analysis (GWAS) that resulted in 
mapping loci under selection with different drugs (Mu et al., 2010).   
The main advantage of these studies is that they propose candidate markers 
with likely diagnostic value in the field without any prior knowledge regarding the 
genetics or mechanism of action of the drug.  Moreover they take into account the 
entire genetic spectrum of the parasite population allowing the identification of many 
alleles and relationship between them while supplying data about the evolution and 
spread of resistance alleles.  
The major drawback of this strategy is that it can be used only when the wide 
array of drug resistant strains are already present in the population (retrospective 
analysis), which means that the resistance is well established in the wild.  It would be 
preferable to identify the genetic markers before (predictive analysis), to enable early 




1.7. The P.chabaudi model of CQ and ART resistance 
1.7.1. Why use the rodent model? 
As rodent malarias share many similarities with human parasites in terms of 
life cycle, physiology and structure (Carter, 1978) they are often used as a convenient 
laboratory model.  So far four African species of Plasmodium (P.chabaudi, 
P.berghei, P.yoelii and P.vinckei) have been adapted to growth in laboratory mice.  
They have supplied valuable data concerning the parasite life cycle (Talman et al., 
2004; Poudel et al., 2008), host immune responses (Li et al., 2001; Cheesman et al., 
2010a), infection dynamics (Bell et al., 2006; Reece et al., 2008) and pathogenesis 
(de Souza and Riley, 2002; Lamikanra et al., 2007). 
The murine malaria model has some critical advantages.  Principally, it 
provides a tractable experimental system to study the Plasmodium infection in vivo.  
The parasites can grow in their mammalian host in which they are exposed to the 
range of factors that are important for infection development but difficult to replicate 
in the culture flask (like anaemia, action of immune system, shearing forces caused 
by movement of parasites in the blood vessels, etc.).  Moreover the rodent models 
give the possibility to safely follow the whole parasite lifecycle (including mosquito 
transmission) in laboratory conditions without the ethical constraints surrounding the 
use of the primates to study human malaria.  Finally the recent publication of three 
rodent malaria genomes (P.chabaudi, P.berghei and P.yoelii) 
(http://plasmodb.org/plasmo/) revealed high degrees of synteny and gene 
conservation between rodent and human parasites (Carlton et al., 2002; Hall et al., 
2005; Kooij et al., 2005) and provided a tool facilitating genetic and genomic 
investigations using these parasites. 
In the case of the genetics of drug resistance, drug-resistant rodent malaria 
parasites are conveniently selected by the passage of parasites with increasing drug 
pressure (Carlton et al., 2001).  Moreover, as both parental strains and selected 
mutants can be analysed, the relationship between the appearance of mutations and 
drug-resistance phenotypes may be studied within the same genetic background.  In 
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addition the influence of host genetic factors can be avoided by using inbred mice 
strains.  Finally, pharmacokinetics and pharmacodynamics processes in rodent and 
human host may be similar, even though their kinetic parameters differ (Cambie et 
al., 1994; Batty et al., 2008). 
Although all rodent malarias have been used to investigate the action of, and 
resistance to, drugs (e.g. P.berghei (van Dijk et al., 1994; Gervais et al., 1999; 
Syafruddin et al., 1999), P.yoelii (Cheng and Saul, 1994; Srivastava et al., 1999) and 
P.vinckei (Powers et al., 1969; Puri and Chandra, 2006)), P.chabaudi has been most 
exploited for the genetic analysis of genetically stable phenotypes (Carlton et al., 
2001). 
1.7.2. The lineage of resistant P.chabaudi 
The work presented here exploits an ‘isogenic’ lineage of drug resistant 
P.chabaudi, selected over the years in David Walliker’s laboratory for resistance to 
various antimalarials (Fig. 1.9).  The original all-sensitive AS-sens strain is a cloned 
isolate obtained in 1969 from Thicket rat (Thamnomys rutilans) in Central Africa and 
adapted to growth in laboratory mice (Carter and Walliker, 1975).  From that strain 
with single step pyrimethamine treatment (i.e. one mouse passage), the 
pyrimethamine resistant strain AS-pyr was selected (Walliker et al., 1975).  This 
strain was subsequently used for two different selections. On one hand a single step 
selection for increased resistance to pyrimethamine/ sulfadoxine combination 
resulted in AS-50SP strain (Hayton et al., 2002).  On the other hand, the parasites 
were exposed to increasing dose of chloroquine over five consecutive mouse 
passages, generating the AS-3CQ strain (Rosario, 1976).  The additional selection of 
the latter with higher chloroquine doses resulted in AS-15CQ and AS-30CQ – an 
intermediate and highly resistant strain selected over 10 and 35 passages respectively 
(Padua, 1981).  The AS-15CQ strain was further selected for mefloquine resistance 
for 23 mouse passages (Cravo et al., 2003) generating AS-15MF strain.  Later, AS-
15CQ and AS-30CQ were selected for increased artesunate and artemisinin 
resistance respectively for 14 mouse passages (Afonso et al., 2006) resulting in AS-
ATN and AS-ART strains.  All strains, except AS-15CQ were cloned by limiting 
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dilution.  In each case the resistance was stable through >20 passages in the absence 
of drugs, mosquito transmission and deep–freezing. 
Interestingly, during the process of selection for artemisinin resistance it was 
revealed that the AS-15CQ and AS-30CQ already possessed an increased level of 
tolerance to this drug (artemisinin resistance phenotype I) in comparison to the AS-
3CQ and AS-sens that were sensitive.  Further selection resulted in artemisinin 
resistance phenotype II observed in AS-ART (unpublished observations).  Therefore 
in the P.chabaudi lineage the resistance to artemisinin arose spontaneously under 
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Figure 1.9 The resistant AS lineage of P.chabaudi 
Each arrow represents the selection step, the known mutations/loci with potential role in the resistance 




1.7.3. Past investigations of the genetics of drug resistance in 
P.chabaudi lineage 
The AS lineage of parasites (Fig 1.9) has been used to investigate the genetic 
basis of resistance to pyrimethamine, S/P, CQ, MF and ART, and to map the 
underlying genes generally by the application of classical linkage analysis:  
recombinant clones of genetic crosses are analysed by in vivo phenotyping of drug 
response, and genotyping in order to determine the genetic markers inherited along 
with drug response. 
1.7.3.1. Pyrimethamine resistance  
The candidate gene approach was used to study the genetic background of 
resistance leading to a discovery of S106N mutation dhfr gene (Cowman and Lew, 
1990), situated on chromosome 7.  Later an advanced linkage analysis confirmed that 
the dhfr locus is the main determinant of resistance (Culleton et al., 2005).  
The identified gene is an orthologue of pfdhfr which has previously been 
connected to pyrimethamine resistance in P.falciparum (Peterson et al., 1988).  Also 
the causative mutation S106N is analogous to the S108N conferring resistance in 
human malaria.   
1.7.3.2. Chloroquine resistance 
Chloroquine resistance was selected by multiple passages in increasing drug 
concentration and three strains of different level of resistance were obtained (AS-
3CQ, AS-15CQ and AS-30CQ).  The cross performed between the low resistant AS-
3CQ and the genetically different, sensitive strain (AJ) established that resistance had 
genetic basis.  Moreover, the typical Mendelian inheritance of this trait suggested the 
existence of a single locus responsible for low CQ resistance (Rosario, 1976).  
Linkage analysis of AS-3CQxAJ cross indicated that the location of this main locus 
of resistance was on chromosome 11 (Carlton et al., 1998).  Later, with addition of 
more genetic markers, this region was narrowed to ~ 250 kb fragment containing ~50 
different genes (Hunt et al., 2004b) but no obvious gene candidates were proposed.   
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A genetic cross was also performed between the highly resistant AS-30CQ 
strain and AJ.  This time intermediate levels of resistance were observed in 
recombinants suggesting that the high CQ resistance is multigenic.  No additional 
loci have been identified.   
The two genes responsible for chloroquine resistance in P.falciparum – pfcrt 
and pfmdr1 were investigated for their role in chloroquine resistance in P.chabaudi.  
Firstly, no mutations in either gene were found in the AS lineage (Hunt et al., 2004a).  
Secondly, there was no linkage in genetic crosses (AS-3CQ x AJ or AS-30CQ x AJ).  
Therefore the involvement of these genes in CQ resistance in P.chabaudi is highly 
unlikely.  
Interestingly, despite being founded of a different genetic basis, CQ resistance 
in P.chabaudi seems to share a lot of features with those observed in human malaria 
including the reduced CQ accumulation in resistant parasites (Miki et al., 1992), 
changes in the morphology of digestive vacuoles (Ohsawa et al., 1991) and reversal 
of resistance by calcium channel blockers like verapamil (Tanabe et al., 1990).  The 
orthologues of causative P.chabaudi genes may prove to be additional factors 
influencing CQ response in P.falciparum or the main determinants of resistance in 
P.vivax (in which the genetic basis of resistance is still unknown and unlinked to 
pfcrt). 
1.7.3.3. Mefloquine resistance 
In P.falciparum mefloquine resistance was associated with mutations (Reed et 
al., 2000) and amplification (Cowman et al., 1994; Peel et al., 1994) of pfmdr1 gene.  
In P.chabaudi, the mefloquine-resistant clone AS-15MF also bears a duplication of 
the mdr1 gene, and this event was linked to mefloquine resistance in the progeny of 
the AS-15MF x AJ cross although other genes may be involved (Cravo et al., 2003).   
1.7.3.4. Artemisinin resistance 
In the case of artemisinin resistance, the data from the rodent model cannot be 
compared to human parasites because the determinants of artemisinin responses are 
not known yet.  However previous work on P.chabaudi indicated the existence of 
one main locus of artemisinin resistance is situated on chromosome 2 (Hunt et al., 
2007).  Within this locus the ubp1 gene was discovered. It was mutated in both AS-
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ATN (V2697F mutation) and AS-ART (V2728F mutation) parasites.  However, both 
mutations did appear during the CQ selection in AS-15CQ parasite and, its direct 
role in the resistance phenotype is still not fully understood.  For instance, the 
possibility that there are other mutations in genes linked to ubp1 was not explored. 
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1.8. New gene identification strategy – a combination of 
Linkage Group Selection and next generation 
sequencing on isogenic drug resistant lines of parasite 
The aim of this section is to describe the approach that I have taken to identify 
novel genes involved CQ and ART resistance. It uses a variant of genetic linkage 
analysis called Linkage Group Selection (LGS), in order to map the potential loci of 
resistance and next generation sequencing of isogenic drug resistant parasites to 
identify specific mutations within these loci.  It is anticipated that the genes 
identified can be evaluated in P.vivax and P.falciparum in the field and in laboratory 
transfection studies.  
1.8.1. Linkage Group Selection – a fast method to map resistance 
loci 
In contrast to classical genetic linkage analysis, which maps genes by defining 
the co-inheritance of genetic markers and the phenotype in individually cloned 
recombinant progeny, Linkage Group Selection (Carter et al., 2007) (LGS) analyses 
the ‘phenotype’ and ‘genotype’ of large populations of uncloned recombinant 
progeny.  It applies a selection (such as drug treatment or host immunity) to the 
pooled progeny of a genetic cross and analyses the proportions of parental alleles at 
many polymorphic loci in the selected and unselected populations.   
LGS was previously developed by Richard Carter and collaborators and 
applied to pyrimethamine resistance and strain-specific immunity in P. chabaudi 
(Culleton et al., 2005; Martinelli et al., 2005).  It has subsequently been successfully 
applied to artemisinin resistance (Hunt et al., 2007), strain specific immunity in 
P.chabaudi (Cheesman et al., 2010b) and growth rate in P.yoelii (Pattaradilokrat et 
al., 2009).  Another approach called Bulk Segregation Analysis has some similar 
features and was also used for the successful identification of genes underlying 
various traits in yeast (Wenger et al., 2010) and maize (Liu et al., 2010) 
The basic elements of the LGS strategy are discussed in the three sections 






























Figure 1.10 The design of a Linkage Group Selection experiment 
















































1.8.1.1. Generation of experimental cross 
As in classical linkage analysis, LGS requires a genetic cross between two 
unrelated parasites, one of sensitive and the other resistant to the relevant selection 
pressure (e.g. drug treatment).  In P. chabaudi the cross is generated by infecting the 
mice with a mixture of resistant and sensitive strains of the parasites and feeding 
them to Anopheles mosquitoes.  In a mosquito’s midgut the gametes from both 
strains fuse to form a zygote.  Recombination results in the formation of new 
parasites (parentals and recombinants).  These can be used to infect new mice and to 
recover progeny as haploid asexual parasite forms in mouse red blood cells.   
1.8.1.2. Selection 
In contrast to the classical linkage analysis, where independently cloned 
parasites are phenotyped (e.g. tested for drug response), in LGS, a population 
approach is used.  The pooled, uncloned progeny are grown in two groups of mice, 
one treated with drug and the other untreated.  
If the cross was successful initially both groups will contain the parasites 
populations containing mixture of parental alleles at all loci according to the 
principles of Mendelian genetics.  Later however the structure of both populations 
will change reflecting the relative fitness of various genotypes in the growth 
environment.  Assuming that the drug resistance was only phenotyping difference 
between the parental strains, in the untreated group most parasites will have equal 
chances to grow and only minimal deviation from initial population structure will be 
observed.(Fig 1.11a).  In treated animals however, the drug-sensitive recombinants 
and the sensitive parental parasite will be eliminated by drug treatment (Fig 1.11b).  
It generates a population in which all the parasites will carry the alleles of resistant 




























Figure 1.11 The possible results of genetic analysis 
The unselected (a) and selected (b) parasite population and their genome scans.  The bars are 
representing fragments of sensitive (yellow) and resistant (blue) genotypes. Circles are representing 
the genetic markers. The scans are results of plotting the frequency of markers from resistant parent 











































































1.8.1.3. Genetic analysis 
The frequency of genome-wide genetic markers from the sensitive parent is 
studied in the DNA from the pooled progeny and plotted along the genomic distance 
presenting a so-called “genome scan”.  
In the unselected population, the proportion of markers across the genome is 
expected to reflect the initial proportions of the two parentals (typically 50%).  
Therefore a proportion of markers of each parent plotted against the genomic 
distance will be represented by a straight line (Fig 1.11a).  In the selected population 
however, the markers from the sensitive parent that are linked to the locus of drug 
resistance tend to be eliminated from the population and this effect is related to the 
genetic distance between the marker and the resistance locus.  In this situation we 
will observe a “selection valley” indicating the causative locus (Fig 1.11b). 
While classical genetic linkage analysis employed any ‘binary’ genetic or 
protein marker, such as enzyme mobility (Rosario, 1976), RFLP (Carlton et al., 
1998), AFLP (Grech et al., 2002), microsatellite or sequenced SNP; for LGS, 
quantitative markers are required to estimate allele proportion in selected population.  
Initially AFLP markers were adapted to LGS analysis (Martinelli et al., 2004).  Now 
however, to avoid some disadvantages and inconvenience of these assays, 
quantitative SNP Pyrosequencing
TM
 is used (Cheesman et al., 2007) (see section 
3.1.3).  
1.8.2. Next generation sequencing – a method of mutation 
discovery 
The existence of each selection valley indicates the presence of a ‘major effect’ 
gene conferring resistance to the selection pressure applied in LGS.  Because the 
bottom of a selection valley may extend over about 100 kb, large numbers of gene 
candidates are generated by the selection scan.  Previously, candidate gene 
approaches were used to search for the resistance gene and a significant amount of 
sequencing work was required in order to specify the causative mutation.  This 
approach however required a lot of effort and (unless a single obvious candidate 
could be localised in the selection valley, based on the knowledge of biology of the 
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studied phenomenon or analogy with other species), usually did not lead to discovery 
of causative mutation. 
Now for the first time, high-throughput genome re-sequencing was employed 
in order map the causative mutations within the selection valleys.  The Illumina 
Solexa genome analyser is a sequencing system that allows rapid and accurate 
sequencing on a genome scale.  It is based on the short reads (>50bp) that can be 
sequenced and mapped to the pre-existing genome scaffold (here the published 
P.chabaudi genome).  Differences between the ‘assembled’ sequence and the 
‘reference’ sequence can be used to identify candidate mutations. 
In this work Solexa is used for identification of genetic changes between two 
congenic strains in order to identify the genes mutated within predicted loci.  Both 
resistant mutant and its sensitive progenitor can be sequenced and all the genetic 
changes that occurred during the drug selection in the locus indicated by LGS can be 
identified.   
In summary the Linkage Group Selection indicates the regions of the genome 
linked to the resistance and Solexa genome resequencing provides the list of 
mutations that appeared in the strain under drug pressure.  If there is only one change 
that appeared with a selected locus under drug pressure, it is a very strong candidate 
for the resistance-conferring mutation, although additional studies (e.g. transfection 
of the mutated gene-candidate into drug-sensitive parasite) are required to 
unambiguously prove this connection. 
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1.9. Aims and content of this thesis 
This thesis describes how Linkage Group Selection and Solexa genome re-
sequencing were used to map the genes conferring different levels of CQ and ART 
resistance. 
In Chapter 2, I describe the confirmation of chloroquine resistance phenotypes 
in the AS lineage and preliminary experiments that establish the optimum 
chloroquine concentrations for LGS experiments  
In Chapter 3 and 4, I describe the generation of a cross and a subsequent 
backcross between the chloroquine and artemisinin resistant AS-30CQ strain and the 
genetically different, sensitive AJ strain, the selection of these crosses with 
previously established chloroquine and artemisinin concentrations and their genetic 
analysis. These experiments are designed to identify loci involved in increasing 
resistance to chloroquine and to confirm the existence of a locus responsible for 
resistance to artemisinin. 
In Chapter 5, I describe the genome re-sequencing of AS-30CQ strain and its 
chloroquine and artemisinin sensitive predecessor – AS-sens strain in order to 
establish the full inventories of mutations accumulating between the two strains. This 
list, combined with LGS data from previous experiments allowed us to identify: 
 A strong candidate for a main determinant of CQ resistance in P. chabaudi  
 two possible candidates contributing to the intermediate CQ response 
 the main determinant of ART resistance and the highest level of resistance to 
CQ 
In Chapter 6, I investigate the fitness cost arising with high CQ resistance by 
comparing the growth of low and high-CQ resistant mutants in competition.   
These data and their implications for understanding CQ- and ART resistance 




2. The preliminary experiments – establishing the 
selection conditions for LGS experiments 
2.1. Introduction 
This chapter describes preliminary experiments performed in order to confirm 
the relative phenotypes of strains later used for the genetic cross and to establish the 
optimal selection conditions in LGS experiments.  
2.1.1. The importance of the selection in LGS 
In section 1.8 of Chapter 1, I proposed an approach to identify the loci of 
chloroquine and artemisinin selection in the rodent malaria parasite P.chabaudi.  Its 
crucial component is Linkage Group Selection – the genetic analysis of the pooled 
progeny of a genetic cross between a resistant and a sensitive strain, after a drug 
selection.   
The resistant parent of the cross described in chapter 3, AS-30CQ, has been 
derived from its predecessors of lower (AS-3CQ) and intermediate (AS-15CQ) 
resistance to CQ (Fig. 1.9, Chapter 1).  Therefore, it is likely that at least three genes 
contribute, one after another, to the highest level of resistance (however other 
possibilities like the accumulation of epigenetic changes, or three completely 
different genetic mechanisms in each of the consecutive strains cannot be excluded).  
Additionally, the differences in growth rate (which is probably determined by many 
loci) exist between the two parents of the cross, AS-30CQ and AJ (de Roode et al., 
2005).  In the cross both parental genotypes will be reassorted during the meiotic 
recombination, producing parasites of different level of resistance and growth rate.   
In order to select from that pool the parasites of a desired level of resistance, a 
carefully designed drugging regime (length of the treatment, drug dose, frequency) 
needs to be used.  On the one hand, insufficient treatment would allow the growth of 
some sensitive recombinants which would interfere with further analysis.  On the 
other hand, too much drug might kill some resistant parasites, not yielding enough 
recombinants in the pool of genotypes in the population.  The length of infection may 
also be a factor because each day/round of sexual reproduction after the end of the 
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treatment when the parasites are already selected, the drug in serum is being 
metabolised and other factors (such as the mouse immune system, competition for 
remaining resources), can modify the structure of the population.  The optimal drug 
treatment is likely, therefore, to be large enough for efficient selection, but low 
enough to yield large numbers of recombinant parasites in short time.  
2.1.2. The requirements of different drugging regimes 
My aim was to select the AS-30CQxAJ cross with different CQ concentration 
in order to map the loci required for different levels of resistance (this concept is 
fully explained in section 4.1.3 of Chapter 4).  Therefore, I needed to establish at 
least two different drugging regimes.  The first one would select for the highly 
resistant parasites (AS-30CQ phenotype) only, eliminating the sensitive and low 
resistant ones.  This regime would have an advantage of providing a maximal level 
of selection on all the loci involved in resistance.  However it is likely to provide less 
genetic material and, as the recrudescence of parasites is likely to take longer, be 
more susceptible to other selection pressures that may appear during infection (like 
the selection for faster growth or the efficient evasion of the immune system).   
The second regime would select parasites exhibiting any level of resistance 
(even the low resistant AS-3CQ phenotype) and remove only the fully sensitive ones 
(like AJ phenotype).  This would have the advantage of generating a larger parasite 
population containing more DNA and more diverse recombinants improving the 
quality of genetic analysis.  However, the lack of complete selection on loci involved 
in the highest levels of resistance could make the latter one difficult to map.  
Once these drugging regimes were established, the more suitable one or 





2.2. Experimental design 
The two parents of the cross: AJ (sensitive) and AS-30CQ (highly resistant) as 
well as AS-3CQ (the low-resistant progenitor of AS-30CQ) were used as models of 
sensitive, high–resistant and low-resistant progeny of the cross, respectively.  The 
selection conditions were estimated using mixed infections of two strains treated 
with different drug concentration and monitored using a genetic marker between the 
two strains.  At the time of this experiment no genetic marker distinguishing between 
AS-3CQ and AS-30CQ was defined.  However, a proportional sequencing assay 
based on 4 SNP in pcdhps (PCHAS_142850) gene was available and could be used 
to measure the proportions between AJ and strains from the AS lineage in a single 
infection (Hunt et al, 2005).   
Two competition experiments were therefore performed: AS-30CQ + AJ and 
AS-3CQ + AJ.  
2.2.1. AS-30CQ+AJ 
The aim of the first experiment (AS-30CQ +AJ) was to establish the best 
drugging regime to select the highly resistant recombinants.  To this effect four 





 – the highly resistant strain AS-30CQ was selected using this concentration.  Three 




) were also employed – all of 




 used to select the low resistant AS-3CQ 
strain.  Additionally the influence of a different number of days of treatments was 
tested – 3, 4 and 5 day drugging regimes were used. 
The plan of the experiment is presented on Fig 2.1: The 1:1 mixtures of highly 
resistant (AS 30CQ) and sensitive (AJ) clone were inoculated into 5 groups of mice, 
3 mice each.  Each group was drugged with a different CQ concentration – 0, 5, 10, 




.  The drugging process started on the day of infection 
(day 0 p.i.) and continued for respectively 3, 4 and 5 days for mice 1, 2 and 3 in each 
group.   
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Independently, single infection controls were prepared – 2 mice infected with 
AS-30CQ and 2 with AJ parasites – one of each group undrugged and one treated 




for 4 days.   
In summary only one mouse was used per each drug dose/treatment 
length/strain combination.  This decision was taken, because the aim of these pilot 
experiments was to confirm the identity of the used strains and estimate the range of 
the concentrations that could be used for the actual selections, rather than quantify 
the parasites responses to particular treatment regimens (to this effect the 
experiments similar to the ones described in chapter 6 would have to be performed).  
Therefore, in the light of limited number of animals that could be managed during 
one experiment testing of various regimes even with one animal was judged more 
important than producing the biological replicates. 
The parasitaemia and proportion of resistant and sensitive parasites in the 
infection were monitored for 16 days.  
 
2.2.2. AS-3CQ+AJ 
The first objective of the second experiment (AS3CQ+AJ) was to find the 
lowest drug concentration eliminating AJ and allowing the growth of low resistant 
parasites that could be used to separate all the resistant recombinants from sensitive 
ones.  The second objective is to establish a concentration inhibitory for both the 
sensitive (AJ) and low-resistant strain (AS-3CQ) that would still allow the growth of 
the highly resistant one (AS-30CQ) (from previous experiment).  Again four 
different concentrations were used: 
• 1.5 mg of CQ kg-1 day-1– the very low concentration, probably allowing the 
growth of all resistant strains 
• 3 mg of CQ kg-1 day-1– concentration used to select the low resistant AS-3CQ 
strain, therefore permissive for all resistant parasites  
• 5 mg of CQ kg-1 day-1 – higher than the concentration used to select AS-3CQ but 




used for selection of AS-15CQ and therefore 
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likely to select the intermediate and highly resistant parasites from the low 
resistant and sensitive ones 
• 20 mg of CQ kg-1 day-1– as inferred from selection data inhibitory for AS-15CQ 
and AS-3CQ but allowing the growth of AS-30CQ. 
The design of the experiment is presented in Fig. 2.2.  Five groups of 4 mice were 
infected with a mixture of AS-3CQ and AJ parasites, in proportion 50:50.  All mice 
were drugged for three days with different chloroquine concentrations for each group 




).  In parallel, controls were set as described in 
the previous experiment: two mice were infected with AS-3CQ and two with AJ 





.   
As the three day treatment regime was decided in the previous experiment and 
the range of the concentration to be tested was narrower this time mixed infections 
were performed in 4 replicates in order to assess the influence of the host factors on 
the selection. 
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Figure 2.1 The design of AS-30CQ+ AJ experiment.   
The numbers inside animals indicate the number of days of treatment.  The description above – the 
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No drug 3mg CQ
AS-3CQ
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Figure 2.2.The design of AS-3CQ+ AJ experiment  
The numbers inside animals indicate the number of days of treatment.  The description above – the 




2.3. Materials and methods 
2.3.1. Parasite and mice strains 
Three strains of P.chabaudi were used in this experiment.  Two of them (the 
highly resistant AS-30CQ and low resistant AS-3CQ) are part of the resistant lineage 
selected from the original sensitive AS-sens strain, described in detail in section 1.7.2 
of Chapter 1.  Third one (AJ) is a genetically different, sensitive strain isolated in 
1969 (Carter and Walliker, 1975) from central African thicket rat (Thamnomys 
rutilans). 
All parasites were grown in 8-14 weeks old female CBA mice.  The animals 
were housed at the University of Edinburgh animal unit (March Building) according 
to animal husbandry and veterinary standards.  All the animal procedures were 
approved under the U.K.  Home Office Animals (Scientific Procedures) Act 1986 
(Project license number 60/3578, personal licence number 60/10747).  The mice had 
unlimited access to food (RM3 diet, SDS UK Ltd.) and water enriched with 0.05% of 
para-aminobenzoic acid (PABA).  All animals were observed and, if the symptoms 
of severe disease were noticed, the animal was killed according to the regulations of 
Schedule 1 humane killing. 
2.3.2. Setting up the experimental infections 
2.3.2.1. Preparation of inoculum 
Initially parasites for inoculation were propagated from the cryopreserved 
samples.  The capillary containing the aliquot of blood from infected animals, 
suspended in deep-freezing solution (see Appendix A), was defrosted in ice and the 
recovered blood was injected intraperitoneally.  Once the parasites were observed in 
peripheral blood the mouse could be used as the donor for a larger group of 
experimental mice. 
2.3.2.2. Single strain infections 
On the day of infection the full cell blood count of a donor mouse was 
performed using a Coulter counter (Beckman Coulter, Inc.) and parasitaemia 
determined using the thin blood smear as described in section 2.3.4.  This was used 
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to calculate the parasite density and, hence, the amount of blood containing the 
number of parasites required for infections (10
6
 of parasites per 20 g mouse were 
used unless specified otherwise).  The appropriate volume of blood was taken from a 
mouse tail vein using a thin glass capillary and diluted with citrate saline (see 
Appendix A) to contain the desired number of parasites in 100µl.  This solution was 
intraperitoneally injected into new mice in a volume 100 l per 20 g of mouse 
bodyweight. 
2.3.2.3. The mixed infections 
Mixed infections were set as above except that both strains were propagated 
separately, diluted to 10
6 
parasites / 100 l using the protocol from section 2.3.2.2. 
and mixed in a 1:1 proportion.  Then the mice were injected with 100 l of this 
mixture/20 g of bodyweight  
2.3.3. Drugging 
The mice were treated with chloroquine sulphate (Beacon Pharmaceuticals), 
diluted to desired concentration with water and administered to the animals by 
gavage (100 l of solution/20 g of mouse body weight).  The untreated animals were 
receiving an equivalent volume of water.  All drugging started at day 0 and continued 
for 3, 4 or 5 days according to Fig. 2.1 and 2.2.  The treatment took place the same 
time each day. 
2.3.4. Monitoring the parasitaemia 
Daily thin blood smears were taken from all the animals, fixed with methanol 
and stained with Giemsa’s reagent (BDH) to monitor the parasitaemia.   
Parasitaemia was determined by counting infected and total red blood cells on 
five representative microscope fields.  At least 5 fields containing a minimum of 100 
RBC each were counted.  The parasitaemia was calculated according to the formula:  
Parasitaemia = Infected RBC/Total RBC 
The erythrocytes containing more than one parasite were counted as one 
infected cell.  
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2.3.5. Proportional sequencing of pcdhps gene 
The proportions of the AS and AJ strains were established using the method of 
proportional sequencing.  This method (described in detail in (Hunt et al., 2005)) 
estimates the proportions of SNPs in a mixture by measuring, on a DNA sequencing 
electropherogram, the heights of the peaks corresponding to two different bases of 
the polymorphism.  In this case four bases within pcdhps gene, polymorphic between 
AJ and AS lineage were used.  This assay was previously described and calibrated 
showing the good efficiency with experimental error of ~2% (Fig. 2.3 b) (calibration 
and efficiency of that particular assay are discussed in detail in Hunt et al., 2005). 
2.3.5.1. Blood sampling and small scale DNA isolation 
In order to monitor the proportion of the strain in mixed infections every 
second day 10l of the blood from a mouse tail vein was taken on 180 µl of PBS (see 
Appendix 1) and frozen for genetic analysis.  The animals were sampled every 
second day.  
Later all the blood samples were defrosted and DNA was isolated using High 
Pure PCR Template Preparation Kit (Roche). 
2.3.5.2. Proportional sequencing of pcdhps gene 
The DNA from each sample was used as a template in triplicate PCR reaction 
amplifying the fragment of pcdhps gene containing four polymorphisms.  The 
standard PCR protocol (see Appendix B) was used with following primers: 
Outer PCR: 





The products were purified using QIAquick PCR purification kit (Qiagen) and 
sequenced (forward and reverse) using an ABI Prism0® BigDye™ Terminator 
dideoxy sequencing system (Applied Biosystems). 
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2.3.5.3. Estimation of proportions of parasites in the mixture 
The sequencing results were analysed using Chromas 2.33 software 
(Technelysium Pty Ltd) and the heights of peaks corresponding to the two bases 
were measured on each of the four polymorphic positions using the “y” coordinate of 
the highest point of each peak (see Fig. 2.3 a). 
The proportion of the AS strain (fAS) was estimated for each of four SNPs 
(forward and reverse) with the following equation:  
fAS = kp × (hAS × 100/(hAS + hAJ))  
where hAS and hAJ are the heights of peaks corresponding to the AS and AJ alleles 
respectively for the further details and kp is a coefficient calculated for each of the 
polymorphisms based on calibration data, reflecting the systematic error of the 











Figure 2.3 The proportional sequencing. 
a)The chromatogram representing the fragment of pcdhps gene. The two positions polymorphic 
between the AS and AJ parasite are visible and the measurements of the height of the peaks can be 
used to estimate the proportions of both strains in the mixed infection  
b) The calibration data obtained for the four polymorphisms in pcdhps gene (according to Hunt et al., 
2005).  The x axis on each of the graphs represents the proportion of AS strain in prepared mixtures, 
obtained by real-time quantitative PCR.  The y axis represents the proportional sequencing 
measurement using one of pcdhps polymorphisms.  Each of the four repeat of this measurement was 







2.4.1. AS-30CQ+AJ competition experiment 
2.4.1.1. Single infection controls.  
Two mice were infected with either of the two strains (AS-30CQ and AJ) and 




for 16 days.  The 
parasitaemias of all infections was monitored daily (Fig. 2.4). 
Untreated controls.  In an untreated mouse, AS-30CQ parasites were observed 
first at day 5 p.i.  Parasitaemia increased until it reached a peak of ~30 % on day 9 
and started to recede, disappearing completely by day 13.  No parasites were 
observed for the remaining time of the experiment.   
In a mouse infected with the sensitive AJ strain, parasites grew noticeably 
faster than those of the AS-30CQ strain.  The parasitaemia appeared one day earlier 
(on day 4) and by day 8 it reached 37.8%.  At that point of the infection the mouse 
started showing symptoms of severe disease and had to be sacrificed. 
Treated controls.  The treated mouse infected with highly resistant AS-30CQ 
strain developed parasitaemia.  However it was significantly delayed in comparison 
to untreated infections (parasites did not appear till day 11) and the peak of 
parasitaemia reached on day 14 was only 8.9%. 
No parasites were observed in CQ-treated animal, infected with sensitive AJ 
strain. 
Together, these data confirm that both AS-30CQ and AJ were viable and that 
their drug responses were as expected; sensitive for AJ, resistant for AS-30CQ. 
2.4.1.2. Parasitaemia in mixed infections 
Five groups of 3 mice were infected with 50:50 mixtures of AS-30CQ and AJ 
and treated with CQ at various doses for three, four or five days as shown in Fig. 2.1. 
All animals developed infections.  The parasitaemias of all animals were monitored 
daily during the course of experiments and are shown in Figures 2.5 and 2.6 (violet 
bars). 
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In untreated mice, parasitaemias developed similarly to the single infection 
with AJ strain, appearing on day 4 and quickly reaching an average parasitaemia of 
43.1± 1.6% on day 8 at which point mice were disposed of (Fig 2.5). 




 (Fig 2.6 a-c) the infection was 
similar to the AS-30CQ treated with the same concentration – the parasites appeared 
later (day 9 or 10) and reached peak of parasitaemia was lower (9.9 ±2.3%) and 
delayed (day 12/13) in comparison with the previous group.. 




also developed infections 





 group (peaks of parasitaemia on average on day 14, 15 and 16 respectively).  
However, no significant decrease of parasitaemia was observed– the maximum 





.   
All groups contained mice treated for 3, 4 or 5 days.  As expected, the number 
of days of treatment seemed to decrease the peak parasitaemia (the peaks 
parasitaemias in animals treated for 3, 4 and 5 days were 12.6±0.38%, 9.0±3.0 and 
7.8±2.4 respectively) and delay the infection (on average the parasites in animals 
treated for 3 days appeared a day or two earlier than in those treated for 5 days). 
2.4.1.3. Proportions of parasites in mixed infections 
All mixed infections consisted of an inoculum containing an equal proportion 
of both strains AS and AJ. Proportional sequencing was used to confirm this 
proportion and to monitor the changes of proportion throughout the infection.  The 
results are presented on Fig. 2.5 and Fig. 2.6 (green lines). 
The proportion of the AS parasites in the original inoculum was 47.2±0.6% 
which suggests that the inoculum was accurately prepared. Later, however, this 
proportion underwent significant changes in all the groups. 
In untreated animals the proportion of resistant (AS-30CQ) parasites dropped 
dramatically.  From the initial 47.2±0.6% it was reduced to 21.3±0.9% on day 4 and 
3.9±1.2 on day 6.  By the day 8 the resistant parasites could no longer be detected. 
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In treated animals initially the more resistant AS-30CQ dominated the early 
part of the infections, as expected.  Almost all samples taken on day 7 (no reading 
could be obtained from the earlier samples possibly due to the very low number of 
parasites) showed 100% AS in the infections and this proportion was maintained at 
least until the peak of parasitaemia.  The only exception was an animal treated with 




 for 5 days (Fig 2.6-i) which showed 41.2 % of resistant strain 
on day 6 and subsequent gradual increase of proportion of AS-30CQ till it reached 
the 100% on day 16 (coincidentally the parasitaemia of this animal was the most 
delayed and lowest of all infections).   
Later in the infection however, some animals showed a decrease of proportion 
of AS-30CQ.  The sensitive strain (AJ) had re-emerged and again constituted a 
significant part of infection.  This re-emergence seems to be correlated with low 





 (the lowest used dose of CQ) and in animals treated with 10 and 30 




for 3 days (the shortest time of treatment).  It always appeared 




Figure 2.4 The controls for AS-30CQ + AJ infections.   
The bars are representing the parasitaemia of   - the untreated AJ infection,  - the AJ infection 




,  - the untreated AS-30CQ infection,  - the AS-30CQ infection 





























Figure 2.5 The mixed infections with AS-30CQ and AJ strains in untreated animals.   
The changes in parasitaemia (violet bars) and proportion of resistant strain in the mixture (green line) 



























































































































































































Figure 2.6 The mixed infections with AS-30CQ and AJ strains  




.  In each group mice have been 
treated 3 (a,d,g,j), 4 (b,e,h,k) or 5 (c,f,i,l) days.  The changes in parasitaemia (violet bars) and 
proportion of resistant strain in the mixture (green line) during the course infection are recorded. Each 
graph is representing one animal



































































































































































































































































































































2.4.2. The AS-3CQ +AJ competition experiment 
2.4.2.1. Single infection controls 
Analogously to the previous experiment, two control infections were 
established for each of the strains; the low resistant AS-3CQ and the sensitive AJ.  





for 3 days.  The parasitaemia of all infections is presented on (Fig. 2.7). 
Untreated controls.  The mouse infected with AS-3CQ strain developed 
parasitaemia on day 4 and reached the peak of infection on day 9 with 41.5% of 
parasitaemia followed by sharp decrease.  Compared to the highly resistant AS-
30CQ strain from previous experiment, AS-3CQ seems to grow quicker as the 
parasitaemia appears earlier and its peak is higher. 
In the animal infected with the sensitive AJ strain parasites appeared on day 4.  
By day 7 the peak parasitaemia was 43.1% and, because of the symptoms of disease 
the animal was sacrificed. 





developed parasitaemia on day 12 and reached its peak day 18 with 
20.4%.  It presents a significant delay in comparison with AS-30CQ from previous 
experiment, which managed to develop infection 4 days earlier when treated with 




).  However the peak of 
parasitaemia AS-30CQ reached was only half of the one of AS-3CQ.   
The sensitive AJ strain failed to develop measurable parasitaemia during the 
time of experiment.   
Together, these data confirm that both AS-3CQ and AJ were viable and that 
their drug responses were as expected; sensitive for AJ, resistant for AS-3CQ.  It also 
confirms that AJ grows faster than both AS clones.  However no valid comparison 
can be made between the two AS strains as they were characterised in different 
experiments, using slightly different treatment regimens and with only one animal 
per treatment. 
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2.4.2.2. Parasitaemia in mixed infections  
Five groups of mice were infected with a mixture of AS-3CQ and AJ and 
treated as shown on Fig 2.2  The parasitaemia of all infections was monitored daily is 
presented as green bars on Fig. 2.8-2.11.  
All untreated animals (Fig 2.8) developed infections with an average peak 
parasitaemia of 42±3.8% on day 7.  Afterwards the mice started to show the 
symptoms of illness and had to be killed on day 10.   




- the lowest concentration - 
also developed infections (Fig 2.9).  However, even this very low treatment 
significantly delayed the parasitaemia – the first parasites were not observed until 
day 13 and the peak of the infection was on day 17-18.  The obtained parasitaemia 
was also lower – the maximum was 22.3±3.1% which was around half of the values 
obtained in untreated infection.   




 (Fig 2.10) only two animals out 
of four developed a detectable parasitaemia during the time of experiment (Fig 2.10 
b and c).  In both cases the maximal values of parasitaemia (35.6% and 15.3% 
respectively) were observed on the last day of experiment (day 19). 





) no parasites could be detected on the blood smears during the course of 
experiment suggesting that the drug inhibits both sensitive and resistant strain.  




 (Figure 2.11) a PCR product could be obtained 
which can be explained by the presence of very low numbers of parasites in mouse 
blood, undetectable by microscopy. 
2.4.2.3. Proportions of parasites in mixed infection 
As in the previous experiment, all animals were inoculated with a 50:50 
mixture of both AJ and AS strains and the proportion of parasites was followed using 
the proportional sequencing of pcdhps SNPs.  The obtained data are presented as 
orange lines on Fig. 2.8-2.11. 
In untreated infections (Fig 2.8) there was an initial decrease in the proportion 
of the resistant AS-3CQ strain.  On day 3 the average proportion of AS-3CQ was 
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29.6 ±1% which means that majority of infection was composed from the sensitive 
AJ strain.  However later instead of further decreasing (as observed in AS-30CQ 
experiment), the proportion of AS-3CQ stabilised itself at a level of ~20% for the 
remainder of the infection – the lowest observed value was 16.2% and the highest 
26%.  




group (Fig 2.9) initially the resistant strain 
dominated the infection and achieved the proportion of 100% on day 4, when first 
blood samples were taken.  In two of the animals (Fig 2.9 a, d) this proportion was 
maintained until the end of the experiment.  In the other two, however, a gradual 
decrease in the proportion of the resistant strain was observed.  In mouse no 2 (Fig 
2.9 b)) this decline started on day 14 and on day 18 its proportion in the infection 
was 50.35% - similar to the one in the initial inoculum.  In animal n 3 (Fig 2.9 c)) 
the process started on day 9 and by day 19 the proportion of resistant AS-3CQ strain 
was only 13.4%.  In both cases by the time the peak of parasitaemia was reached, the 
sensitive parasites constituted the major part of the infection 




 (Fig 2.10) the resistant strain AS-3CQ was 
selected quickly and reached 100% in all infections.  However, similarly to the 
previous concentration, a drop of AS proportion in one mouse suggested the re-
emergence of the sensitive AJ strain (Fig 2.10 a) is possible.  Interestingly this 
animal was the one that developed the highest parasitaemia and the only one to reach 
a peak of infection during the course of experiment. 




group (Fig 2.11), results of proportional 
sequencing were obtained despite the lack of detectable parasitaemia during the 
course of an experiment.  The interpretation of this data was difficult due to lower 
quality of sequences (most likely caused by the small amount of genetic material).  
However, it suggests the complete selection for resistant strain with the possibility of 
re-emergence of the sensitive strain later in the infection. 




 (the other group in which no 
parasitaemia was observed) no proportional sequencing results could be obtained 
either due to lack of PCR product or very low quality, unreadable sequences.  It 
 70 
suggests that the use of this drug concentration reduced the numbers of parasites in 



























Figure 2.7 The controls for AS-3CQ + AJ infections 
The bars are representing the parasitaemia of   - the untreated AJ infection,  - the AJ infection 




,  - the untreated AS-3CQ infection,  - the AS-3CQ infection 









































































































   
 




















































.   
The changes in parasitaemia (green bars) and proportion of resistant strain in the mixture (orange line) 





























The changes in parasitaemia (green bars) and proportion of resistant strain in the mixture (orange line) 
































































































   
 





























.   
The changes in parasitaemia (green bars) and proportion of resistant strain in the mixture (orange line) 


























.   
The changes in parasitaemia (green bars) and proportion of resistant strain in the mixture (orange line) 






























































































   
 













































































































2.5.1. The confirmation of the phenotypes of studied strains 
The behaviours of the studied strains were consistent with previous studies 
(Rosario, 1976, Padua, 1981) confirming the sensitive, low resistant and highly 
resistant status of the three strains (AJ, AS-3CQ and AS-30CQ, respectively) used in 
the present study.  
The sensitive AJ strain presented a good pattern of growth in the untreated 
controls and was present in significant proportions in all the untreated mixed 
infections.  No growth was observed in any of the treated single infection controls 
and in mixed infection the chloroquine treatment invariably resulted in infections 
composed in 100% from the resistant strain.    
Interestingly the cases of recrudescence suggest that the AJ parasite is present 
in some of the treated infections in low numbers.  It is possible that in favourable 
conditions, such as the reduced CQ plasma concentration following CQ 
administration, AJ can resume growth.  Further research is required whether this 
phenomenon is characteristic for mixed infections only (no recrudescence was 
observed in any of the controls). 
The low resistant AS-3CQ produces good infections in untreated animals.  It 
can also produce moderate but delayed parasitaemias at lower drug concentrations 




).  This parasite is, however, completely inhibited by 





Finally the highly resistant AS-30CQ was able to grow after all the CQ 




for 5 days) although the 
higher concentrations reduced and delayed its growth, relative to untreated controls. 
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2.5.2. The drugging regime to select the highly resistant 
recombinants from low resistant and sensitive ones 





) offer complete selection (varying growth of AS-30CQ, no growth 
of AJ) ensuring that the infection consisted exclusively of the AS-30CQ resistant 
strain until the peak parasitaemia had passed.  Moreover, the AS-3CQ+ AJ 




 (and higher doses) are enough to 
inhibit also the low resistant clone, AS-3CQ.  However, all concentrations used also 
significantly delay and decrease the parasitaemia potentially generating less material 




) treatments are, therefore, 
preferred as these negative effects are lower, although the higher ones may also be 
useful as they are likely to provide a stronger selection.   
As the number of days of drugging doesn’t seem to affect the strength of the 
selection but only the time of re-emergence of sensitive parasites and appearance of 
peak of parasitaemia, the shortest drugging regime has been chosen and used in all 
following experiments. 
As some cases of AJ recrudescence were observed after the peak of 
parasitaemia in order to ensure the optimal selection the parasites were need be 
harvested before it occurs.  As the peak of parasitaemia can be determined only 
retrospectively and can vary great, for practical purposes it was decided that the 
parasites are going to be harvested once the infected animals reached 5% of 
parasitaemia which always seem to occur a day or two before the peak. 
 
2.5.3. The drugging regime to select all resistant recombinants 
from sensitive ones 
Initially all of the concentrations used selected for the resistant strain.  





the parasites reach a detectable peak parasitaemia during the course of experiment.  
Others reduced parasitaemia below the detectable threshold and, therefore, were 
discarded as potential treatment regimes.  Moreover, in the majority of the mice that 
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developed acceptable parasitaemia, the re-emergence of the sensitive AJ strain was 
observed very early and by the time parasites could be observed, AJ was reaching a 
significant percentage of infection.  It makes selection of low resistant recombinants 
of the cross difficult as they are likely to be outgrown either by highly resistant 
recombinants (at the higher drug concentrations) or by the sensitive one (at lower 




is the only concentration that offers 
relatively good (although not complete) selection for resistant parasites when the 
parasitaemia can be observed.  Therefore I decided to use it for the selections, taking 
into account that the results may be distorted by re-emerging sensitive strain. 
 
2.5.4. The fast-growing sensitive parent: implications for the cross 
The sensitive parent AJ used in subsequent genetic crosses has, in untreated 
animals, consistently exhibited higher growth rates than the resistant AS parasites 
(AS-3CQ and AS-30CQ).  It may be caused by the general differences between AS 
and AJ genotypes.  The previous experiments (de Roode et al., 2005) comparing the 
growth of various strains selected from AS-sens and AS-pyr parasite (the progenitors 
of AS lineage, Fig. 1.7.2) to AJ indicated that, despite the observed variation 
between various AS clones, they were overall characterised by the lower virulence 
than AJ strain (both in single and mixed infection).  However, it is also possible that 
the observed differences are caused by the negative effects of mutations conferring 
the CQ resistance in the AS lineage (as discussed in the section 1.3.3.)  
This feature of sensitive parent may have a strong impact on prospective 
crosses.  The higher growth rate of this sensitive parental strain means that the highly 
resistant recombinants would be at great disadvantage when the cross progeny is 
grown without drug selection if they have inherited the AS alleles.  It could 
significantly decrease the numbers of resistant recombinants (or even eliminate them 
completely if the growth disadvantage is due directly to resistant mutations) during 
the drug free passages that take place before the selections.  It has to be taken into 
account during the analysis and interpretation of LGS results (see section 3.5 of 
Chapter 3). 
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2.5.5. Possible fitness cost of chloroquine resistance in 
P.chabaudi 
It was already mentioned that the fitness cost of CQ resistance may be one of 
the factors contributing to the slower growth rate of the resistant parasites compared 
to the AJ strain.  However further experiments (like the competition between the CQ 
sensitive and CQ resistant strain from the lineage) would be required to confirm this 
possibility. 
Additionally some differences could be observed between the behaviour of the 
two resistant AS clones in untreated infections.  In the ‘single infection controls’ the 
highly resistant AS-30CQ clone appears one day later and is reaching a peak 
parasitaemia which is 10% lower than that of the low resistant AS-3CQ.  Moreover, 
during the untreated mixed infection the AS- 30CQ is completely outgrown by 
sensitive AJ strain within the first seven days (i.e. reduced below the threshold of 
detection of proportional sequencing assay for the reminder of the infection).  The 
low resistant AS-3CQ clone instead, in the presence of the same competitor, is 
reduced but is still present to a level of at least 20%.  These data indicate that the 
more resistant clone (AS-30CQ) may have a lower fitness than AS-3CQ.  As the two 
clones are congenic it is possible that this difference is caused by the fitness cost of 
high CQ resistance present in AS-30CQ. 
In Chapter 6 I describe further investigations of this phenomenon and a 
competition experiment between the two resistant strains. 
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3. Generation and LGS analysis of AS-30CQ x AJ 
cross 
3.1. Introduction 
In the next two chapters I describe the use of Linkage Group Selection (LGS) 
to map the loci related to drug resistance in Plasmodium chabaudi.  The general 
description of this method as well as an overview of the experimental design is 
presented in Chapter 1 section 1.8.1.  In summary LGS includes the generation of the 
cross between the resistant and sensitive parent, the phenotypic selection of the 
pooled progeny, and the quantitative analysis of the frequencies of genetic markers in 
derived populations.  Therefore before the start of experiment the resistant and 
sensitive strain, the drug selection regime and quantifiable genetic markers had to be 
decided upon. 
3.1.1. The resistant and sensitive strain 
Two strains with different levels of drug resistance were required for the 
genetic cross. 
AS-30CQ, a clone belonging to the P.chabaudi AS lineage (described in 
Chapter 1 section 1.7.2), was chosen as the drug-resistant parent.  Being the final 
product of three rounds of CQ selection (Padua, 1981); it must contain all of the 
mutations that contribute to the highest level of resistance in the lineage.  Therefore it 
can be used to map all of the loci involved in high-level chloroquine resistance in a 
single series of experiments.  Additionally, recently it has been demonstrated that 
AS-30CQ is also artemisinin resistant even though no selection for resistance to this 
drug was applied.  Consequently the same genetic cross can be used to investigate 
the genetic basis of ART resistance as well. 
The AJ, another P.chabaudi strain, genetically different from AS lineage was 
chosen as the sensitive parent.  Its drug response phenotypes are well-characterised: 
it is sensitive to both CQ and ART.  It has previously been used for numerous genetic 
crosses showing the ability to recombine with the AS genotypes (e.g. Padua, 1981, 
Carlton 1998, Cravo et al., 2003, Culleton et al., 2005, Hunt et al., 2007).  Moreover, 
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a large number of quantitative genetic markers between AJ and parasites of the AS 
lineage were available to map the proportion of parental alleles in the progeny 
(Martinelli et al., 2004 Cheesman et al., 2007). 
3.1.2. LGS drug selection conditions 
The aim of the LGS experiment described in this chapter was to map all of the 
loci involved in high-level CQ resistance.  Therefore a drug dose selecting the highly 
resistant genotypes (containing all the loci under selection) from the rest of the 
population had to be used.  The preliminary experiments described in chapter 2 were 
performed in order to establish the optimal selection conditions.  The 3 day (d 0-2 pi) 




 should select the highly resistant parasites 
from the low resistant and sensitive ones and were used for cross selection. 
3.1.3. Pyrosequencing 
A genome-wide genetic analysis of progeny requires the use of quantitative 
genetic markers, spaced across the genome.  Here, a set of pyrosequencing assays 
was used for that purpose.  
Pyrosequencing markers are based on “sequencing by synthesis” approach and 
can be used to estimate the proportion of SNPs in a mixture, (Fig. 3.1).  As each 
assay is based on the previously identified SNP, in contrast to AFLP or RFLP 
markers, it can be designed in the chosen fragment of the genome and its location is 
known without the subsequent mapping.  Currently >100 of such assays were 
designed between the AS lineage and AJ strain and they have been successfully used 








































Figure 3.1 The use of pyrosequencing to calculate the proportion of SNP based genetic markers 
in the population. 
A single stranded template containing the polymorphism is prepared by PCR amplification with 
biotinylated primer, and hybridisation of the product to the streptavidin beads (a).  It is then 
hybridised with sequencing primer in the presence of an enzymatic complex (including DNA 
polymerase, ATP sulfurylase, luciferase, and apyrase) and the substrates (adenosine 5' phosphosulfate 
(APS) and luciferin . To this mix the dideoxy nucleotides are added sequentially (b). The 
incorporation of each nucleotide by polymerase results in generation of equimolar amounts of free 
pyrophosphate (PPi) which is a substrate of sulfurylase, that catalyses the generation of adenosine 
triphospate (ATP) from APS.  This in turn is used in reaction catalysed by luciferase converting 
luciferin into oxyluceferin and resulting in the emission of light.  The cycle is than completed by 
apyrase metabolising the remaining dideoxynucleotide and ATP.  The emitted light is detected by 
charge coupled device chip and is presented on the output as a peak with the height proportional to the 
amount of the incorporate nucleotide (c).  In each assay the sequence of ~10 nucleotides is added, 
including the two bases of studied polymorphism.  The peaks from the two bases of polymorphisms 
are used in order to calculate the respective proportion of both bases in the mixture.  Other peak 







3.2. The experimental design 
3.2.1. The generation of the cross 
The design of this experiment is presented schematically in Fig. 3.2.  In order 
to generate the initial cross, a group of 5 mice was infected with 10
5
 of a 1:1 mixture 
of the resistant (AS-30CQ) and the sensitive (AJ) strain.  Assuming the similar rates 
of gametocyte generation in by both strains in mixed infection, random mating and 
equally efficient mosquitoes transmission rates of both genotypes; this proportions 
should provide the maximal numbers of recombinant parasites in the cross progeny 
(50%). 
On day 5 post infection, when the mice had developed gametocytes, each 
animal was fed to a mosquito cage containing ~ 200 Anopheles stephensi 
mosquitoes.  Fertilisation, recombination and meiosis took place within the 
mosquitoes.  Booster blood feeds were performed (after 5 days) using uninfected 
mice, to maximise maturation of parasites.   
After 7-8 day post infection, a sample of mosquitoes was dissected to check 
for the presence of oocysts – the transitory parasite stage - and therefore prove 
successful transmission.  The number of oocysts counted was used to estimate the 
total number of progeny present in all the mosquitoes.  Ten days later, when the 
oocysts had burst and the sporozoites had migrated to the salivary glands, the glands 
were collected and used as inoculum to infect another group of 5 mice (such an 
"artificial" infection is generally more efficient then the natural one (i.e. occurring 
during the mosquitoes feeds).  On day 6 p.i. the blood samples were taken from all 
infected animals and the proportional sequencing of pcdhps gene, on chromosome 
14, was used to confirm the presence of alleles from both parents in the infection.  
Then the progeny were recovered and used for further passages and selection.  At 
this step the parasites were frozen down to be used for subsequent selections and 
backcrosses. 
3.2.2. The amplification of the cross progeny 
The extra amplification step had to be introduced in order to generate enough 
progeny to infect all animals for selection.  In order to amplify the parasites while 
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maintaining the diversity of the population, the cross was passaged in two groups of 




 3 days (d 0-2) and one 
left untreated.  The treatment was used in order to preserve the highly resistant 
parasites that otherwise might have been eliminated from the cross due to their lower 
fitness.  
When the mice in both groups reached the detectable parasitaemia the parasites 
were mixed in a 1:1 proportion and used to infect the animals for subsequent 
selection.  
3.2.3. Selection 
During the selection, four groups of 4 mice each were infected with 10
6
 of AS-




 respectively.  
The growth of parasites was monitored and when all parasites from the groups 
reached > 5% parasitaemia the mice were killed and bled out.  The blood from all 
animals from the same group was pooled and DNA isolated for further genetic 
analysis. 
3.2.4. Genetic analysis 
The allele frequencies of the genetic markers in the population were estimated 
using the AS/AJ pyrosequencing assays and the generated data were analysed to 
detect selection valleys.   
Out of ~100 developed pyrosequencing assays 66 were used for the analysis 
presented in this chapter (see Appendix C for the detailed list).  Initially 3 or 4 
markers on each chromosome were chosen in order to assess the overall shape of the 
genome scan.  Later additional assays were added starting with the regions of 
particular interests (like chr 11, 2 or 7 that have previously been connected with CQ, 
ART and PYR resistance respectively) with the intention to test all the available 
markers.  The addition of new markers however was stopped after the analysis of 







Figure 3.2 The schematic diagram of AS-30CQxAJ LGS experiment 
The full arrows represent the transfer of the parasites, the dashed ones – a sample taken for control 
step.  The number inside each mouse represents the number of animals used. The drugging regime 
























3.3. Materials and methods 
3.3.1. Parasites, mice and mosquitoes: 
The origins and phenotypes of the resistant AS-30CQ strain and the sensitive 
AJ have been described elsewhere (Chapter 2, section 2.3.1.).   
10-12 week old CBA mice were used for passage and selection of parasites.  
10-14 week old C57BL/6 black mice were used for mixed infections for mosquito 
feeds as this strain is known to develop higher gametocytemias and milder disease 
symptoms compared to CBA mice (Richard Carter, Paul Hunt, personal 
communication).  All animals were housed and fed as described in section 2.3.1 
The mosquitoes for the experiments were taken from the Anopheles stephensi 
colony maintained at the University of Edinburgh under standard insectary 
conditions; 27°C temperature, 70% humidity, 12h/12h light/dark cycle, and 
unlimited access to water supplemented with 10% glucose.  Routinely, female 
mosquitoes were allowed to feed on rats and to deposit eggs in eggbowls provided 
for 2 days, 2 days after each rat feed.  Experimental pupae were collected from low-
density larval trays and allowed to hatch in experimental cages (~250 pupae per 
cage).  One day before feeding to infected mice, the glucose solution was replaced 
with water.  
3.3.2.  Mouse infections 
All single and mixed infection were set up, drugged and monitored as 
described in sections 2.3.2,- 2.3.4. of chapter 2. 
3.3.3. Mosquito feeds 
On day of feeds the mice were anesthetised with Rompun/Vetaler mixture and 
placed on the top of mosquito cages, one mouse per cage.  The mosquitoes were 
allowed to feed for 20 minutes.  The mice were killed immediately after feeding.  
The booster feeds were arranged similarly. 
3.3.4. Dissection for oocysts 
A sample of 10 mosquitoes from each cage was dissected.  The mosquitoes 
were killed with chloroform and placed under binocular dissecting microscopes.  
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Two cuts were made between abdomen and thorax using syringes with needles 
attached.  Then the abdomen and thorax were pulled apart. The exposed gut was cut 
out and suspended in a drop of Ringer solution.  These guts were placed on 
microscope slides, covered, and observed under microscope in order to count 
oocysts. 
3.3.5. The recovery of sporozoites from salivary glands 
16-17 days after infection mosquitoes were killed with chloroform and 
dissected.  Needles attached to syringes were used to separate the head and salivary 
glands attached.  The glands were removed, suspended in 50% Ringer/Fetal Calf 
Serum solution (see Appendix A) and sheared in a glass mortar with Teflon pestle.  
The resulting suspension was diluted to an appropriate volume (allowing the 
injection of 100ul per mice) and injected intraperitoneally into a new group of mice  
3.3.6. The proportional sequencing of dhps gene 
As described in section 2.3.5 of chapter 2. 
3.3.7. Large scale DNA isolation 
In order to isolate the parasite DNA, the mouse blood was put through two 
columns, containing fibrous cellulose powder, and two Plasmodipur filters (Euro-
Diagnostica) in order to remove the mouse white blood cells.  The RBC obtained 
were lysed with 0.15% saponin solution and washed with PBS buffer till the 
supernatant was clear.  The resulting parasite pellets were re-suspended in parasite 
lysis solution (see Appendix A) and incubated at 37
o
C overnight.  From the lysed 
solutions, DNA was extracted with standard phenol/chloroform extraction protocol 
and ethanol precipitation. 
3.3.8. Estimation of frequencies of genetic markers using the 
pyrosequencing 
3.3.8.1. Design of pyrosequencing assays 
 
The design of pyrosequencing assays set was a collaborative effort to which many 
people contributed.  My part in this project consisted on design of 7 pyrosequencing 
assays on chromosome 11 (marked in the table in Appendix C) 
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Each pyrosequencing assay was based on SNPs identified between the AS and 
AJ.  Because the complete P. chabaudi genome was not yet available, the 
Plasmodium falciparum genome (http://www.ncbi.nlm.nih.gov/Taxonomy/Browser 
/wwwtax.cgi?id=36329) and the known syntenic relationships between the 
P.falciparum and rodent malaria (Kooij et al., 2005) was used to place assays in the 
desired positions..  The following approach was used  
• a fragment of P.falciparum genome syntenic to the locus of interest in 
P.chabaudi was identified using the syntenic map generated by Kooij et al.,  
• a protein encoded by the gene situated within that region was chosen and used 
to search the translated contig sequences of P.chabaudi database 
(http://www.sanger.ac.uk/cgi-bin/blast/submitblast/p_chabaudi) 
• .the identified contig’ sequence was compared back to the P.falciparum 
protein database in order to confirm the unique match 
• DNA sequence in syntenic contigs was used to design SNP finding primers  
• a ~1000 bp fragment from the genomes of AS and AJ parasites was sequenced 
using dideoxy sequencing.  The genetic distance between the two strains 
ensured that within most of the 1000 bp fragments one or more SNPs could 
normally be identified.   
• the discovered polymorphism and surrounding sequence was used to design 
the pyrosequencing primers used in the PSQ Assay design software (Biotage).  
Each assay was composed of three primers – two amplifying primers (one of 
them biotinylated) and one sequencing primer. 
Each assay was named according to its putative orthologue position in the 
P.falciparum genome.  Pcpfxx-yyyy annotation was used where xx is the 
chromosome and yyyy is the putative distance on that chromosome in kb (e.g. assay 
06-1001 was localised on the fragment of the genome syntenic to the one found 1001 
kb from the left along chromosome 6 in P.falciparum).  The effort was taken to space 
the designed assays at the regular intervals across the genome and to keep the 
distances of less than 100 kb between the assays.  However it was not always 
possible because either no suitable polymorphism could be found in the particular 
region, or no working assay good be deigned based on it. 
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3.3.8.2. Pyrosequencing 
The PSQ 96A HS pyrosequencing system from Biotage (currently acquired by 
QIAGEN, http://www.pyrosequencing.com) was used to estimate the proportions of 
SNP alleles in the progeny.  DNA was amplified using the primers designed in 
previous section (see Appendix C for the complete list), the standard PCR protocol 
(see Appendix B) and the following PCR program: 
 
Temperature Time 








The amplified PCR product was purified using the streptavidin beads, mixed 
with the sequencing primer and inserted into the PSQ 96A HS machine according to 
the manufacturer’s instructions.  The PSQ_HS_96A software was used to program 
and control the run. All consumables and reagents used for these parts of the 
experiment were supplied by Biotage/Qiagen. 
In order to minimize the technical variation for each marker, all the sample 
DNAs and the negative control were genotyped during the same run (same 96 well 
plate) whenever possible.  All analysis was performed in triplicate using 
independently amplified products.   
3.3.8.3. Data analysis 
The three replicates for each assay were averaged.  As a general guideline, 
when the standard error of the mean was >~5% of the mean itself, the assay was 
repeated and if no improvement showed, discarded from the analysis   
29 x 
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The comparative index (CIi) was calculated for each SNP marker by dividing 
the AJ allele frequency at assay i in the treated population (treatedi) by the AJ allele 










The comparative index is therefore a measure of the change in allele frequency 
of a marker between the treated and untreated population. 
The marker frequencies and/or CI were plotted against their cumulative 
genomic position in P.chabaudi.  Initially it was calculated using the distances 
between the markers estimated according to P.falciparum genome with extra 50 kb 
added at the end of each chromosome in order to account for P.chabaudi specific non 
syntenic regions.  Later after the publication of assembled P.chabaudi genome the 
distances between the markers were adjusted according to P.chabaudi data.  The 





3.4.1. Generation of the AS-30CQxAJ cross 
The 5 mice carrying mixed infections of resistant and sensitive strains were 
used to infect mosquitoes in 5 cages.  Oocysts were detected in three cages (Table 
3.1).  The two cages with the highest oocysts count per mosquito (Cage 1 and 2, with 
means of 16.4 and 3.45, respectively) were chosen and the salivary glands from all 
the females (73 from first cage and 55 from the second) were dissected and used to 
infect the new group of 5 mice.  
Once the infections developed in all 5 animals, proportions of pcdhps AS/AJ 
alleles in the recovered progeny were estimated, using proportional sequencing.  The 
results are shown in Table 3.2.  No PCR product could be obtained from one of the 
mice. The proportion of AJ alleles in the other four cages lay between 52% - 67%.  
These data indicate the presence of both parental alleles in these infections.   
 
Table 3.1 The results of mosquito dissections for AS-30CQxAJ cross.   
The number of oocysts found in each mosquito is given.  When the number of oocysts was too large 
for the exact count, an estimate (~) is given.  The results from the cages chosen for salivary glands 




Cage 1 Cage2 Cage 3 Cage4 Cage5 
1 10 ~50 0 0 0 
2 1 12 0 0 0 
3 3 2 1 0 0 
4 4 0 0 0 0 
5 0 0 0 0 0 
6 0 0 3 0 0 
7 9 0 7 0 0 
8 11 0 4 0 0 
9 0 ~55 7 0 0 
10 0 ~45 2 0 0 






















Table 3.2 The results of proportional sequencing of recovered progeny from AS-30CQxAJ 
cross. 
 
3.4.2. Selection of the cross 
In order to ensure that the LGS analysis was carried out on a population 
containing both CQS and CQR parasites, the propagated parasites were passaged in 




 and re-mixed.  These pooled 





in order to select for the high CQ resistant parasites.  The parasitaemias in 
each group were monitored and the results are shown in Fig 3.3. 
In the untreated animals the parasites exhibited the fastest growth appearing on 
day 3 and reaching over 20% parasitaemia on day 6.  All the treated mice also 
developed parasitaemia.  However, parasites appeared much later than in the 
untreated group and this delay was correlated with the concentration of drug used 





group respectively).  These growth curves were very similar to those observed 
in AS-30CQ+AJ mixtures during the experiment described in Chapter 2 (Fig. 2.5 and 
2.6 Chapter 2). 




2 66.9 % 
3 52.2% 




Parasites were harvested when all mice from each group had reached >5% 





































Figure 3.3 The parasitaemia of AS-30CQxAJ cross 








3.4.3. The quantitative genetic analysis of the initial cross 
Having isolated the DNA, the frequencies of parental alleles at 66 SNP 
markers distributed across the genome were estimated.  The resulting genome scans 
are presented in figure 3.4.  
3.4.3.1. Untreated population 
In the untreated population we observe very high frequencies of AJ alleles 
across the whole genome (Fig. 3.4a). The average percentage of the sensitive (AJ) 
parental alleles was 89.9% (range 77.5 – 100%).  Overall, the distribution of parental 
alleles across the genome is very uniform – no selection valleys were observed.  This 
distribution (~90% AJ) contrasts with estimations of AJ pcdhps allele frequency in 
the untreated progeny arising from the sporozoite infections in which more even 
proportions of both strains were observed (Table 3.2).  Therefore the parasites 
containing mainly AS alleles appear to have been lost during the growth in untreated 
animals. 
3.4.3.2. Treated populations – general picture 
All the treated populations gave similar genome scans to each other but 
strikingly different to that arising from the untreated population (Fig 3.4 b-d).  
Overall, the genome-wide mean percentage of AJ alleles in the treated mixtures 
was strongly decreased in comparison to the untreated population, being on average 













.  These data suggest that, in general, AS alleles are being selected, 
or at least maintained, by the drug. 
The dominant feature of these scans is the extremely bimodal distribution of 
parental allele proportions: i.e. markers have either a very high or a very low AJ 
proportion with few markers showing intermediate values.  For example, in all three 
scans, markers on chr 7 all show high AJ proportions (>90 % AJ) while those on chr 
8 are universally decreased (<25% AJ).  Furthermore, there are many instances 
where a bimodal distribution can be observed within a chromosome.  For example, 
chr 1, 2, 6, 9, 11 and 13 all contain markers with a strong bias towards either AS or 
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(when no markers with a value between 20 and 80% AJ allele can be observed) and 





Overall, these data give the appearance that whilst drug treatment appears to 
have decreased the total proportion of AJ alleles (genome-wide), individual AJ 
markers tend to be close to either 0 or 100%.  Many regions of the genome therefore 
appear to show heavy selection (either positive or negative).  
3.4.3.3. Treated population – potential loci of CQ selection? 
In total around 60% of the tested markers show the reduction of AJ allele 
between the untreated and treated population – a sign of potential CQ selection.  On 
at least five chromosomes (3, 5, 8, 11 and 12) all markers are consistently decreased 
with all three treatments and many single markers on the other chromosomes are also 
strongly reduced.  In some cases the group of decreased markers forms a shape that 
could be interpreted as selection valley (e.g. chr 5, 8 and 11).  More often however, 
the small number of markers and/or sudden changes of frequency (e.g. chr 13) do not 
allow a definitive interpretation.   
Interestingly in all the cases, the selection seems to be the strongest at 
10mg/kg/day of CQ and not at the highest concentration.  



























Figure 3.4. The results of genome scan of AS-30CQxAJ cross. 
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pyrosequencing assays are plotted against the cumulative genome distance described in section 
3.3.8.3.  The lines are separating the different chromosomes.  The results are presented either as the 







































































Figure 3.4 The results of genome scan of AS-30CQxAJ cross. 
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3.5.1. The AS-30CQxAJ cross 
Several data suggest that a cross between the resistant and sensitive parent was 
successfully generated.  A number of mosquitoes with 10 oocysts were sampled, 
suggesting quite intense transmission.  Moreover, after propagation of the progeny, 
proportional sequencing indicated the presence of both parental alleles of pcdhps 
gene (chr 14) in the parasite population, in very even proportions (around 60:40).  
Although this single locus may not be representative for the rest of the genome, the 
fact that both parasites are represented in proportions very similar to those in the 
original inoculum (50:50) supports the speculation that no major allele loss/selection 
was observed in mosquito transmission.  Also the behaviour of the cross during 
selection (very similar to those of mixtures of resistant and sensitive parents in the 
same conditions) suggests a balanced content of resistant and sensitive parasites.  
An essential factor decisive for cross quality however is how many 
independent recombinant parasite genotypes are present in the progeny:  The amount 
of recombination events is decisive for quality of the cross and the mapping of traits. 
In total the progeny of ~1200 oocysts were recovered.  Therefore, assuming the 
random mating and equal proportions of both strains in the pool of gametocytes 
contributing to the fertilisation, around 600 resistant recombinant clones were 
generated, which should be enough to map the major resistance loci.  Unfortunately, 
there is no easy way to estimate how many recombinants are present in the 
population so these numbers could not be confirmed.   
3.5.2. The untreated population – the selection for multiple loci for 
virulence? 
In the untreated population a uniform, high percentage of AJ alleles at all the 
tested loci was observed.  A possible explanation would be that this high baseline 
reflects the high proportion of AJ gametocytes in the mosquito meal/better survival 
of AJ genotypes in mosquito host etc.  In that case the population composed from 
80% of AJ and 20% of AS gametes would manage to recombine and produce 
progeny).  However the proportion of alleles in samples taken soon after propagation 
suggested more equal proportions of both strain.  Therefore, it was concluded that 
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parasites with higher-than-average combinations of AJ alleles were selected during 
growth in untreated mice. 
Because in mixed infection without the drug treatment, AJ grows faster than 
AS-30CQ (see section 2.5.4.) selection of AJ alleles at loci underlying this “growth 
advantage” was expected.  This trait is likely to be multigenic, involving genes 
expressed in many different pathways like DNA replication, erythrocyte invasion and 
re-modelling or immune system evasion etc.  All of these processes may undergo 
some level of selection during the rounds of asexual growth.  If the number of 
selected loci is high enough (e.g. 2-3 on every chromosome), instead of few isolated 
“selection peaks” we will observe a uniform level of selection across the whole 
genome.  In other words, the parasites that inherited a significant portion of AJ 
genome will grow better than the ones that are carrying mostly AS alleles, effectively 
regardless of their position on the genome.  Moreover our population contains a 
significant amount (~25% if the assumptions mentioned in section 3.5.1. are 
fulfilled) of AJ parasites being the results of mating of two AJ gametes. Presence of 
the fast growing AJ parasites that were likely to constitute a substantial proportion of 
infection was likely to uniformly increase the percentage of AJ allele at all loci, thus 
further increasing the baseline of genome scan (even for non-selected chromosomes). 
It is most likely explanation of observed results.  
3.5.3. The treated population – many loci under selection or 
sampling error? 
In contrast, in all three treated populations, a highly bimodal distribution of 
allele frequencies was observed (most markers showed either ~0% or ~100% AJ 
proportion).  In the two highest drug concentrations almost no markers with 
intermediate allele frequency were observed.  Moreover, large fragments of the 
genome (for example across adjacent markers) appear to have been inherited from 
one or other of the same parent.   
One explanation would be that these selection signatures are the biological 
reality.  The chloroquine resistance might be controlled by say 10 loci (which would 
be in a striking contrast with low CQ resistance in AS-3CQ mapped to a one single 
locus (Hunt et al., 2004b)) and the strong selection on them would decrease the 
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frequency of the whole group of surrounding markers.  The rest of the genome would 
be selected for AJ alleles (rapid growth) as proposed in the previous section.  This 
might result in the observed polarisation.  In that case, the treatment would be 
selecting for one specific combination of parental genotypes – a “superparasite” 
being the perfect balance between the high drug resistance and high growth rate. 
There is however another, more worrying possibility.  Similar results could be 
obtained if a very low number of recombinants was sampled in the quantitative 
genotyping.  Whole chromosomes would appear to be selected because few of the 
resistant recombinants happened to carry it.  It would also explain the sudden 
changes of frequency between the neighbouring markers (what we call the scatter of 
the data) – it would simply reflect the single crossing over event in one major 
recombinant.  In that case instead of optimal genotype(s) the scan would represent an 
extremely small number of recombinants that by chance managed to dominate the 
infection.  
3.5.4. The loss of recombinants? 
The main concern arising from the genome scan of the treated populations is 
that a very low number of recombinants may be present in the analysed progeny 
either because a very low number were generated during the cross or because of 
massive loss that occurred during propagation and passage in the generated 
population. I found the latter more likely. Unfortunately, maintaining Plasmodium 
parasites in the laboratory involves bottlenecks where parasite numbers are greatly 
reduced; for example, passage from mosquito to mouse, from one animal to another, 
freezing down and rethawing.  Bottlenecks will eliminate some of the parasites and 
their genotypes.  Moreover, each day of an infection gives parasite the chance to 
compete with each other.  In the present case, previously obtained data suggests that 
there are fitness differences between the resistant and sensitive strain (described in 
chapter 2) and possibly fitness costs of the chloroquine resistance mutation itself (see 
section 2.5.5. of Chapter 2).  Thus most of the parasites eliminated over time may 
tend to be resistant recombinants. 
In that situation the original plan to increase the number of pyrosequencing 
markers in order to obtain better resolution of putative selection valleys was 
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discarded as it was unlikely to substantially improve the quality of the data.  Instead I 






4. Generation and genetic analysis of AS-30CQ x AJ 
backcross 
4.1. Introduction 
This chapter features the backcross of the progeny of AS-30CQ x AJ cross to 
the sensitive parent AJ and its analysis in the search for loci involved in the 
resistance to chloroquine and artemisinin.  These new experiments exploit previous 
work and introduce some modifications to the original protocol, aimed to improve 
the quality of the cross, selections and data analysis. 
4.1.1. Rationale for backcross 
In Chapter 3, I described the cross between AS-30CQ strain (selected for high 
level of chloroquine resistance and spontaneously artemisinin resistant, see section 
1.7.2.) and a genetically different sensitive strain, AJ.  The conclusion reached was 
that the quality of the original cross was not sufficiently diverse to study the 
resistance loci in sufficient detail – either because the trait is determined by multiple 
(>10) loci or because the tested population is dominated by a small number of 
random recombinants.   
In such a case the backcross to the sensitive parent can be used to improve the 
results.  It is preferred to the generation of a new cross as, in addition to creating new 
recombinants, it introduces additional crossing-overs in already existing ones and 
saturates the population with alleles from sensitive parent.  It improves the genome 
scan in at least two ways (Fig. 4.1).  Firstly the increased percentage of sensitive 
alleles at all the loci lifting the baseline of the genome scan and eliminate the 
majority of false positives that may appear as selection artefacts.  Therefore “real” 
selection valleys are easier to identify.  Secondly, the increased amount of 
recombination events narrows the selection valleys, allowing its lowest part to be 






Figure 4.1 The improvement of data quality by the backcross.  
The full line presents the hypothetical genome scan of the cross and the dashed one of the subsequent 
backcross.  The valley on the left side of the diagram (in the cross) represents the false positive – an 
accidentally selected part of the genome, eliminated in the backcross, and the right one- a selection 
valley selected by the resistance.  
 
 
4.1.2. Modifications of LGS protocol- aiming for a higher number 
of recombinants 
As mentioned previously, one of the main concerns arising from the analysis of 
original cross is that only a small handful of resistant recombinants may be present in 
the final population.  Therefore the main objective of the backcross should be to 
obtain high numbers of progeny and make sure that they survive to the selection.   
A number of modifications designed to generate and maintain higher numbers 
of recombinants were considered: 
 The donor mice for mosquitoes’ infections were treated with erythropoietin.  
This drug is known to increase the numbers of gametocytes in animals by 
stimulating the production of reticulocytes (parasites infecting reticulocytes 
are more likely to become gametocytes) (Reece et al., 2005).  Increased 
gametocytaemia before the feeds should result in increased transmission to 
the midguts of mosquitoes and in consequence generate more recombinants 
 At various stages parasites were grown independently in untreated and treated 
mice and then pooled.  This would retain the sensitive, fit parasites (that are 
going to be transmitted in untreated infection) and the highly resistant, slower 
growing parasites that can survive in treated infections, in order to supply a 
diverse population of recombinants for cross or drug-selections.  
 Laboratory procedures (passages, deep freezing) that may cause 
‘bottlenecking’ prior to selection experiments were minimised. 
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4.1.3. Modifications of selection procedure – the use of low, 
intermediate and high drug concentration 
In Chapter 3 selection protocols aimed to select the highly resistant 
recombinants and thus map onto one genome scan all of the loci involved (see 
section 3.1.2 in Chapter 3).  The results suggested that a large number of loci may be 
selected.  In this chapter, the backcross is treated with multiple drug concentrations 
that were designed to select recombinants of various level of resistance and thus 
reveal a fine resolution of loci conferring low resistant, intermediate and highly 
resistant phenotypes.  These multiple selections can be used to maximise the chances 
to map all of the responsible loci and the relationship between them.  For example, if 
the loci are acting independently, we are likely to select all of them with low drug 
concentrations although none of them will be fixed in the population.  The higher 
doses would gradually deepen the valleys (Fig. 4.2a).  On the other hand, if some loci 
contribute only to increase a pre-existing resistance but do not confer any advantages 
by themselves, with increasing drug concentration we may observe first the selection 










Figure 4.2  Predicted patterns of appearance of selection valleys in an experimental population.   
All the graphs are schematic representations of whole genome scan.  The two paths are representing 
the loci either acting independently and selected together (a), or acting one on a top of another and 




No drug Low Intermediate High 
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4.2. Experimental design 
Figures 4.3 and 4.4 present a schematic of backcross and selections of obtained 
progeny.  
4.2.1. Pre-selection of the cross and genetic analysis of obtained 
material 
In order to generate the mixture of parasites containing both resistant and 
sensitive recombinants from the previous cross, the parasites were recovered from 




 for 3 days 
(Fig 4.3).   
After being used as donors for the backcross, the mice from three pre-selected 
groups were bled and parasite DNA was isolated for genetic analysis.  The genome 
scan was performed on each sample as described in section 3.2.4. using 59 
pyrosequencing markers (see Appendix C for details).  This was primarily done in 
order to estimate the quality of the material introduced into the backcross (the 
proportional sequencing of one locus could no longer be used for this purpose 
because of the presence of recombinants in the mixture).  However this quality 
assessment also supplied a new set of genome scans, that could be used for the 
identification of the resistant loci (if the data quality is better than the one obtained in 
the initial selection in Chapter 3). 
4.2.2. Generation of the backcross 
The populations generated in the pre-selection were mixed with sensitive 
parent AJ (using the protocol described in section 2.3.2.3.) in following proportions: 
 
AJ: 30% 
cross treated with 0 CQ 10% 













The prepared mixture was injected into the set of five C57 mice pre-treated 
with erythropoietin and grown for 5 days before mosquito feeds.  The cross protocol 
described in chapter 3 was followed. 
The progeny were recovered into a group of 10 animals, with sporozoites from 
each mosquito cage injected into 2 specific mice.  The resulting parasites were 
subjected to two series of selections, called Selection 1 and Selection 2 (Fig 4.3 and 
4.4, respectively). All CQ concentrations used in these selections were established in 
Chapter 2.  The ART concentrations were determined from the similar phenotyping 
experiments performed by Richard Fawcett and Louise Rodrigues (data not shown).  
 
4.2.3. Selection 1 
Selection 1 aimed to discover the contribution of loci to the different levels of 
CQ resistance.  It was performed immediately after the progeny was recovered from 
the backcross (the use of the larger numbers of mice made it possible to skip the 
amplification step used in the original cross procedure).  4 groups containing 5 mice 
each were set up and treated for the first 3 days of infection as follows: 
 no drug –allows the growth of all the parasites and can be used as a control 
for other groups 
 1.5 mg CQ kg-1 day-1 –a low concentration that should separate of all the 
resistant parasites (even those with very low level of resistance) from the 
sensitive ones.  It has to be reminded however that the previous results 
obtained with that concentration were very variable (see Fig 2.8) and some 
recrudescence of sensitive parasites was possible in with that treatment 
regime. 
 5 mg CQ kg-1 day-1– the intermediate concentration that had been proven to 
kill the sensitive parasites and significantly delay the growth of low resistant 
ones.  We aimed to select the intermediate and highly resistant progeny with 
this treatment. 
 10 mg CQ kg-1 day-1– the high concentration chosen to select for the most 




4.2.4. Selection 2 
Selection 2 was subsequently designed to optimise the data obtained in 
Selection 1.  The starting parasites were obtained from a sample of parasites deep-
frozen from the mice used to recover blood forms from sporozoites (Fig. 4.4).  These 




 and then pooled.  This pool 










4.2.5. The genetic analysis of backcross progeny 
The parasites were harvested before the peak of infection and analysed using 
the set of quantitative pyrosequencing markers as described in previous chapter (see 
section 3.2.4.).  For the selection 1, 60 markers were tested before it was judged that 
the addition of supplementary ones will not result in substantial data improvement 
(see section 4.5.1.).  For selection 2 all available markers (and some new ones 
designed in the loci of interest) were tested in order to map the potential loci 
involved in the resistance with the high resolution.  In total the data from 93 assays 
were obtained (see Appendix C).  Additionally the data from selection 2 was 




Figure 4.3 The backcross and selection 1 of its progeny.   
Parasites from the AS30CQ x AJ cross were recovered and pre-selected with 0, 1.5 and 10 mg 
CQ/kg/day.  The surviving parasites were pooled and mixed with AJ parasites to generate the 
backcross.  The resulting progeny were recovered in 10 mice and both frozen down (for use in 
Selection 2) and selected in Selection 1.  The solid arrows represent the transfer of the parasites; the 
dashed arrows represent ‘monitoring’ steps.  The number inside each mouse represents the number of 
animals used in that step. The drugging regime used is shown above each mouse (all animals were 
treated on days 0-2).  DF-parasites put into/taken from deep freeze; violet shading - mice used for 






































Figure 4.4  Selection 2 of the progeny of the backcross 





The mix of both populations was used to inoculate mice for selection. The full 
arrows represent the transfer of the parasites.  The number inside each mouse represents the number of 
animals used in that step. The drugging regime used is shown above each mouse (all animals were 



























4.3. Materials and Methods 
Most of the Materials and Methods used in this chapter were described in 
Chapter 3. Only the details of additional methods are mentioned here. 
4.3.1. EPO treatment 
The C57 mice used for mosquito feeds were treated with mouse erythropoietin 
(Roche) for 5 consecutive days starting two days before the parasite injections (d -2 
to 2 p.i.).  The EPO was diluted with water to 100U l
-1
 and injected intraperitoneally 
in a volume of 100 l per mouse per day. 
4.3.2. The recovery of the cross progeny from liquid nitrogen 
The cryopreserved parasites were defrosted in ice and the deep-freeze solution 
was removed by a series of three washes in 1) 12% sodium chloride. 2) 1.6% sodium 
chloride 3) 0.9% sodium chloride, 0.2% glucose.  The recovered parasites were re-
suspended in equal volume of citrate saline and injected intraperitoneally into 
uninfected mice in a volume of 100 µl per mouse 
4.3.3. Artemisinin treatment 
For artemisinin treatments, the pre-calculated amount of artemisinin powder 
(Amersham, UK) was weighed and dissolved in Dimethyl sulfoxide (DMSO) to 
obtain the highest needed concentration.  Lower concentrations were achieved by 
further dilution with DMSO.  The mice were force-fed with drug solutions using 
gavage needle.  
4.3.4. Statistical analysis 
The statistical analysis described in this section was designed and performed by 
Laurence Loewe, Dario Beraldi and Paul Hunt 
In order to test whether observed selection valleys are significant, two different 
statistical approaches have been developed.   
 108 
The first one is based on computer simulations.  The population of virtual 
parasites (each containing 100 genetic markers spaced across the gnome at distances 
equivalent to the ones used in the real experiments) was generated.  The 
experimental design (generation of recombinants, rounds of asexual replications, 
selection of the population and sampling of genetic material for analysis) was 
modelled.  Then, LGS scans were simulated under the null hypothesis (i.e. the 
hypothesis that we want to disprove with calculated significance) that the resistance 
in due to a large number of independently acting loci.  With no dominant loci, no 
selection valley would be observed, so any fluctuations in the observed allelic 
frequency would be due to variation in allele sampling, experimental error etc.  After 
running the simulations 500 times the frequency with which the selection valley of 
given depth appeared in the model could be calculated and use to assign the P-value 
of similar valley observed in the experimental data.  For example, if a selection 
valley of a given depth would be observed in one out of 10 simulations the P-value 
of this valley when it is observed in our experiment is P=0.1 and therefore it is 
discarded as insignificant.  If however we observe the selection valley that appears in 
one out of 10 000 simulations, with P=0.001 we consider it significant. 
The second approach consists of comparing the mean of sliding windows 
containing 3-5 alleles from the same chromosome in the treated population, with the 
mean of all the alleles from untreated population.  In order to make the test more 
stringent, the values of all AJ allele frequencies in the untreated population are 
reduced by an arbitrary percentage (25%), reflecting the overall decrease of 
frequency of AJ allele in treated populations (caused by the elimination of sensitive 
parental genotypes and part of the recombinants).  To estimate the P-value, Mann-
Whitney U-test was used because it does not require any prior knowledge about the 
data distribution.  With this method the groups of markers that are decreased more 
than average can be identified. 
 
 109 
4.4. Results  
4.4.1. Reselection of cross progeny 





place prior to the genetic cross.  All animals developed parasitaemia as expected 
(data not shown).  After the collection of blood necessary for the backcross, the 
genome scans were performed on the remaining material in order to assess the 
quality of the populations introduced in the mixed infection (Fig 4.5).   
The presence of alleles from both parents was observed throughout the genome 
in all the three populations.  In general the data replicated the results from the 
selection experiments in Chapter 3 with the lack of treatment increasing the 




causing the high representation 
AS alleles in many loci.  Additionally the variation was observed between the 
markers suggesting the presence of recombinants in all infections.   
Therefore the mixture of the pre-selected populations with AJ parent was likely 






























































































































































































































































4.4.2. The generation of the backcross  
The mixture of pre-treated infections and AJ parasites was set up as described 
in section 4.2.1 and fed to 5 mosquito cages (250 mosquitoes each).  The results of 
oocyst dissections are presented in Table 4.1 together with an estimation of oocysts 
present in each of the cages.  This analysis suggests that a total of ~8800 oocysts 
were produced.  All the female mosquitoes were dissected and the sporozoites 
recovered in new group of 10 mice. 
 
Table 4.1 Oocyst analysis during backcross generation.   
The average number of oocysts per mosquito and number of dissected mosquitoes leads to estimates 
of the number of oocysts obtained from each cage. 
Mosquito 
number 
Cage 1 Cage2 Cage 3 Cage4 Cage5 
1 12 24 ~60 6 1 
2 0 38 20 24 3 
3 6 ~30 1 9 5 
4 ~30 1 17 12 0 
5 27 5 ~40 21 9 
6 0 25 26 0 2 
7 10 ~50 15 7 0 
8 1 17 ~30 ~35 0 
9 0 22 3 0 2 
10 3 ~40 2 2 0 




112 133 102 183 102 
Estimation 
of oocyst in 
cage 
996.8 3351.6 2182.8 2122.8 224.4 
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4.4.3. The selection of the backcross 
4.4.3.1 Selection I.   






All parasites developed parasitaemias (Figure 4.6).  In the untreated group 
parasites appeared on day 3.  In the treated groups the onset of infection was delayed 
in proportion to the concentration used (parasites emerged on day 5,10 and 12 
respectively).  Groups of mice were killed on day 6, 8, 13 and 16 respectively and 
DNA recovered for genetic analysis.  
 
4.4.3.2. Selection II.   
The parasites were selected in 7 groups of mice – untreated and treated with 








.  The 
growth of parasites is presented in Figure 4.7.  The parasites grown in CQ-treated 
and untreated animals behaved as in the previous experiments; i.e. that the delay of 
parasitaemia was proportional to the drug concentration used.  For example in the 




 parasites appeared on day 7 and reached 
~25% on day 10 when mice were bled for parasites.  Artemisinin treatments also 
delayed the appearance of parasites and the growth in these infections was 
comparable to those observed with the highest CQ treatments.  For example in the 




 parasites were growing in parallel with 














Parasites were harvested on the following days – untreated and those treated 

















on day 11 































































































4.4.4. The genetic analysis of the backcross – selection I 
The frequencies of alleles at 60 parental markers were tested in all selected 
populations.  The data obtained (AJ allele percentages) is presented in Figure 4.8a-d.  
Comparative indices (allele proportions in drugged samples relative untreated 
samples) are shown in Fig 4.9 
4.4.4.1. The untreated population 
Here, a uniformly high (90 ± 1.1%) percentage of AJ markers is observed 
along the genome (Fig. 4.8 a).  It is consistent with the behaviours of the original AS-
30CQ x AJ cross that showed similarly high proportions of AJ markers in untreated 
infections 
4.4.4.2. The 1.5 mg CQ kg-1 day-1 treated population  
Here also the majority of the markers showed a high proportion of the sensitive 
allele (80.1 ± 2.2 %) similar to the untreated population (Fig 4.8b).  This time 
however one strongly reduced group of markers can be observed on chromosome 11.  
The lowest marker on this chromosome (pcpf 06-1338) is reduced to 23.3% 
(compared to 72.2% in untreated population).   
4.4.4.3. The 3 mg CQ kg-1 day-1 treated population.   
The baseline AJ allele frequency is 72.1 ± 2.5% and the markers are much 
more scattered. (Fig 4.8c).  Again the most prominent feature of the scan is the 
selection on chromosome 11 (now greatly deepened - the lowest marker, pcpf 06-
1004, is 18.6 %).  Moreover, some other markers are reduced in comparison to both 




).  Notably, markers on 
chr 3 shows signs of selection -the three markers on this chromosome (pcpf 02-0275, 
pcpf 02-0452, pcpf02675) are reduced from 90, 90, 82 % (untreated) to 49, 54 and 
58% respectively.  Other supplementary loci may possibly be present on 
chromosomes 5, 6 or 12. 
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4.4.4.4. The 10 mg CQ kg-1 day-1treated population 
The ‘baseline’ is further reduced with a mean AJ allele frequency of 70 ± 2.6% 
(Fig 4.8d).  The scatter of the markers is increased in this selection, making the 
interpretation of a selection valley more difficult.  Markers on chr 11 and chr 3 are 
still the lowest in the genome.  However, even at this relatively high concentration of 
drug, none of the AS alleles on chromosome 11 are selected completely.  Even the 
lowest point of the selection valley (marker pcpf 06-1154) is 38.9%, showing that a 
surprisingly high proportion of the parasites which apparently carry the sensitive 
allele.  Moreover the selection valley appears to be more shallow than that observed 





The selection valley on chr 3 is slightly deeper than in the previous group, but 
none of the markers are completely reduced. 
Additionally the markers on many other chromosomes are decreased in 
comparison with the previous concentration (see for example chr 4, 5 and 6) however 
it is difficult to established whether they represent minor selection signatures or the 
general decrease of frequency across the genome. 
An interesting feature can be observed on chromosome 2.  This chromosome is 
characterised by a high percentage of AJ alleles in all previous selections (the mean 
marker density of 93.2%, 92.3% and 84.7% for untreated, 1.5mg and 3mg groups 




 group, the % of all AJ markers on 
this chromosome is on average 64.3 %.  It is the most visible difference between this 
scan and the previous one. 
It is therefore possible that an additional locus involved in CQ resistance is 
located on this chromosome.  
4.4.4.5. Summary of selection 1 
In summary, all three chloroquine treatments selected for AS markers situated 
on chromosome 11.  However in each case different pyrosequencing marker is the 
lowest point on this chromosome.  Also the shape of selection valley changes with 
each drug concentration.  The intermediate and high treatment seems to select at least 
one additional locus on chromosome 3 and possibly, at the highest CQ concentration, 
one on chromosome 2.  However none of the concentrations reduces AJ alleles of 
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any of the markers to zero which would be expected if at least one locus required for 
resistance exists.   










































1 2 6543 14131110987 12
P. chabaudi chromosomes
 
Figure 4.8  Whole genome scans (selection 1) 
The graphs are representing the proportions of sensitive allele in the selected mixture: untreated (a) 









































1 2 6543 14131110987 12
P. chabaudi chromosomes
 
Figure 4.8.b Whole genome scans (selection 1)  
The graphs are representing the proportions of sensitive allele in the selected mixture: untreated (a) 




























































































































































































4.4.5. The genetic analysis of the backcross – selection 2 
Here, the frequencies of AJ alleles at 93 genome-wide markers were 
determined using the library of pyrosequencing assays (Fig 4.10 – 4.16).  
4.4.5.1. The untreated population  
The mean percentage of AJ alleles genome-wide was (87.6 ± 0.8%) (Fig 4.10).  
This compares with 90% in Selection 1. No selection valley was observed. 
4.4.5.2. The population treated with 1.5 mg CQ kg-1 day-1 
The mean percentage of AJ alleles genome-wide was 87.7 ± 0.7% (Fig. 4.11).  
No selection valley can be observed.  This was similar to the results observed in the 
untreated sample.  Note, however, that this is in contrast with the data from selection 
1 when a selection signature on chr 11 was observed with the same drugging regime. 
4.4.5.3. The population treated with 3 mg CQ kg-1 day-1 
Here, the mean percentage of AJ alleles genome-wide was 63.6±2.8% (Fig. 
4.12 a).  This represents an apparent loss of AJ alleles across the genome, relative to 
those samples subject to lower doses of CQ.  The most prominent features of this 
scan however are two clearly identifiable selection signatures. 
The most dominant one is the clearly defined, reasonably symmetrical 
selection valley located on chromosome 11, between the markers pcpf06-1154 and 
pcpf12-2207 (Fig. 4.12 b).  The marker showing the lowest percentage of AJ alleles 
is pcpf06-1338 with an AJ frequency of only 2.5 %.  These data mean that there is 
almost complete selection for AS alleles within that locus.  The statistical analysis 
revealed that this valley is highly significant (P value< 0.001 obtained with both 
statistical approaches taken). 
A second region of selection was identified on chromosome 3 (Fig. 4.12 c).  
This time however the region of selection cannot be further narrowed – all three 
markers on this chromosome (pcpf 02-0452, pcpf02-0452 and pcpf02-0675) are 
inherited with very similar AJ allele frequencies (17.9. 17.0 and 23.3% respectively).  
Therefore a whole chromosome must be considered in the search for potential 
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resistant determinants.  The statistical analysis showed that the valley is statistically 
significant (P-value = 0.034) with one of the exploited statistical methods (simulation 
based) but not significant with the Mann-Whitney test. 
No other chromosome contains markers decreased below 30%.   
These data confirm the results for Selection 1 where AS alleles of markers on 
chr 11 and chr 3 were also selected at 1.5, and 3 mg CQ/kg/day. 
4.4.5.4. The population treated with 10 mg CQ kg-1 day-1 
Here, a further decrease in AJ alleles is observed (mean percentage genome-
wide equal to 52.5±3.5% (Fig. 4.13 a).  This time three potential selection signatures 
were observed – two previously identified (chr 11, chr 3) and another on chr 2.  None 
of them is classified as significant with both used methods of statistical analysis 
(probably due to the higher noise level in AJ allele frequency compared to previous 
concentrations) 
The valley situated on chromosome 11 (Fig. 4.13 b) was deeper and its bottom 
is defined by the pcpf06-1154 marker and reaches 1.5% (within the standard error of 
measurement) suggesting that all of the parasites in this population inherited this part 
of the genome from the resistant parent.  Although its bottom was less clearly 
defined spanning from pcpf06-1001 to pcpf 13-2207 it was clear that the resistance is 





A region of selection on chromosome 3 is also present (Fig. 4.13 c), but there 





A new, additional locus can be identified on chromosome 2 (Fig. 4.13 d), 
consistent with the data from selection 1 in which the AJ alleles on this chromosome 
were decreased in parasites treated with high but not with intermediate CQ 
concentration. The clear selection valley was identified between the markers pcpf01-
265 and pcpf07-1006 with the lowest AJ marker (pcpf01-0158) reduced from 79.2% 




scan) to 14.0 %.   
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4.4.5.5. The population treated with 20 mg CQ kg-1 day-1 





mean AJ allele proportion is only slightly lower (50 ± 3.7%) and no new loci under 
selection were discovered in comparison to the previous concentration (Fig 4.14 a). 
The three selection valleys (on chr 11, 03 and 02) were still present (Fig 
4.14.b-d).  The lowest percentages of AJ alleles on these three chromosomes were 
0.8 % (marker pcpf 06-1044 on chr 11), 13.4% (marker 02-0453 on chr 3) and 6.9% 
(marker 01-0158 on chr 2). 
4.4.5.6. The population treated with 100 mg ART kg-1 day-1 
The mean percentage of AJ allele along this genome scan is 60.5 ± 2.8% 
showing that ART treatment also selects for AS alleles in the population (Fig 4.15 a).   
The main feature of the genome scan was one clear selection valley identified 
on chr 2, similar to that obtained with the highest chloroquine concentrations (P 
value <0.001 with both statistical methods used) (Fig 4.15 b).  However, the 
selection was not complete. The proportion of the AJ allele of one marker only on 
this chromosome (pcpf01-0158) was decreased below ten percent (8.4%). 
4.4.5.7. The population treated with 200 mg ART kg-1 day-1 
Here, the mean percentage of AJ alleles along this genome was decreased to 
54.5 ± 3.7 (Fig 4.16 a).  Again the dominant selection valley was observed on 
chromosome 2 (Fig 4.16 b).  The group of three markers on this chromosome 
(pcpf01-0197, pcpf01-0158 and pcpf01-0150) were reduced to below 10% and the 
lowest of them (pcpf01-0197) barely contained traces (>0.1%) of the AJ allele.  
Therefore at least part of this chromosome was under almost complete selection. 
Interestingly AJ allele proportions on chr 11 are also strongly reduced, forming 
the selection valley similar to those generated with intermediate and high CQ 
treatments (Fig 4.16 c).  For example, the proportion of the pcpf06-1154 (the lowest 
marker on this chromosome in this selection and also in CQ selections) was reduced 
to 3.8 % showing almost complete selection. 
In addition one marker on chr 7 (pcpf04-0820) showed a very strong reduction.  
However as none of the others markers on this chromosome shown any signs of 
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selection (90% of AJ allele was observed in all of them).  It was therefore possible 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.5.1. The improvement in the quality of data  
In the discussion of the previous chapter (section 3.5.4 of Chapter 3), I 
expressed concerns regarding the quality of the data generated using the original AS-
30CQ x AJ cross and the number of resistant recombinants in the final mixture.  
Therefore modifications of the original LGS protocol, presented in the introduction 
to this chapter, were introduced to generate and maintain the higher numbers of 
recombinants in the mixtures and to improve the selection conditions.   
The initial results obtained during the backcross generation were encouraging.  
Firstly the study of the pre-selected progeny before the backcross revealed a well-
balanced population containing both AJ and AS alleles as well as evidence of a 
reasonable number of recombinants.  They also confirmed ideas regarding the 
extensive loss of resistant parasites in untreated infections. In fact, by following the 
original backcross protocol (the amplification of progeny without drug pressure and 
backcross to sensitive parent) the populations may have contained on average ~90% 
of AJ markers at most loci, generating very few recombinant parasites which are 
drug-resistant. 
Secondly the numbers of oocysts generated during the backcross were around 
8-fold greater than in the cross, therefore potentially supplying many more 
recombinants.  Whether this was due to EPO treatment, to improved savoir-faire or 
to some other factors cannot be established.  
As expected from these data, the significant improvement of data quality was 
observed during the analysis of the initial selection of the backcross (selection 1).  
Thus, the distributions of allele frequencies were less bimodal (allele proportions 
were well distributed over the range ~0% AJ – ~100% AJ), there was more evidence 
of linkage between adjacent markers (similarities in allele proportion) and there were 
fewer highly distinct regions of selection.  In fact these data allowed me to dismiss a 
large number of the potential loci suggested in the original cross.  It also mapped 
chromosome 11 as the main locus of resistance and suggested the involvement of 
chromosomes 3 and 2. 
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However further improvement was required.  The variation between the 
neighbouring markers was still relatively high and this “background noise” did not 
allow resolution of the selection valleys within the chromosomes identified.  
Moreover all of the mapped selection valleys were relatively shallow: none of the 





 this result can be easily explained - the experiment described in chapter 2 (see Fig. 
2.9) demonstrated that this concentration offers incomplete selection and allows 
some of the sensitive parasites to survive.  Therefore we would expect only the 
moderate decrease in the frequency of AJ markers at the loci of resistance.  However 
at higher concentrations the sensitive parasites were expected to have been 
eliminated and the selection should result in complete elimination of AJ markers at 
that locus. 
There are a few possible explanations for this phenomenon.  For example, 
inefficient drug treatment of one or more animals in the treatment group would 
reduce the apparent selection in the pooled material by allowing the growth.  
Alternatively, the proportion of the AJ alleles after the first (untreated) passage after 
the cross was already very high and the growth in the treated animals during 
selection was perhaps not long enough to change the proportion completely in favour 
of resistant allele.  Yet another possibility was that (possibly due to the number of 
resistant parasites) the length of the infection was sufficient to allow the 
recrudescence of the very low numbers of potentially surviving sensitive parasites.  
Such recrudescence was observed even with very high CQ treatments in chapter 2 
(see Fig 2.6).   
Trying to further improve the quality of the data I therefore pre-selected the 
backcross progeny in order to increase the numbers of resistant parasites and 
subjected it to another series of selections (selection 2). 
These resulted in a spectacular improvement in data quality resulting in a 
consistent pattern of selection valleys associated with CQ and ART resistance. 
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4.5.2. Three levels of resistance to chloroquine conferred by three 
loci? 
Three loci of interest have been discovered during the treatment of the 
backcross with chloroquine –chr 11, chr 3 and chr 2. 
A deep selection valley on chromosome 11 between markers pcpf 06-1154 and 
pcpf 13-2057 was the most prominent common feature of all the genome scans with 
the intermediate and high CQ treatments.  It was also the only locus selected with the 




) in one of the selections.  Moreover 
during selection 2 some AJ alleles within this locus were completely or nearly 
completely selected in populations treated with intermediate and high CQ doses, 
indicating that it is necessary for the highest level of resistance.  Interestingly, the 
same region had been previously identified as conferring CQ resistance during 
classical linkage analysis (in independent recombinant progeny clones) of the AS-
3CQ x AJ cross (Carlton et al., 1998; Hunt et al., 2004a).  Taken together, these data 
strongly suggest that chr 11 contains a mutation that appeared during the selection of 
AS-3CQ from AS-PYR1, that confers the low level of CQ resistance and seems to be 
necessary (but not sufficient) for the higher CQ resistance levels. 
A secondary locus selected (although not completely) with intermediate and 
high level of CQ resistance was selected on chromosome 3.  A mutation on chr 3 is 
therefore expected to confer higher levels of chloroquine resistance, possibly acting 
epistatically in addition to the main locus on chromosome 11.  Therefore a mutation 
here is likely to appear later in the lineage, possibly between the low resistant AS-
3CQ and intermediate–resistant AS-15CQ.   
Finally chromosome 2 was selected in both selection 1 and 2, only with the 
highest level of CQ.  The lack on selection on this locus with the intermediate 
concentration suggests that the mutation within it appeared during the selection for 
highest level of resistance (possibly between AS-15 CQ and AS-30CQ.)  
Interestingly, one mutation that appeared within that locus under chloroquine 
pressure (between AS-3CQ and AS-30CQ) has already been identified - a 
V2728Fsubstitution in the ubp1 gene (Hunt et al., 2007).  However the data 
presented here does not allow us to confirm or reject the theory that said mutation 
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contributes to the chloroquine resistance phenotype. Other genetic changes may be 
present on this chromosome and the ubp1 mutation could be selected together with 
the critical mutation due to close genetic linkage.   
Taken together, the LGS data from all the CQ selection experiments allowed 
the construction of a possible model of CQ resistance acquisition, in which only one 
locus would be responsible for each increase of the resistance (Fig. 4.17).  Thus one 
locus, situated on chromosome 11, containing a mutation that appeared first in the 
lineage between AS-PYR1 and AS-3CQ, would be responsible for lowest level of 
resistance.  Two loci (chromosomes 11 and 3) would contain mutations conferring an 
intermediate level of resistance to in AS-15CQ.  Finally the third locus (on 
chromosome 2) would appear in AS-30CQ allowing it to achieve the highest level of 
resistance.  This last mutation may be ubp1 V2728F. 
 
 
Figure 4.17 A model of how mutations may confer CQ resistance in AS lineage.   
The strains are presented in black.  The arrows are representing the selection and on red there are loci 
potentially mutated during the said selection. 
 
It has to be noted however that this model is one of many possibilities.  For 
example the mutation within three loci could have all appeared during the initial 
selection for AS-3CQ and the later increase of resistance would be caused either by 
additional mutations within the same loci/genes (similarly to acquisition of resistance 
to pyrimethamine (Lozovsky et al., 2009)) or many small effect mutations that would 
be undistinguishable from background noise.  Alternatively the mutations within all 
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of the predicted loci could arise only in AS-30CQ and other genetic mechanisms are 
responsible for the lower level of resistance. 
 
4.5.3. .Artemisinin resistance – confirmation of existence of the 
locus on chromosome 2 
It has been previously reported that a locus on chromosome 2 may be 
responsible for artemisinin resistance (Hunt et al., 2007).  However, at that time, no 
complete selection on this locus could be observed in the AS-ART x AJ cross.  Also 
the appearance of a potential candidate mutation in the ubp1 gene appeared not to 
correspond to the AS-30CQ phenotype (which was originally thought to be ART-
sensitive).   
During my work on CQ resistance however, re-phenotyping of some of the 
strains in the AS lineage (performed by Richard Fawcett and Louise Rodrigues) 
established that AS-30CQ also shows an artemisinin-resistance phenotype and that 
higher ART concentrations than those explored in the previous work should be used 
in selection experiments.  These findings opened the opportunity to use the AS-30CQ 
x AJ cross for mapping of the loci of ART resistance in the lineage.   
Now, using the AS-30CQ x AJ backcross and high artemisinin concentrations 
I have confirmed that in the resistant population almost all parasites carry resistant 
parental AS alleles on chromosome 2 thus establishing this locus as the main 
determinant of ART resistance in the lineage.  The generated selection valley is very 
similar to that observed with the highest chloroquine concentration prompting the 
hypothesis that the same mutation could be responsible for both an increase of the 
resistance to chloroquine and appearance of resistance to artemisinin.  This would 
explain why the artemisinin resistance seem to appear “out of nowhere” (without the 
prior exposure to artemisinin) in the AS lineage.  The mutation in ubp1 would be 
selected by CQ and then confer ART resistance in a multi-drug resistance phenotype.  
However, as explained previously, these genetic data do not allow us to confirm or 
reject the specific importance of ubp1 mutations. 
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4.5.4. The possible locus of ART resistance on chr 11 
Surprisingly with the highest artemisinin concentration, AS alleles on 
chromosome 11 were also selected, forming a selection valley similar to that 
obtained from CQ selected populations.   
One possibility is that a locus on that chromosome (possibly identical with the 
main determinant of CQ resistance) is responsible for the higher level of artemisinin 
resistance.  Therefore two very similar loci (on chr 2 and 11) would be selected by 
two different drugs (although in the reverse order).  It would imply either strong 
structural/functional similarities between the two drugs (so far not supported by the 
literature) or the existence of “multidrug resistance” phenotype conferring the 
resistance to various drugs (similar to pfmdr1 phenotype (Duraisingh and Cowman, 
2005)). 
There is, however another simple explanation of the data here.  It is possible 
that the observed result is an artefact of the used experimental design.  In particular 
case, the two selections are not totally independent – the parasites that are taken for 
artemisinin selection have previously been growing in untreated or chloroquine-
treated mice.  In this case, linkage disequilibrium can appear between the two loci as 
explained below.   
Let us assume that in the absence of drug the mutation on chromosome 2 is not 
neutral and confers some cost to parasites such as slower growth etc.  At the same 
time it increases the level of chloroquine resistance but only if found in the presence 
of mutation on chromosome 11.  In that case, if parasites are grown in untreated 
animals those bearing the mutation on chromosome 2 will be at disadvantage.  In 
chloroquine treated mice the parasites either with a mutation on chr 11 or those 
bearing mutations on both chr 2 and chr 11 will be selected.  Those bearing 
mutations on chromosome 2 alone will carry the fitness cost and because they are not 
resistant to CQ, these parasites will be eliminated in both populations.  So before 
selection, we combine the two populations in which the proportion of clones bearing 
the mutation on chromosome 2 alone is decreased, although many double mutants 
(chr 11/chr 2) are present.  If we now treat these parasites with ART selecting for the 
locus on chromosome 2, we are likely to select many parasites bearing the mutation 
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on chr 11 although the latter is not directly involved in resistance.  This would result 
in a genome scan similar to that observed in experiments presented here.  At 100 mg 
of ART this effect wouldn’t be as visible because the selection on chr 2 is not 
complete and therefore the putative selection valley on chr 11 would be very shallow 
and impossible to distinguish from the background noise (however it needs to be 






In summary this chapter has used genetic approaches to define the dominant 
genetic loci underlying resistance to CQ and ART.  We expect to find mutations 
within these loci in the resistant parasite AS-30CQ relative to its sensitive precursors.  







5. The specific mutations connected with CQ and 
ART resistance 
5.1. Introduction 
The genetic experiments described in chapter 4 identified three loci involved in  
increasing levels of chloroquine resistance (on chromosomes 11, 3 and 2) and one 
locus involved in artemisinin resistance (on chromosome 2).  All the identified loci 
however are relatively large.  For instance the best resolved locus containing the 
main determinant of CQ resistance was mapped to ~300 kb fragment on 
chromosome 11.  In the P.chabaudi genome, this translates to ~79 gene candidates 
(Table 5.1), many of which may possess functional or structural characteristics 
consistent with a role in CQ resistance, such as the involvement in intracellular 
transport, proteolysis, transcription control etc. 
The narrowing of these loci using LGS would require additional cycles of 
backcrossing and selection, combined with an increase of marker density in the 
regions of interest.  A significant amount of work would be involved and the 
improvement with each backcross would be smaller.  Therefore a different approach 
was needed to map the candiaite mutation within identified loci.  
During the course of the project next-generation sequencing methodologies 
became available.  We adopted the Illumina-Solexa platform - a novel, high-
throughput, next generation sequencing system.  This technology, based on the 
generation of short (36 or 50bp) reads allows the re–sequencing of the entire genome 
at high coverage in relatively short periods of time (less than 2 weeks for a 
Plasmodium size genome).  Therefore two clones of different levels of resistance 
could be sequenced, mutations identified and all differences between them mapped 
and confirmed. 
This chapter describes Solexa sequencing of the genomes of two clones from 
the AS lineage, namely AS-sens (the sensitive clone) and AS-30CQ (chloroquine and 
artemisinin resistant clone used as resistant parent in the genetic cross).  These data 
are analysed and the critical genes genes connected with CQ and ART evaluated. 
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Table 5.1 The initial list of gene candidates on chromosome 11 
This list includes all the genes present within the predicted selection valley according to PlasmoDB 
database (http://plasmodb.org). 
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5.2. The experimental design 
DNA from clones AS-sens and AS-30CQ was sequenced at high coverage 
(around 20x for AS-sens and >30x for AS-30CQ) in short DNA sequence strings.  
All the reads were mapped onto a pre-existing fully assembled and annotated P. 
chabaudi AS reference genome sequence (AS-WTSI, ftp://ftp.sanger.ac.uk/pub/ 
pathogens/P_chabaudi/September_2009_ assembly) allowing the reassembly of the 
genome sequences of both AS-sens and AS-30CQ.  This analysis was performed in 
parallel, using MAQ (http://maq. sourceforge.net) (Li et al., 2008) and SSAHA2 
(http://www.sanger.ac.uk /resources/software/ssaha2/) (Ning et al., 2001) software 
packages. 
The data were than analysed for SNPs and indels and the list of all genetic 
changes between the two strains compiled. This list was than filtered to remove poor 
quality calls on the basis of their associated quality indices and properties (e.g. read 
coverage, Phred-like scores, uniqueness and mapping quality, see section 5.3.3. for 
detailed description).  Then the comparison of the data from AS-sens and AS-30CQ 
sequences allowed the identification of changes that appeared within AS lineage, 
during the selection for drug resistance.  Once the putative mutations were identified, 
dideoxy sequencing was used to validate the results of bioinformatics analysis.   
Later all confirmed changes were sequenced in all the other strains in the AS 
lineage in order to establish the place of their appearance within the lineage.   
 
In order to be considered as a potential cause of drug resistance, the mutations 
had to fit two major criteria:  
 they are situated within the limits of the predicted locus of resistance 
(identified in chapter 4 during genetic analysis) 
 they appear during the chloroquine selection along with the change in 
chloroquine resistance phenotype (they could not be present in AS-sens 
strain) 
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Critical mutations affecting drug responses were expected to be non-
synonymous as they are most likely to alter the function of the expressed protein in 
the parasite.  However, it was important to note that synonymous and intergenic 
point mutations, indels and copy number variations (CNVs) could also mediate drug 
resistance by changing the levels of expression of a given protein and must therefore 
be considered as potential resistance determinants.  
Once putative resistance conferring mutations were identified, proportional 
sequencing was used to assess the level of these mutations in the selected backcross 
progeny.  This confirms that they were amongst the lowest points in the selection 
valleys and therefore the likely cause of the observed selection. Additionally the 
allele proportions in populations treated with different drug concentration could be 
used to estimate the strength of selections.  
Finally, the properties of the candidate genes and proteins including their 
function, localisation, secondary structure, conservation in the Plasmodium genus 




5.3. Materials and Methods 
5.3.1. The preparation of DNA 
The parasites used for this experiment were described in section 1.7.2. of 
Chapter 1.  Both parasites were grown in groups of 20 male CBA mice, infected and 
monitored as described in section 2.3 of Chapter 2.  DNA isolation was performed as 
described in section 3.3.7. of Chapter 3.  DNA was quantitated 
spectrophotometrically and its quality and quantity confirmed by agarose gel 
electrophoresis. 
5.3.2. Illumina-Solexa genome re-sequencing:  
Both DNA samples were sequenced using Illumina-Solexa genome analyser 
(http://www.illumina.com/systems/genome_analyzer.ilmn) by Gene Pool sequencing 
service of the University of Edinburgh (http://genepool.bio.ed.ac.uk/).  AS-sens and 
AS-30CQ were sequenced using 4 and 6 lanes of a flowcell respectively.  36 bp (AS-
sens) or 50 bp (AS-30CQ) single-ended reads were generated.  
5.3.3. The bioinformatic analysis of Solexa genome re-sequencing 
data 
This part of the work was performed by Dr Axel Martinelli, members of the 
GenePool sequencing service (Marian Thomson, Urmi Trivedi, Sujai Kumar and 
Prof. Mark Blaxter) and Dr Paul Hunt.  
5.3.3.1. Genome reassembly and SNP identification using MAQ software 
In MAQ the obtained reads were mapped against the AS reference sequence 
(AS-WTSI, ftp://ftp.sanger.ac.uk/pub/pathogens/P_chabaudi/September 
2009_assembly) using the “easyrun” command, run with default parameters.  This 
automatically generated a list of SNPs between a clone and the reference sequence 
(as a “cns.final.snp” file) filtered using following criteria: 
• minimum coverage of 3 (the base needed to be covered by at least 3 reads to 
be called as SNP) 
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• minimal Phred-like score of 30 (the Phred-like score is calculated on the basis 
of Phred-scores assigned by Solexa sequencing software to each sequenced 
base and reflecting the certainty of the call) 
This list of SNPs was than further filtered, using three custom perl scripts. The first 
two were applied to both AS-sens and AS-30CQ dataset and used to remove the non-
unique and heterozygous calls.  Non-unique calls are the SNPs identified by the 
reads aligned to more than one place to the genome and therefore likely to be 
incorrectly positioned.  Heterozygous calls are identified when two possible bases 
were identified on the given position with the “recessive” base constituting at least 
20% of the calls.  The major base was always identical to the one in reference 
sequence.  The minor base represented either incorrectly mapped reads, or a 
polymorphism present within the sequenced strain.  The third script was used to filter 
the AS30CQ calls against the AS-sens one generating the list of SNPs that appeared 
during the selection of drug resistant lineage.  All if the identified SNPs were 
visualised using “mapview” command and further inspection. 
Locations spanning SNPs were subsequently characterized using BLAST 
searches against the PlasmoDB (http://plasmodb.org) and GeneDB 
(http://www.genedb.org) databases.   
5.3.3.2.Genome reassembly and SNP/indels identification using SSAHA2 
software 
In SSAHA2 the reads from both strains were aligned against AS-WTSI using 
the “pileup” command for single end reads with the appropriate options as described 
in ftp://ftp.sanger.ac.uk/pub/zn1/ ssaha_pileup/ssaha_pileup-readme.  It generated 
three files calling snp (*.snp), 1-3bp deletions (*.del) and 1-3bp insertions (*.ins).  
They were all combined in Artemis-compatible “*.gff” file and divided according to 
their chromosomal location (a separate file was generated for each chromosome).  
The data from these files were filtered according to the following criteria: for the 
SNPs the minimal coverage of >3 was required and heterozygous calls were 
removed. For indels only the calls called by over 50% of the covering reads were 
kept.  The resulting list of mutations was filtered against AS-sens. 
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The “gff” files were then imported into Artemis (http://www.sanger.ac.uk/ 
resources/software/artemis/) (Carver et al., 2008), a DNA sequence viewer which 
allowed the visual inspection, identification and evaluation of these mutations on the 
fully annotated genome.  Further information was obtained by consulting the 
PlasmoDB and GeneDB.  
5.3.3.3.Mapping the indels and CNV (copy number variations) between the two 
strains 
As both MAQ and SSAHA2 don’t have an automatic algorithm for 
identification of larger deletions (>3bp) and CNV,  a separate approach, based on the 
comparison of local read coverage in AS-30CQ and AS-sens was adopted using both 
MAQ and SSAHA2 outputs and custom designed script.  This method is based on 
the assumption that insertions and deletions result in a reduction of read coverage 
that can be measured, and also upon the observation that (relative) read-coverage 
varies across the genome but in a regular way (in different clones) (Axel Martinelli, 
personal communication).   
The datasets generated by both MAQ and SSAHA2 were used for that analysis. 
For MAQ data this  required running the “pileup” command on both the AS-30CQ 
and AS-sens reads using the variable “-q 1” (which excludes reads with a mapping 
quality <1).  The pileup files thus produced were then used for coverage analysis.  
For SSAHA2 the output of the “pileup” command was used directly for coverage 
analysis.  The relative coverage at any base in one clone was defined as the actual 
coverage relative to the overall (genome-wide) coverage.  The comparative coverage 
was defined as the ratio of the relative coverage in the mutant clone relative to that of 
AS-sens.  Differences in coverage were evaluated separately for potential CNVs and 
potential large indels using custom made scripts.  A potential CNV was defined as an 
increase in comparative coverage of at least 1.5-fold over a stretch of at least 200 
contiguous bp.  A potential large indel was defined as a reduction in comparative 
coverage of at least 75% in the mutant clone compared to AS-sens over at least 10 
contiguous bp.  Additionally, a minimum coverage of at least 20-fold in clone AS-
sens was required, in order to remove an excess of false positive calls due to areas 
with insufficient coverage.   
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All suspected indels were visually confirmed using MAQ and Artemis 
software. 
5.3.3.4.Calculation of numbers of mapped reads and genome coverage 
The number and proportion of reads mapped in MAQ was calculated 
automatically.  For the calculation of genome coverage, the output of the “pileup” 
command used to calculate the overall coverage, using a custom designed script.   
For SSAHA2 a custom-made perl script was used to calculate the number of 
mapped reads.  For coverage analysis, an “awk” script (supplied by Thomas D. Otto, 
Sanger Institute) was used to produce a plot from the “pileup” file.  This plot was 
read by the ARTEMIS software which automatically produced the average coverage 
for each chromosome.  The average coverage of the whole genome was based on the 
average of the coverage for all chromosomes, adjusted by the size of each individual 
chromosome. 
5.3.4. Dideoxy sequencing  
To confirm the bioinformatics predictions, a set of PCR primers was designed..  
The standard PCR protocol was used to amplify fragments containing mutations of 
interest (Appendix B).  The list of the primers used for mutations investigated in this 
chapter is presented in Table 5.2. 
5.3.5. Proportional sequencing 
The primers designed for the sequencing of the mutations (Table 5.2) were 
also used to confirm the proportions of parental alleles by proportional sequencing.  
Amplified products from the selection 2 of the backcross (Fig 4.9 in chapter 4) were 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.3.6. Protein characterisation 
The publicly available PlasmoDB database (http://plasmodb.org/) was used to 
obtain the basic information concerning the predicted gene structure, coding 
sequence, possible function and expression profile.  PlasmoDB was also used to find 
the sequences of the predicted proteins and their homologues in other Plasmodium 
spp. genomes.  The Clustal W2 software (http://www.ebi.ac.uk/Tools/clustalw2 
/index.html) was used to generate alignments between orthologues.  The analysis of 
secondary structure was performed using TMHMM (http://www.cbs.dtu.dk/services/ 
TMHMM/) and Jpred 3 (http://www.compbio. dundee.ac.uk/www-jpred/). 
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5.4. Results 
5.4.1. The genome re-sequencing and Solexa data analysis 
5.4.1.1. Sequencing and initial data analysis: 
All animals used for DNA amplification developed parasitaemia as expected 
and DNA was isolated on day 6.  Both samples were sequenced as described in 
section 5.3.2.  Given the size of the Plasmodium genome, such sequencing should 
result in the approximate coverage (number of times each base was sequenced) of 
20X and 30X respectively. 
The initial data analysis (Table 5.3) showed that with both the MAQ and 
SSAHA2 software the vast majority of reads could be mapped against the reference 
genome and the overall coverage for both AS-sens and AS-30CQ was better than 
expected (40x and 75x  respectively).  Moreover, in both strains the majority of the 
genome (~98%) was covered with reads with the coverage of at least 5X which 
indicated that only a very small portion of the genome was not covered by analysis.  
Additionally, the comparison of coverage on particular chromosomes in AS-30CQ 
(Table 5.4) indicates that the part of the genome that could not be covered with 
uniquely mapped reads was mostly confined to the contigs not assigned to any of the 
chromosomes (“bin”) and therefore likely to be a part of the low complexity regions 














           Table 5.3 The summary of Solexa sequencing metrics of AS-sens and AS-30CQ strain.   
 















Total (chrs only) 98.31% 






Table 5.4 The summary of the coverage of AS-30CQ by chromosome in SSAHA2.  
“bin” represents the contigs that were not mapped to any of the chromosomes 
 
Clone analysed AS-sens AS-30CQ 
Amount of DNA used for sequencing 2 µg 2 µg 
Number of lanes on a flowcell 4 6 
Read length 36 41 
Nominal coverage (calculated based on 
the minimal amount of data generated 
with each lane) 
20X 30X 
% reads allocated to sequence (MAQ) 90.83% 96.60% 
% reads allocated to sequence (SSAHA) 93% 97% 
Actual coverage (calculated by MAQ) 39.28X 77.91X 
Actual coverage (calculated by 
SSAHA2) 
39.48X 75.86X 
% of the genome with coverage >10 95.86 96.96% 
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5.4.1.2. The identification of SNPs between the two strains 
This analysis was performed in parallel using MAQ and SSAHA2 software. 
Initial mapping of the reads against reference sequence, using default 
parameters of MAQ software (coverage >3 and Phred-like score>30), resulted in 
identification of hundreds of SNPs between each of the strains and reference 
sequence (see Table 5.5).  The removal of non-unique and heterozygous calls 
however (as described in section 5.3.3.1.), reduced the SNP numbers to 34 and 41 in 
AS-sens and AS-30CQ respectively.  The majority of those were shared between AS-
sens and AS-30CQ and therefore either appeared very early in the history of AS-sens 
strain or were due to the errors in reference sequence and thus were unlikely to be 
connected with CQ/ART resistance. The remaining 17 SNPs that were detected in 
AS-30CQ strain only are presented in Table 5.6.   
After the visual verification 7 out of those 17 were kept for further analysis.  
Two of the others (the ones chr 7) were discarded because they were situated on the 
edge of predicted deletion which caused the visible errors of read mapping and low 
coverage in this region.  For the remaining 8, the analysis of AS-sens sequence 
revealed that they were present in this strain and were not called as SNPs between 
AS-sens and the reference sequence only because of poor quality and/or read 
coverage.  The rejected SNPs were characterized by lower Phred-score than the 
confirmed ones suggesting that they were covered by lower quality, uncertain reads.  
 
A similar analysis was performed using SSAHA2 software.  First, the reads 
were uniquely mapped to the reference sequence without any filtering criteria which 
resulted in the generation of a large list of SNPs for each of the chromosomes (over 
4000 for the whole genome, data not shown).  The subsequent filtering for minimal 
coverage of 3, removal of heterozygous calls and comparison with AS-sens (as 
detailed in section 5.3.3.2.), reduced this list to 12 proposed SNPs between the two 
strains (Table 5.7).  7 of those were characterised by high coverage and quality score 
(value assigned by SSAHA2 and reflecting the probability that the SNP was called 
correctly) close to the maximal value of 99 percent.  They were the same ones as 
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identified with MAQ and therefore judged to be likely mutations.  The other 5 were 
all characterised by low coverage and very low quality score (<20) and lack of visual 
confirmation and therefore were judged as unlikely. 
 
In summary 7 high quality SNPs were identified using both approaches.  
Additionally each of the two approaches produced few additional low-likelihood 










  AS-sens AS-30CQ 
Initially identified SNP 836 699 
After removing heterozygous calls  54 59 
After removing non-unique calls 34 41 
Filter against AS-sens - 17 
After visual inspection - 7 
 
Table 5.5 Number of point mutations identified on each step of analysis with MAQ software   
“Initially identified SNPs” refers to the MAQ software output. Heterozygous calls are the ones where 
two possible bases are called in particular position. Non-unique call refers to the mutation identified 




  AS-sens AS-30CQ 





















1  bin 107946 C 6 A 11 A 59 present in as-sens 
2  bin 145080 C 8 T 54 T 146 present in as-sens 
3  bin 208863 A 7 G 19 G 83 present in as-sens 
4  chr02 216954 C 42 C 80 A 249 - 
5  chr03 70553 G 28 G 123 T 255 - 
6  chr03 474123 C 40 C 59 A 205 - 
7  chr07 876917 A 16 A 16 A 72 proxy to indel 
8  chr07 876919 C 23 C 23 C 91 proxy to indel 
9  chr07 994546 G 66 G 92 A 255 - 
10  chr10 634932 T 22 T 38 C 141 - 
11  chr11 996332 G 59 G 117 T 255 - 
12  chr13 1792583 C 1 T 9 T 54 present in as-sens 
13  chr13 690908 A 10 T 22 T 93 present in as-sens 
14  chr13 1063028 C 1 A 6 A 44 present in as-sens 
15  chr13 1063060 C 3 A 4 A 39 present in as-sens 
16  chr13 1063059 T 3 C 4 C 39 present in as-sens 
17  chr14 936945 T 14 T 27 G 99 - 
Table 5.6 The point mutations identified with MAQ software and the results of their visual 
confirmation.   
The likely SNPs are marked in green, the unlikely ones are grey and the reason for rejection is given.  
a) the base on the described position in reference sequence (AS-WISI) b) number of reads covering 
the given position in MAQ assembly, c) a base identified by visual analysis, d) a score assigned to 
each SNP identified by MAQ software in AS-30CQ, reflecting the certainty of the call (max.= 255) 
 
 
Table 5.7 The point mutations identified with SSAHA2 software.   
The calls rejected because of the low read depth, low quality score and lack of visual confirmation are 
marked in grey.  a) the software calling given SNP, b) number of reads calling given SNP in SSAHA2 
assembly, c) quality score assigned by SSAHA software, representing the probability that given SNP 
is not a false positive  
AS-sens AS-30CQ 














1 2 216,954 SSAHA/MAQ C 42 A 72 99 
2 3 70,553 SSAHA/MAQ G 28 T 61 99 
3 3 474,123 SSAHA/MAQ C 40 A 57 99 
4 5 681,914 SSAHA T 3 A 4 6 
5 7 994,546 SSAHA/MAQ G 66 A 87 99 
6 10 634,932 SSAHA/MAQ T 22 C 37 99 
7 11 996,332 SSAHA/MAQ G 59 T 111 99 
8 13 113,002 SSAHA G 2 A 4 8 
9 14 936,945 SSAHA/MAQ T 14 G 26 92 
10 bin 116,902 SSAHA A 34 C 25 16 
11 bin 167,611 SSAHA T 1 C 4 15 
12 bin 221,856 SSAHA T 20 G 6 2 
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5.4.1.3. The identification of indels between the two strains 
 
A separate approach was used to map small (1-3bp) indels and larger indels 
and CNV.  The summary of the results is presented in Table 5.8. 
For identification of small indels (<3bp) SSAHA2 internal algorithm was used 
based on identifying the 1 to 3 bp indels within the reads (see section 5.3.3.2.). It 
yielded a list of 30 potential indels present between AS-sens and AS-30CQ.  
However none of them could be confirmed by visual analysis and the majority was 
characterized by low coverage (<10) and/or was called only by some of the covering 
reads.  None of them was judged as likely. 
For the detection of large indels and CNV the approach based on the 
comparative coverage was used as described in section 5.3.3.3.  The analysis using 
SSAHA2 output identified 11 such changes between the two strains.  However, the 
visual analysis confirmed two of them: a 34bp deletion on chr 7 and a large 1.2 kb 
deletion on chr 5.  They were also the only ones called by the analysis with MAQ 
software as well.  The rest was classified as unlikely.   
It has to be added here that indel identification algorithms are less stringent 
than those used for SNP identification.  The simulation approach consisting on 
inserting artificial deletions into the genome “in silico” and replicating the SOLEXA 
re-sequencing showed that it is likely to generate a substantial amount of false 
positives however it is unlikely to miss the actual changes (Axel Martinelli personal 


































































Identified by SSAHA2 
1 1 Deletion 13,917 1   20/38 
2 1 Deletion 19,767 1   28/50 
3 1 Insertion 203,105 1   10/19 
4 2 Insertion 32 1   2/3 
5 3 Deletion 350,001 1   2/4 
6 4 Deletion 104,874 1   14/16 
7 5 Insertion 311,828 1   26/30 
8 5 Deletion 410,773 1   2/3 
9 7 Insertion 910,274 1   2/2 
10 7 Deletion 910,327 2   2/3 
11 7 Insertion 910,341 1   6/7 
12 8 Insertion 1,184,534 1   2/3 
13 9 Deletion 911,419 1   6/11 
14 9 Deletion 1,301,305 3   13/25 
15 10 Deletion 290,661 1   43/47 
16 10 Deletion 718,122 1   57/71 
17 11 Insertion 356,249 1   2/3 
18 11 Deletion 760,507 1   24/24 
19 11 Deletion 836,567 1   36/45 
20 12 Insertion 142,723 1   4/8 
21 12 Deletion 203,419 1   11/18 
22 13 Deletion 872,812 1   5/8 
23 13 Insertion 879,482 1   29/37 
24 13 Deletion 1,188,222 1   21/30 
25 13 Deletion 1,792,799 1   3/5 
26 13 Insertion 2,115,249 1   5/9 
27 14 Insertion 82,779 1   2/2 
28 bin Insertion 798 1   12/24 
29 bin Deletion 35,739 1   2/2 
30 bin Deletion 262,255 1   9/9 
Identified by coverage analysis 
1 1 indel 581,324 75 0.02   
2 4 indel 793,932 50 0.17  
3 5 indel 683,724 1,266 0.24   
4 6 indel 372,860 24 0.00   
5 7 indel 169 13 0.00   
6 7 indel 13,193 17 0.18   
7 7 indel 876,927 34 0.19   
8 11 indel 788,143 17 0.23   
9 13 indel 2,307,750 12 0.25   
10 14 CNV 1,595,078 254 3.20   
11 14 indel 2,015,046 15 0.25   
 
Table 5.8 The list of indels identified by bioinformatic analysis.  
 a) represents the difference in comparative coverage between AS-sens and AS-30CQ (defined in 
section 5.3.3.3.).  b) the quality index representing the relationship between the number of reads 
calling given indel (first number) and total number of reads covering the potential change (second 
number).  The two deletions confirmed by MAQ and visual analysis are marked in green. 
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5.4.2. The validation of Solexa data 
 
In order to confirm the results of the bioinformatic analysis a number of 
dideoxy-sequencing primers were deigned.  The results are presented in Table 5.9. 
All seven high quality SNPs called with both software packages (see Table 5.6 
and 5.7) were sequenced and confirmed.  Also the smaller one out of the two 
predicted indels (table 5.8) could be confirmed (a 34bp deletion on chr 7).  
Unfortunately due to its size and position no successful primers could be designed 
for the larger 1.2 kb deletion on chr 5.   
Additionally some of the changes identified with only one type of software 
were also sequenced.  It included two putative SNPs on chr7 identified by MAQ 
software (see Table 5.6), a chr 13 SNP identified by SSAHA2 (Table 5.7) and two 
out of the 39 rejected deletions identified by SSAHA2 which were judged as most 
likely (covered by the high number of reads and called by over 90% of them).  All of 
them proved to be false positives.  It has to be mentioned here that attempts were 
made to sequence also the other four low quality SNP calls identified with SSAHA2 
only (see Table 5.7) but no successful primers could be designed to amplify those,, 
probably because of their location in low complexity regions (three of them map to 
unassigned, telomeric contigs) 
Finally, a number of SNPs rejected at the initial stages of bioinformatic 
analysis with MAQ software were also sequenced.  These SNPs were situated within 
the selection valleys on chromosome 3 and 11 and predicted to cause the coding 
change within existing proteins, were also sequenced.  None of those SNPs were 
confirmed.  
In summary the dideoxy sequencing data showed 100% correlation with the 
results of bioinformatics analysis.  All changes predicted as likely by bioinformatics 
analysis were present in the sequence and all potential mutations rejected because of 
the low call quality and/or lack of visual confirmation were absent. 
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indel size  
Confirmed? 
High quality calls by both types of software  
2 216,954 MAQ/SSAHA2 SNP  C/A Yes 
3 70,553 MAQ/SSAHA2 SNP  G/T Yes 
3 474,123 MAQ/SSAHA2 SNP  C/A Yes 
7 994,546 MAQ/SSAHA2 SNP G/A Yes 
7 876,90l MAQ/SSAHA2 deletion 34bp  Yes 
10 634,932 MAQ/SSAHA2 SNP T/C Yes 
11 996,332 MAQ/SSAHA2 SNP G/T Yes 
14 936,945 MAQ/SSAHA2 SNP  T/G Yes 
Low quality calls, rejected by visual inspection, identified only with one type of 
analysis 
13 113,002 SSAHA2 SNP G/A No 
7 876917 MAQ SNP  A/G No 
7 876919 MAQ SNP  C/A  No 
10 290,661 SSAHA2 Deletion  1bp No 
11 760,507 SSAHA2 Deletion 1bp No 
Initially identified by MAQ but rejected by later bioinformatic analysis 
3 180,102 none SNP G/A No 
3 180,086 none SNP A/C No 
11 946,436 none SNP G/T No 
11 946,392 none SNP C/T No 
11 432,447 none SNP T/C No 
11 1,013,413 none SNP C/G No 





5.4.3. The summary of genetic changes between AS-sens and   
AS-30CQ 
 
The Table 5.10 summarizes all of the predicted mutations occurring between 
AS-sens and AS-30CQ.  In total seven point mutations and two deletions were 
proposed with high confidence and validated.  Importantly, they include two 
previously identified point mutations.  Those are PCHAS_072830 (pcdhfr) S106N, 
the main determinant of PYR resistance in the lineage (Cowman and Lew, 1990), 
and PCHAS_020720 (ubp1) V2728F that was identified in AS-30CQ in 
investigations regarding artemisinin resistance (Hunt et al., 2007).  Now, 4 additional 
non-synonymous point mutations, 1 non coding point mutation and two deletions 
(one small, non-coding and one whole gene deletion) are revealed.  All the mutations 
were identified in AS-30CQ only and absent in both AS-sens and in the reference 
sequence. 
 
Table 5.10 Predicted genetic changes between the AS-sens and AS-30CQ.   
The previously known SNP are marked in green.  The gene IDs are given according to the annotation 








SNPs) or size 




2 216,954 SNP C/A PCHAS_020720 V2728F 
3 70,553 SNP G/T PCHAS_030200 T707N 
3 474,123 SNP C/A PCHAS_031370 T719N 
5 683,724 Indel 1266 bp PCHAS_051920 deleted 
7 876,909 Indel 34 bp intergenic na 
7 994,546 SNP G/A PCHAS_072830 S106N 
10 634,932 SNP T/C PCHAS_101550 Y162H 
11 996,332 SNP G/T PCHAS_112780 A173E 
14 936,945 SNP T/G intergenic na 
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5.4.4. The candidate mutations associated with CQ/ART resistance 
and their origin in the lineage 
 
In this section I combine the genetic data from Chapter 4 with the results of the 
Solexa sequencing in order to determine the changes within predicted loci of 
resistance on chromosomes 11, 3 and 2 that may be connected with CQ/ART 
resistance.   
The initial strategy to identify the origin of various mutations in the AS lineage 
was to sequence only the immediate progenitors of AS-30CQ, i.e. AS-sens , AS-pyr, 
AS-3CQ and AS-15CQ. However during these studies, concerns arose concerning 
the genotype of the AS-15CQ strain.  It was the only uncloned strain in the lineage 
and, as a consequence, any genotyping was likely to be questionable. Therefore two 
cloned strains derived from AS-15CQ, namely AS-15MF and AS-ATN were also re-
sequenced.  As no further CQ selection was applied to any of these two branches of 
the lineage, any mutation connected to CQ resistance, found in AS-ATN, AS-15MF 
and AS-30CQ was likely to have its origins in AS-15CQ. 
5.4.4.1.  Chromosome 11 
The LGS experiments with CQ selection characterised the most prominent 
selection valley to a central part of chromosome 11.  This selection valley precisely 
coincides with the ~250 kb region between two specific AFLP markers defined to 
contain a locus conferring CQ resistance by previous classical linkage analysis (Hunt 
et al., 2004a).  Within the entire chromosome 11 only one genetic change was 
identified - a G to T substitution at position 996,332 that is situated within the centre 
of the identified valley.  It maps to the PCHAS_112780 gene (that I later refer to as 
aat1 because of its putative function as amino acid transporter) and is predicted to 
cause a non-synonymous (A173E) substitution with the encoded protein..   
The fragment of the aat1 containing the predicted mutation was sequenced in 
all the strains from AS lineage and in AJ (Fig 5.1).  The three CQ sensitive strains 
(AJ, AS-sens and AS-pyr) showed the wild-type G nucleotide and all of the CQ 
resistant strains starting from low resistant AS-3CQ have the mutated T nucleotide.  
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Therefore, as predicted, the mutation appeared during the selection of AS-3CQ from 


















Figure 5.1 Point mutation resulting in A173E substitution in PCHAS_112780 (aat1) gene in 
various strains of AS lineage.   
a) The chromatograms showing the substitution of the base in the aat1 sequence b) the schematic of 
the AS lineage with the strains carrying the wt version of the aat1 gene marked in black and those 
carrying the mutated version in red. The uncloned population of AS-15CQ strain is marked with a 
circle and its genotype is inferred from the genotyping of other strains in the lineage. 
 
In summary, the aat1 contains the only discovered mutation that arose within 
predicted locus and at the predicted step of selection and, therefore, is a very strong 
candidate for the main determinant of the CQ resistance in AS-lineage. 
 
5.4.4.2. Chromosome 3 
A secondary locus contributing to the CQ resistance was identified on 
chromosome 3 and Solexa genome re-sequencing identified two mutations here; G/T 
substitution at position 70,553 and C/A at position 474,123.  They are both non-
synonymous mutations in predicted genes.  The C474123A mutation localises in a 
conserved Plasmodium spp. gene in the central syntenic part of the chromosome 
(PCHAS_031370, that was labelled tm12 because of the presence of 12 
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transmembrane domains) and encodes for a T719N substitution.  The G70553T 
translates into a T707N substitution in a P.chabaudi-specific gene (PCHAS_030200) 
in the non-syntenic part of the chromosome.  Because the chr03 valley could not be 
further narrowed (i.e. all markers on chr03 were selected more or less equally), both 
mutations must be considered as possible candidates.   
The sequencing of the two fragments of these genes in all strains of the lineage 
revealed that both mutations were absent in the sensitive (AJ, AS-sens, AS-pyr), low 
resistant (AS-3CQ) and intermediately resistant (AS-15CQ, AS-ATN and AS-15MF) 
strains.  They were present only in the highly resistant AS-30CQ (Fig 5.2 and 5.3).  
These data suggest that either one or both of these mutations may confer highest 
level of CQ resistance which was in contrast with the previous predictions according 
to which the mutation on chromosome 3 was likely to be involved into the 

















Figure 5.2 Point mutation resulting in T707N substitution in PCHAS_030200 gene in various 
strains of AS lineage 
a) The chromatograms show the substitution of the base in the sequence b) the schematic of the AS 
lineage with the strains carrying the wt version of the PCHAS_030200 gene marked in black and 
those carrying the mutated version in red.  The uncloned population AS-15CQ strain is marked with a 
circle and its genotype is inferred from the genotyping of other strains in the lineage. The dashed 




















Figure 5.3 Point mutation resulting in T719N substitution in PCHAS_031370 (tm12) gene in 
various strains of AS lineage   
a) The chromatograms show the substitution of the base in the sequence b) the schematic of the AS 
lineage with the strains carrying the wt version of the PCHAS_031370 gene marked in black and 




During the investigation of AS-15MF from the AS lineage, however, another 
mutation was on chromosome 3 was discovered– a 3bp deletion (472273 – 5) 
(Sophia Borges, PhD thesis).  Remarkably, it was also localised within tm12 gene 
and encoded for a deletion of I102.  Further investigation of the respective fragment 
of this gene in the AS lineage revealed that this mutation was present in all three 
intermediate resistant strains of the lineage – AS-15MF, AS-15CQ, AS-ATN), but 
absent in the highly resistant AS-30CQ (Fig .5.4).  This is further discussed below in 




















Figure 5.4 The 3bp deletion in PCHAS_031370 (tm12) gene in various strains of AS lineage. 
The AS lineage with the strains carrying the wt version of the tm12 gene marked in black and those 
carrying the mutated version in red.  The genotype of AS-15CQ strain and the place of appearance of 
the mutation within the lineage could not be established for the reasons mentioned in the text. 
 
In summary, 2 potential determinants of CQ resistance were determined on 
chromosome 3 in AS-30CQ – PCHAS_030200 and PCHAS_031370 (tm12).  The 
first one was mutated in highly CQ resistant strain only.  The second one was 
mutated in both intermediate and highly resistant parasites, however different 
mutations were present the intermediate-resistant strain/clones AS-15CQ, AS-15MF, 
AS-ATN and the highly resistant clone AS-30CQ. 
5.4.4.3. Chromosome 2 
The selection of the AS-30CQ x AJ backcross with ART (Chapter 4, Fig. 4.15) 
confirmed the existence of the major locus on chromosome 2, as was the case with 
ART selection of the AS-ART x AJ cross (Hunt et al., 2007).  Moreover a similar 
locus was selected with the highest CQ concentrations (Fig 4.7 and 4.8 d-e in 
Chapter 4).  Previously, during the design of pyrosequencing markers, a mutation 
within the PCHAS_020720 (ubp1) gene was identified on this chromosome in AS-
ART strain (a progeny of AS-30CQ) (Hunt et al., 2007).  The connection between 
this mutation and ART resistance however, remained speculative because of the lack 
of the full inventory of mutations within the predicted region. 
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The Solexa sequencing results confirmed that, in AS-30CQ, only one mutation 
could be found on the whole chromosome 2 - the previously identified a C216954A 
substitution in PCHAS_020720 (ubp1) gene, that leads to V2728F mutation within 
the UBP1 protein.  Dideoxy sequencing (Fig. 5.5) revealed that three sensitive strains 
(AJ, AS-sens, AS-PYR1) and the low resistant AS-3CQ all bear the wild-type allele.  
The mutation was instead identified in AS-15CQ strain and two clones derived from 
it – AS-15MF and AS-30CQ.  It would indicate that it did occur between AS-3CQ 
and AS-15CQ, coinciding with both an increase of CQ resistance the appearance of 
ART resistance.  Surprisingly however, the third strain derived from AS-15CQ - AS-
ATN - carries the wild type allele, which questions both the place of the appearance 
of the mutation and the AS-15CQ genotype (situation very similar to del I101 in 



















Figure 5.5 Point mutation resulting in V2729F substitution in PCHAS_020720 (ubp1) gene in 
various strains of AS lineage   
a) The chromatograms show the substitution of the base in the sequence b) the schematic of the AS 
lineage with the strains carrying the wt version of the PCHAS_020720 (ubp1) gene marked in black 
and those carrying the mutated version in red 
 
However, the sequencing of PCHAS_020720 in AS-ATN strain (Hunt et al., 
2007) identified the alternative mutation within that gene, – a C217047A point 



















Figure 5.6 Results of previous sequencing of the point mutation resulting in V2697F substitution 
in ubp1 gene in various strains of AS lineage. 
The AS lineage with the strains carrying the wt version of the ubp1 gene marked in black and the ones 
carrying the mutated version in red.  The dashed arrow points the place of the most probable place of 
the appearance of the mutation within the lineage. 
 
In summary, as no other genetic changes were present on chr 2, the ubp1 
mutation was very likely to be both the determinant of ART resistance and a 
contributing factor to the high CQ resistance in AS-30CQ strain.  Additionally all the 
strains of the ART/CQ resistant strains (AS-15CQ, AS-30CQ, AS-ATN and AS-
15MF) are carrying a mutated version of this gene.  However, similarly to the tm12 
gene, two alternative mutations are present in the AS lineage – one in AS-ATN, 
another in the remaining clones.  One possible interpretation of these findings is 
discussed in the section 5.5.2 of this chapter. 
5.4.4.4. Other mutations identified by Solexa sequencing. 
 
This work was performed in collaboration with Sofia Borges, Axel Martinelli and 
Louise Rodrigues 
 
Beside the four mutations situated within the three major selection valleys that 
have just been described, five other genetic changes that arose between AS-sens and 




Three of them arose between AS-sens and AS-pyr, under pyrimethamine 
pressure and therefore were present in CQ and ART sensitive strain.  They were: 
• a previously known G994546A substitution on chr.7.  It results in S106N 
mutation within PCHAS_072830 (pcdhfr) gene, encoding for dihydrofolate 
reductase that was previously identified as the main determinant of 
pyrimethamine resistance. 
• the 34bp indel situated in intergenic region of chr 7 
• the T936945G substitution on chr 14, in intergenic region. 
The involvement of those mutations in CQ/ART resistance is very unlikely, as 
all of them were present in CQ- and ART-sensitive AS-pyr strain.  They also fail to 
generate the repeatable selection valleys with either CQ or ART pressure during the 
experiments described in chapter 3 and 4 (one decreased marker on chromosome 7 
observed under the highest ART concentration on Fig 4.16  is very likely to be an 
experimental error).  Additionally one of them is a well-known mutation, responsible 
for pyrimethamine resistance in both human and rodent malaria and lacking any 
connection with CQ or ART resistance both in field and laboratory conditions.  The 
other two are non-coding changes and therefore less likely to introduce any 
phenotypic change.  Therefore they were no longer investigated in the context of 
resistance. 
 
The two remaining mutations were: 
• a 1.2 kb deletion on chromosome 5 that appeared causes a deletion of 
PCHAS_051920 gene (a possible antigen). This mutation couldn’t be sequenced 
due to its size but Solexa sequencing of other strains in the lineage – AS-15MF 
and AS-ATN and AS-3CQ – (Paul Hunt, personal communication) strongly 
suggests that this mutation happened between AS-3CQ and AS-15CQ strains 
• a T634932C substitution translating to Y162H mutation in PCHAS_101550 (a 
conserved Plasmodium protein of unknown function).   
None of those mutaions generate a strong signature in the experiments 
described in chapter 4 (although chr 5 is one of the many loci selected during the 
initial experiments with cross selection described in chapter 3 (see Fig. 3.4 and 4.9)).  
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However, they both appeared under CQ pressure and are introducing the coding 
mutations within the predicted proteins that may in some way impact the phenotype.  
Therefore, it cannot be excluded that they play some role in the studied resistance, 
but their influence either is not strong enough to generate a selection signature, or 
manifests itself in in the different setting (e g. during different treatment regime or in 
a different part of the life cycle). 
5.4.4.5. Summary 
The combination of the data generated in Chapter 4 with the Solexa sequencing 
suggests that at least four out of 9 mutations present in AS-30CQ may be connected 
with either CQ or ART resistance.  More specifically our data suggests that aat1 may 
be the main determinant of CQ resistance in our lineage and reinforces the 
hypothesis that ubp1 is the main determinant of ART resistance.  Additionally two 
possible gene candidates were located within a supplementary locus on chr 3 
contributing to the high and intermediate level of CQ resistance (tm12 and 
PCHAS_030200) and ubp1 may be involved in the highest level CQ of resistance.  
Other mutations in the lineage failed to result in consistent deep selection valleys and 
therefore, either they are not involved in the studied resistance phenotypes or their 
effect is too small to be observed in our experiments. 
The analysis of the appearance of these mutations throughout the AS lineage 
combined with the discovery of the alternative mutations within two out of four 
predicted resistance determinants (Table 5.11), however, reveals additional genetic 
complexity with  the various pattern of mutations within ubp1 and tm12 genes 
observed in the intermediate and highly resistant strains.  The possible interpretation 



















































































































































































































































































































































































































































5.4.5. Proportional sequencing of predicted mutations in the 
selected backcross progeny 
In order to confirm that the identified mutations may generate chloroquine and 
artemisinin selection signatures, the proportions of three of the four mutations 
identified as the likely resistance determinants (A173E in aat1, V2728F ubp1 and 
T719N tm12 were measured in selected backcross progeny generated by selection 2 
during the experiments described in chapter 4 (see section 4.4.5).  












No drug 75.0 74.4 91.1 
1.5mg CQ 77.1 78.2 93.1 
3mg CQ 1.0 11.6 80.7 
10mg CQ 0.6 1.5 14.7 
20mg CQ 0.2 0.7 8.6 
100mg 
ART 
38.2 35.4 8.8 
200 mg 
ART 
5.8 10.5 0.1 
Table 5.12 The percentages of wt AJ allele within backcross progeny 
5.4.5.1. A173E mutation in aat1 
The proportions of wild type aat1 allele in the untreated populations were 





corresponded with the previous data reporting the lack of selection valley at this 
concentration, in this particular experiment.   
However parasites bearing the wild-type allele almost disappeared during the 




.  In all three cases the 
frequency of the wt allele in the population was below 1%, which is within an 
experimental error of the assay.  Therefore, it is likely that nearly all parasites 
surviving the CQ treatments were carrying the mutated version of the aat1 gene.  The 
plotting of these values on the genome scan shows that this locus was the lowest 
point of the selection valley identified on chr 11 with all three concentrations (Fig. 
5.7). 
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A distinct reduction in the frequency of the wild-type allele was also observed 




).  However, this time 
the selection for the mutated allele is not complete (i.e. a significant portion of 
parasites surviving the ART treatment is carrying the wt aat1 allele) and aat1 is not 
the lowest point of chr 11.  The potential explanation of selection on this 
chromosome can be found in section 4.5.4. 
5.4.5.2. T719N mutation in tm12 










treatment (which first shows evidence of a selection valley on chr 3) and completely 




 treatment suggesting that it may be 
necessary to survive the high CQ doses.  Again some evidence of selection can be 




however it can be easily explained by a 
significant scatter observed on this particular genome scan.  In all selected 
populations this marker gives lower AJ allele values than any other marker on 
chromosome 3. These data therefore is consistent with the hypothesis that the tm12 is 
the main factor contributing to further increase of CQ resistance after aat1 mutation. 
5.4.5.3. V2728F mutation in ubp1 





very high (>80%) proportion of wt allele is observed.  In the populations treated with 




 (those in which a selection valley on chr 2 was 
identified) a very high proportion of the mutant allele is observed instead.  However 
in both cases the wt version of the gene is not completely eliminated in the 
population.   
The strongest reduction of the wt version of the allele, however, is observed 
with ART treatment: at 100 mg/kg/day of ART the mutated allele is present in >90% 
of parasites and at 200 mg - in nearly 100%.   
In all selected populations the proportions of AJ alleles of ubp1 and/or the 




























































































    
 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.4.6. The predicted determinants of CQ and ART resistance  
This section briefly describes the four genes connected in CQ and ART 
resistance in P.chabaudi, summarizing the data concerning their function, 
expression, conservation in Plasmodium spp., the likely impact of the predicted 
mutations and how they might mediate the resistance phenotypes. 
5.4.6.1.PCHAS_112780 (Aat1) 
The main gene associated with CQ resistance, PCHAS_112780 (aat1), 
encodes a 70.6 kDa protein composed of 617 amino acids.  Its predicted product is a 
transmembrane protein with 10 transmembrane domains (Fig. 5.9a).   
No data is available concerning the expression of this gene in P.chabaudi.  Its 
orthologue in P.falciparum (PFF1430c) however, is expressed mainly at the 
intraerythrocytic part of the cycle reaching its peak in the trophozoites (Fig. 5.9b).  
Similar data was obtained also in P.vivax orthologue (PVX_114575) (graph not 
shown).  Therefore it seems likely that aat1 follows similar expression profile 
reaching the peak of its expression at the stage targeted by chloroquine. 
The protein sequence of aat1 shows a high degree of conservation within 
P.falciparum species and within Plasmodium genus.  Only 5 SNPs within this gene 
were discovered so far between various Plasmodium strains (see Table 5.13) and the 
alignment between aat1and its orthologues from three primate and two other rodent 
malarias shows that the core of the protein is practically identical in all six species 
(Fig. 5.10 and Appendix D).  
What is the function of AAT1?  Its orthologue in P.falciparum - PFF1430c - 
has been shown to contain a motif which defines its targeting to the digestive vacuole 
and this has been experimentally confirmed (D. Fidock and P. Moura, personal 
communication).  Additionally PFF 1430c was recently identified as a potential 
member of the amino acid/auxin permease (AAAP) family – a group of proteins 
responsible for transmembrane transport of amino acids in yeast, protozoans, plants 
and animals (Martin et al., 2005) .  Based on sequence similarities Martin et al. 
predict that PFF1430c functions as a Na+ or H+ dependent general-specificity amino 





*Stages: ER = Early Rings LR = Late Rings ET = Early Trophs LT = Late Trophs ES = Early Schizonts LS = Late Schizonts 
|M = Merozoites S = Sporozoites G = Gametocytes  
Figure 5.9 The predicted structure of AAT1 protein and the expression profile of its 
P.falciparum orthologue.  
a) the predicted transmembrane structure of AAT1 protein obtained using TMHMM software.  The 
position of mutation discovered within P.chabaudi lineage is marked.  
b) the expression of PFF1430c transcript in P.falciparum at various life cycle stages, obtained using 
Affymetrix oligonucleotide arrays according to (Le Roch et al., 2003).  The erythrocytes cultures were 
synchronized either with sorbitol (cyan) or with temperature (violet). Sporozoite sample represents 
average of two replicates and gametocyte sample is available for sorbitol cultures only.  The upper 
graph shows Log (base 2) ratio of Affymetrix MOID expression value (normalized by experiment) to 
average MOID value for all time points for a gene. The bottom one Affymetrix MOID expression 



























1214261 null C G 0.71 0.29 non-coding   
1214352 552 G T 0.67 0.33 syn I I 
1215070 313 A G 0.85 0.15 non-syn F S 
1215235 258 G A 0.82 0.18 non-syn S L 
1215316 231 A T 0.91 0.09 non-syn V D 
Table 5.13 Polymorphisms in PFF1430c gene in P.falciparum population 
SNPs obtained by combining the data Broad Institute, NIH and Wellcome Trust Sanger Institute 
(Jeffares et al., 2007; Mu et al., 2007; Volkman et al., 2007). 
 
 
P.falciparum_PFF1430c        SN----DKKKKKKDSKK-------------------NSSNNNNNNTIVDI 139 
P.vivax_PVX_114575           DGYYGEDNNNGAKDVQKNCQEGN----------ENENCDCDNQNSTIVDV 163 
P.knowlesi_PKH_111940        DGYYDQDNNNDVNDTQENYQESN----------ATENYDNENENIAIVDV 189 
P.chabaudi_PCHAS_112780      HWYHQNKNDNKKKNNKNSKNNKN---------ISNQYVSLAHVNDNDQEI 149 
P.berghei_PBANKA_112830      NWYHQNKYNNKMNNSKNSKN------------SHNKHISIAHIKYDDQEI 146 
P.yoelii_PY04168             NWYHQNKYNNKMHNSKNSKNSKNSKSSKNSKHSHNKHISIDHIKDDDQEI 158 
                                   . .:  :: ::                     .  : :    :: 
  
P.falciparum_PFF1430c        SDGD-YTNDEEGTNKPKRNWKGRTFSRFTPGGVRSSTVLFICTAIGVGFL 188 
P.vivax_PVX_114575           GENEKNPEDEEAEKS-KKNWQRRTFSRFTPGGVRSSTVLFICTAIGVGFL 212 
P.knowlesi_PKH_111940        GGNEKNAQDKEEEKKRKKNWKRRTFSRFTPGGVRSSTVLFICTAIGVGFL 239 
P.chabaudi_PCHAS_112780      NENGKNKLCEENETNTKKTWQKRAFGPFTPGGVRSSTVLFLCTAIGVGLL 199 
P.berghei_PBANKA_112830      NEKGKNKLYEENQTNTKKTWKRRAFSPFTPGGVRSSTVLFLCTAIGVGLL 196 
P.yoelii_PY04168             NEKEKNKIYEENQTNKKKTWKKRTFSPFTPGGVRSSTVLFLCTAIGVGLL 208 
                             .        :*  .. *:.*: *:*. *************:*******:* 
 
P.falciparum_PFF1430c        SIPYVFSKLGIILSIILIILNAFESYVTTNILCTSSLEHNTFVYGNLLKK 238 
P.vivax_PVX_114575           SIPYVFSKLGIILSLLLILLNAVESYVTTNILCLSSLEHNTFVYGNLLKK 262 
P.knowlesi_PKH_111940        SIPYVFLKLGIILSLLLILLNGMESYVTTNILCMTSLEHNTFVYGNLLKK 289 
P.chabaudi_PCHAS_112780      SIPYVFSQLGIILSIILILLNALESYITTNILCMSALEHNIFVYGNLLEK 249 
P.berghei_PBANKA_112830      SIPYVFSELGIILSIILILLNSLESYITTNILCMSSLEHNIFVYGNLLEK 246 
P.yoelii_PY04168             SIPYVFSELGIILSIILILLNSLESYITTNILCMSSLEHNIFVYGNLLEK 258 
                             ****** :******::**:**..***:****** ::**** *******:*  
Figure 5.10 The fragment of alignment of homologues of  AAT1 protein between six Plasmodium 
species.  
The alignment was produced with ClusatalW2 software.  The position of the residue mutated in AS-
30CQ is highlighted.  The full alignment is available in appendix D. 
 
 
The mutation associated with the CQ resistance in our model is causing a 
change from alanine in position 173 into glutamic acid.  This change is localised just 
before the 1
st
 predicted transmembrane domain of the protein, on the “outer” side of 
the membrane (equivalent to the interior of digestive vacuole) (Fig.5.9a).  It maps to 
the beginning of a highly conserved region and concerns a semi-conserved residue - 
the alignment between six Plasmodium species reveals that either alanine (A) 
(P.chabaudi and P.berghei) or threonine (T) (P.falciparum, P.vivax, P.knowlesi and 
P.yoelii) is present on the homologous position.  Both A and T are small, uncharged 
residues.  The mutation present in AS-30CQ instead introduces at this position more 
bulky, charged residue (E), and therefore is likely to affect the protein function (e.g. 
change the transporter specificity).  
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5.4.6.2. PCHAS_031370 (tm12) 
 
The tm12 gene was identified as one of two possible determinants of high or 
intermediate CQ resistance localised on chr 3.  It is predicted to encode a 142.5 kDa, 
1218 aa, hypothetical protein.  Structure predictions suggest that it may be another 
membrane protein, containing 12 transmembrane domains (Fig. 5.11a).   
Its homologue in P.falciparum (PFB0675w) and P.vivax (PVX_002795) are 
expressed mainly in merozoites and rings with the minimum of expression on 
schizonts (Fig 5.11b).  The mass spectroscopy however, confirmed its presence in 
trophozoites (main targets of CQ action).  The PFB0675w protein, similarly to the 
previous one, is predicted to target the digestive vacuole membrane (D. Fidock and 
P. Moura, personal communication).  Its function remains unknown.  
Also this gene is characterised by high degree of conservation.  Only 15 SNPs 
were identified within P.falciparum strains (Table 5.14) and the alignment between 
different Plasmodium species reveals several regions highly conserved across all six 




*Stages: ER = Early Rings LR = Late Rings ET = Early Trophs LT = Late Trophs ES = Early Schizonts LS = Late Schizonts 
|M = Merozoites S = Sporozoites G = Gametocytes  
Figure 5.11 The predicted structure of TM12 protein and the expression profile of its 
P.falciparum homologue  
a) the predicted transmembrane structure of TM12 protein obtained using TMHMM software.  The 
position of mutations discovered within P.chabaudi lineage is marked.  
b) the expression of PFB675w transcript in P.falciparum at various life cycle stages obtained using 
Affymetrix oligonucleotide arrays according to (le Roch et al., 2003).  The expression data presented 


























605144 34 T G 0.89 0.11 non-syn C G 
605351 null T G 0.88 0.13 non-coding   
605412 68 C A, T 0.7 0.3 non-syn A E, V 
605419 70 A T 0.9 0.1 non-syn K N 
605425 72 A T 0.9 0.1 non-syn K N 
605645 146 A T 0.71 0.29 non-syn N Y 
606435 409 G A 0.91 0.09 non-syn G D 
606666 486 G A 0.93 0.07 non-syn R H 
607100 631 G T 0.92 0.08 non-syn A S 
607784 859 A C 0.95 0.05 non-syn K Q 
608130 974 A G 0.92 0.08 non-syn D G 
608255 1016 A C 0.64 0.36 non-syn N H 
608501 1098 G T 0.77 0.23 non-syn A S 
608550 1114 A C 0.77 0.23 non-syn E A 
608790 1194 A G 0.5 0.5 non-syn H R 
Table 5.14 Polymorphisms in PFB0675w gene in P.falciparum population 
SNPs obtained by combining the data Broad Institute, NIH, and Wellcome Trust Sanger Institute 
(Jeffares et al., 2007; Mu et al., 2007; Volkman et al., 2007) 
 
Two mutations appeared in within TM12 protein in AS lineage: I102del and 
T719N.  The I102 is located within a central part of highly conserved sequence of 
hydrophobic residues forming the core of TMD 3 and is conserved throughout all six 
Plasmodium species (Fig 5.11a and 5.12).  Additionally, the in silico prediction of 
secondary structure of wild-type and mutated protein suggests that the deletion of 
this amino acid is causing a significant rearrangements within the protein e.g. 10 
instead 12 transmembrane domains are predicted. (Fig. 5.13).  All this indicates that 
this residue may play a crucial role in the maintenance of correct protein structure, 
and its removal is likely to disturb the protein function. 
The second change (T719N) is an amino acid substitution that takes place on 
the ”outer” side of the membrane (DV inner), in the middle of the large loop of the 
protein between transmembrane domains 11 and 12 (Fig 5.11a).  This residue is semi 
conserved throughout the Plasmodium genus.  The homologous position contains 
threonine in all rodent parasites and serine in all primate ones.  It suggests the 
importance of a hydroxyl-containing side-group on this position e.g. as potential 






P.falciparum_PFB0675w        NGIINPAVKIVFHGSIIEDKTKVYENSIIESIWLLFTKGSYFNMAMLLFF 100 
P.vivax_PVX_002795           NGIINPAVKIVFHGNIIADNTQVYENSILESIWLLFTSKSYFNMAMLLLF 100 
P.knowlesi_PKH_040510        NGIINPAVKIVFHGNIIADTTQVYENSILESIWLLFTSKSYFNMGMLLFF 99 
P.chabaudi_PCHAS_031370      NGLIYPAVKIVFHGSVIANQTIVYKNSILESIWLLYTSGSYFNMGVLLIF 99 
P.berghei_PBANKA_031160      NGLIYPAVKIVFHGSVIANQTIVYKNSILESIWLLYASGSYFNMGVLLIF 99 
P.yoelii_PY05194             -------------------------------------------MGVLLIF 7 
                                                                        *.:**:* 
 
P.falciparum_PFB0675w        SIIIPFLKLLMVSDNFYSFIVLYKMNKKREEEKRRRRRRIRAREYNNAKY 150 
P.vivax_PVX_002795           SIIIPILKLIMVSDNFYCFFKLYNLSLQHEEEEKEEE------------- 137 
P.knowlesi_PKH_040510        SIIIPILKFIMVSDNFYCFFKLYNLSLQHEEEEKEEE------------- 136 
P.chabaudi_PCHAS_031370      SVIIPILKFVMVTDNFYSFFKLYNLGLKFNENDKDD-------------- 135 
P.berghei_PBANKA_031160      SVIIPVLKFVMVSDNFYSFFKLYNLSLNFNENDKDD-------------- 135 
P.yoelii_PY05194             SVIIPVLKFIMVSDNFYSFFKLYNLSLNINENDKDD-------------- 43 
                             *:***.**::**:****.*: **::. : :*:.:                 
 
P.falciparum_PFB0675w        NKNRYKMNKYNRNKNINDIYKDDIYYSENIFKNDEINYINTINENEEFIL 200 
P.vivax_PVX_002795           --------------------------------EDDIFFINTVNENEQFIL 155 
P.knowlesi_PKH_040510        --------------------------------EDDIFFINTVNENEQFIL 154 
P.chabaudi_PCHAS_031370      --------------------------------AKLIYYINIVNENEEFAL 153 
P.berghei_PBANKA_031160      --------------------------------AKLIYYINIVNVNGEFAL 153 
P.yoelii_PY05194             --------------------------------AKLIYYINIINENEEFAL 61 
                                                              . * :** :* * :* *  
 
 
P.falciparum_PFB0675w        KSEKIKFCKFLLFILYGLLCFSINLYVNQWEEYITKLKRLKRRILLFEKN 825 
P.vivax_PVX_002795           KSNTVKFCKFLLFVVYGLLCLSINLYVSQWELYVKKLKKTKKRIALFQNN 776 
P.knowlesi_PKH_040510        KSSTVKFCKFFLFVVYGLLCLSINLYVSQWELYVKKLKKTKKRIALFQNN 776 
P.chabaudi_PCHAS_031370      KTDKIHFSKFILFIAFGLICFSINMYVAQWEKLVKKLQKIRKQIYLFEAN 697 
P.berghei_PBANKA_031160      KTDKIHFSKFILFISFGLICFSINMYVTQWEKIIKKLQKIRKQIFLFESN 693 
P.yoelii_PY05194             KTDKIHFSKFILFISFGLICFSINMYVAQWEKLIKKLQKIRKQIFLFESN 594 
                             *:..::*.**:**: :**:*:***:** ***  :.**:: :::* **: * 
 
P.falciparum_PFB0675w        KFSEIVDLNTQKGDGDHFDETQIFSIFFSFLIKKNE--GSKMRDNDMNSD 873 
P.vivax_PVX_002795           RYSEIVDLNIQK---HEHWHVPIYSYFFQFLLKKEHFFSSSLKHNHITK- 822 
P.knowlesi_PKH_040510        RYSEIVDLNIQK---HEHWHVPIYSYFFQFLLKKEHFFSPSIKHNQITK- 822 
P.chabaudi_PCHAS_031370      RCSEIVDLNIQK---NKNWTIPIYTYFFKSLIKPNQIVFKKNKKIDISE- 743 
P.berghei_PBANKA_031160      RCSEIVDLNIQK---NKNWNIPIYTYFFKFLIKQNQNILKKKKKIDISQN 740 
P.yoelii_PY05194             RCSEIVDLNIQK---NKNWNIPIYTYFFKFLIKQNQNIFKKKNKINISQD 641 
                             : ******* **   ..     *:: **. *:* :.    . .. .:..  
 
P.falciparum_PFB0675w        SEDSIYDAYEQQIQLHHGDNMVNGMLMMRRISMQNLEDDETQ-------- 915 
P.vivax_PVX_002795           --EHTDTVQTMMMHRVYENDTSLGYQNTRVDNDELNDFNEFN-------- 862 
P.knowlesi_PKH_040510        --EHTDTVQTMMMYRVYENDTSLGYQNTRVDND---EMVEFN-------- 859 
P.chabaudi_PCHAS_031370      --DNNTHIIRTQSSNMYDYDENR--------------------------- 764 
P.berghei_PBANKA_031160      INNN--HIIRTQSSTMYDNDENK--------------------------- 761 
P.yoelii_PY05194             INNNNNHIIRTQTSTTYDCDANQNYQNCQNYQNYQNCQNYQNCQNYQNCQ 691 
                               :             :  :                                
Figure 5.12 The alignment of two fragments of TM12 protein between six Plasmodium species.  
The positions of I102del and T719N mutations are highlighted.  The full alignment can be found in 






Figure 5.13 The impact of I102del in TM12 on protein structure  
a) the pattern of transmembrane domains predicted for wt protein b) the pattern of TMD predicted for 
a mutant.  The prediction for the mutant protein is more likely to reflect the constraints in assuming 







A second one of the two proteins mutated on chromosome 3.  Because this 
gene is non-syntenic, i.e. localised within the P.chabaudi-specific part of the 
genome, the information about its structure and function is very limited.  It encodes 
for a hypothetical 1287 amino acid protein belonging to the interspersed repeats (pir) 
superfamily.  The members of that family in P.chabaudi are located in telomeric 
regions and expressed mainly at trophozoite stage (Janssen et al., 2004).  At least 
some of the members of this family were shown to be exported from the parasite and 
located at the surface of infected erythrocyte (Sharling et al., 2007).  Their exact 
function is not known - immune evasion, erythrocyte invasion, intracellular transport 
and intracellular signalling have been suggested (Cunningham et al., 2010).   
Due to the lack of data, no hypothesis can be formulated about the potential 




5.4.6.4. PCHAS_020270 (Ubp1) 
 
As the only mutated gene on chromosome 2, ubp1 was found to be both the 
likely main determinant of ART resistance and the contributing factor to the high CQ 
resistance.  This gene encodes a large 416.1 kDa protein composed of 2921 amino 
acids.  Based on the data from P.falciparum and P.vivax orthologues, it is expressed 
throughout the lifecycle with the peak of expression in merozoites and rings and 
minimal expression in early schizonts (Fig. 5.14b).  
Its predicted function is a ubiquitin carboxyl-terminal hydrolase, a de-
ubiquitinating enzyme.  No molecular targets of this enzyme have been identified so 
far, although its P.falciparum homologue (PFA0220w) was shown to interact with 
four proteins  in the budding yeast experimental system (LaCount et al., 2005).  
Those are: PF11_0477 (CCAAT-box DNA binding protein), PF13_0050 (HORMA 
domain protein, potentially involved in mitosis), MAL7P1.155 (a zinc finger protein) 
and MAL8P1.153 (a transcription factor).  This preliminary results have to be treated 
with caution, however they suggests the potential involvement in transcription 
regulation and/or cell division. 
In this case the protein is not as highly conserved as AAT1 and TM12.  The 
number of polymorphisms present in P.falciparum gene is much higher (56, see 
Table 5.15) and the alignment between six Plasmodium species shows less than 50% 
of identical residues between the species (see Appendix D).  However, it also 
identifies a highly conserved region at the C-terminus of this protein (the predicted 
catalytic domain), which is almost identical in all sequenced species and contains no 
coding polymorphisms in P.falciparum population.  Both mutations identified in AS 
lineage (V2697F and V2728F) are located within this region and change the residues 
conserved throughout the Plasmodium genus (Fig. 5.14a and 5.15).   
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The study of the possible effects of the V2728F and V2697F mutations on this 
protein was published previously (Hunt et al., 2007).  In summary, the conserved C-
terminal part of the UBP1 protein was used to interrogate the protein structure 
database revealing the similarity to the human herpes-virus-associated, ubiquitin-
specific protease (HAUSP) for which the crystal structure has been solved (Hu et al., 
2002).  This structure was used as a template for a 3D model of UBP1 catalytic 
domain (presented on Fig 5.14a), revealing the position and potential role of the 
mutated residues.  It indicates that both mutations are likely to cause a significant 
shift in protein structure, potentially affecting its function.  
The V2728 residue (equivalent of HAUSP I332) in the wt UBP1 protein points 
to a hydrophobic pocket required for ubiquitin binding, defined principally by Y2779 
(UBP-1) and F4 (ubiquitin) (Fig. 5.14a and 5.16a).  The introduction into this spot of 
a much more bulky phenylalanine is causing dramatic clashes in the side chain 
orientation and the whole structure of the protein needs to be modified in order to 
accommodate this change.  Therefore the disruption of ubiquitin binding and the 
decrease in the enzymatic activity of the protein is very likely.  
The AS-ATN specific V2697F mutation (equivalent of HAUSP V296) maps to 
an end of alpha helix 5 close to the proposed catalytic cysteine, C2586 (Fig. 5.14a).  
A wt residue fits in the hydrophobic pocket defined by Y2857 and I2845. Again the 
predicted mutation introduces the bulky residue that forces a significant 
rearrangement of the neighbouring amino acids.  It is most likely that the 
phenylalanine side chain would point into a small pocket produced by V2905, I2845 
and L2591 (Fig. 5.16.b).  However, the V2697F side chain comes too close to these 
residues to be accommodated without further movement.  These movements are 
likely to affect the catalytic cysteine, C2586, found on the same helix as L2591.  It is 
also likely that ubiquitin binding will be affected, because Y2857 interacts directly 
with ubiquitin. Therefore also this mutation is predicted to interfere with the catalytic 




*Stages: ER = Early Rings LR = Late Rings ET = Early Trophs LT = Late Trophs ES = Early Schizonts LS = Late Schizonts 
|M = Merozoites S = Sporozoites G = Gametocytes  
Figure 5.14 The predicted structure of the fragment of UBP1 protein and the expression profile 
of its P.falciparum homologue.  
a) the predicted 3D structure of the conserved, C-terminal domain of UBP1 protein.  The positions of 
the mutations discovered within P.chabaudi lineage, as well as the place of ubiquitin-binding side and 
the catalytic cleft with the crucial cysteine residue, are marked.  
b) the expression of PFA0220w transcript in P.falciparum at various life cycle stages obtained using 
Affymetrix oligonucleotide arrays according to le Roch et al., 2003.  The expression data is presented 
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Table 5.15 Polymorphisms in PFA0220w gene in P.falciparum population  
SNPs obtained by combining the data Broad Institute, NIH, and Welcome Trust Sanger Institute 
(Jeffares et al., 2007; Mu et al., 2007; Volkman et al., 2007) 
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P.falciparum_PFA0220w        -------TNSELDYFLEEIKSFFKNMLTTDKSYISADRVLNMLPVELNNR 3270 
P.vivax_PVX_081540           TTPTNQVATAESERFLQELKNLYIIMTTTKKTYVSPDCILGLLPHELNNR 510 
P.knowlesi_PKH_020900        IPPMNHIGTVESERFLQELKNLYIIMTTTNKMYVSPDSILGLLPYELNNR 3342 
P.chabaudi_PCHAS_020720      MNNNNNNANLLSKRFLYELKILFKLMTTTNKKYVSPDNILGILPQELNNR 2692 
P.berghei_PBANKA_020880      PNINDSYTNLLSKRFLYELKILFKLMSTTNKKYVSPYSILSILPQELNNR 2716 
P.yoelii_PY01242             --INDSHKNLLSKRFLYELKILFKLMSKTNKKYISPDNILNILPQELNNK 1781 
                                     .   . ** *:* ::  * .*.* *:*.  :*.:** ****: 
 
P.falciparum_PFA0220w        NQQDVTEVFRYIFDKLGGSEKEFLRLIFSGVVIQKVQCQKCLFISKKKEI 3320 
P.vivax_PVX_081540           NQQDVTELLRYIFDKLGGSSREFLRLIFSGVLVQKVQCQKCFFVSKKEEV 560 
P.knowlesi_PKH_020900        NQQDVTELLRYIFDKLGGSSREFLRLIFSGVLVQKVQCQKCFFVSKKEEV 3392 
P.chabaudi_PCHAS_020720      NQQDVTELFRYTFEQLGGSEKKFLRLIFSGVVIQKVQCQKCFFISKKEEI 2742 
P.berghei_PBANKA_020880      NQQDVTELFRYTFEQLGGSEKRFLRLIFSGVVIQKVQCQKCFFISKKEEI 2766 
P.yoelii_PY01242             NQQDVTELFRYTFEQLGGSEKKFLRLIFSGVVIQKVQCQKCFFISKKEEI 1831 
                             *******::** *::****.:.*********::********:*:***:*: 
 
P.falciparum_PFA0220w        IHDLSFPVPISTNEKLSIQRFFDTFIQKEKIYGNNKYKCSRCNKKRNALK 3370 
P.vivax_PVX_081540           IHDLSFPVPVKASERLSIQKFFDTFVQKEKIHGSNKYRCSKCNKKRNALK 610 
P.knowlesi_PKH_020900        IHDLSFPIPVRASEKLSIQKYFDSFVQKEKIHGSNKYRCSKCNKRRNALK 3442 
P.chabaudi_PCHAS_020720      IHDLSFHVPAKSSKKQSIQKFFDTYIQKEKIYGNNKYKCSKCNKRRNALK 2792 
P.berghei_PBANKA_020880      IHDLSFHVPAKSTKKESIQKFFDTYIQKEKIYGNNKYKCSKCNKRRNALK 2816 
P.yoelii_PY01242             IHDLSFHVPAKSTKKESIQKFFDTYIQKEKIYGNNKYKCSKCNKRRNALK 1881 
                             ****** :*  :.:: ***::**:::*****:*.***:**:***:***** 
  
Figure 5.15 The fragment of the alignment of ubp1 protein between six Plasmodium species  




Figure 5.16 The predicted impact of the V2728F and V2697F mutations on the structure of the 
catalytic domain of UBP1  
a) Residue environment around V2728F.  The amino acid side chains are shown as sticks with carbons 
colored green for the P. chabaudi UBP1 sequence and white for ubiquitin (UbF4, UbE64).  The 
mutation to F2728, in its most likely orientation,  is represented in stick form with carbons colored 
cyan.  A surface representation is shown to indicate the tightness of fit around the phenylalanine. 
b) Residue environment around V2697F. Side chains are shown as sticks with carbons colored green 
for the P.chabaudi UBP1 sequence. The mutation to F2697 in the most likely orientation is 
represented in stick form with carbons colored cyan.  A surface representation is shown to indicate the 





5.5.1. The mutations within the resistant AS lineage 
In this chapter Solexa genome resequencing was used to define the genetic 
changes that appeared in the AS lineage during the selection for chloroquine 
resistance.  The good sequence quality allowed the reassembly of almost the whole 
genomes of both strains with the coverage high enough to discover the mutations. 
Moreover the bioinformatics analysis performed in parallel using two different types 
of software, identified the same mutation set which was later confirmed by dideoxy 
sequencing validation (while all changes classified as false positives were discarded).  
Therefore it is likely that the obtained inventory of mutations between the two strains 
is complete or nearly complete. 
The main feature of this dataset is a very small number of mutations.  Despite 
the multiple passages, mosquito transmissions and cloning events to which both 
strains were subjected, only 9 genetic changes (7 point mutations, 2 deletions) were 
identified between AS-sens and AS-30CQ.  Moreover 6 out of the 7 point mutations 
are non-synonymous.  Due to the compact nature of the Plasmodium genome we 
expected a high proportion of coding to non-coding mutations than in eukaryotic 
organisms with more complex genomes(Mu et al., 2002).  However the bias obtained 
here suggests that many of the genetic changes in this lineage are not likely to be 
random events.  
In fact at least five of them are connected with drug resistance phenotypes.  
The dhfr S106N was previously identified as determinant of pyrimethamine 
resistance in the lineage and my work associates ubp1 V2728F, aat1 A173E, tm12 
T719N and PCHAS_030200 T707N with CQ/ART resistance phenotype.  
Additionally also some of the other changes are situated within regions potentially 
connected to the pyrimethamine (chr 7), chloroquine (chr 5) and artemisinin (chr 7 
and chr 14) resistance.  Therefore the expected number of neutral mutations is very 
low if any.   
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5.5.2. The structure and acquisition of CQ and ART resistance 
The combination of Solexa sequencing with the genetic data generated in 
chapter 4 defined the mutations contributing to the highest level of resistance to CQ 
– one mutation on chr 11 and one on chr 2, and two possible mutations on chr 3. 
All of these were sequenced in AS lineage with an expectation that the order in 
which they appeared would reflect the order in which the chromosomes are selected 
with the increasing level of CQ resistance as presented in the model in Fig 4.17 
(chapter 4).  In fact, in line with these expectations, the A173E mutation in aat1 was 
the first one to appear under CQ selection and is associated with acquisition of the 
first, lowest level of resistance.  The acquisition of higher levels of CQ resistance 
however turned out to be more complex.   
The genetic data suggest that chr 3 selection underlies an intermediate CQ 
resistance phenotype and that the chr 2 selection underlies the high level of CQ 
resistance.  However, the analysis of the mutations present in AS-30CQ suggested 
otherwise, i.e. that the mutation on chr 2 in the intermediate AS-15CQ strain 
occurred before the mutations on chr 3 that were present only in highly resistant 
strain.  The discovery of additional mutations in tm12 and the ubp1 gene and 
sequencing of additional strains in the lineage (AS-15MF and AS-ATN) introduced a 
further level of complexity, resulting in a complicated pattern of mutations on 
chromosome 3 and 2 presented in Table 5.11.   
In summary, all strains characterized by ART resistance and higher level of CQ 
resistance (compared to AS-3CQ) contained one mutation in aat1, one mutation in 
tm12 and one mutation in ubp1.  However two alternative mutations in both tm12 
and ubp1 were identified.   These mutations are difficult to place in the lineage 
because they appear in two out of three clones selected from AS-15CQ.  For each 
gene this means that either one of the strains is a revertant or that the same mutations 
appeared twice in the lineage in different clones.  These explanations are considered 
highly unlikely.  
These apparent contradictions may be resolved by acknowledging the fact that 
AS-15CQ is not clonal and as such cannot be assigned a reliable genotype.  
Therefore it can be a pool of various genotypes from which the three strains were 
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selected independently over time: AS-30CQ, AS-15MF and AS-ATN.  In this 
context, it seems plausible that both mutations in tm12 and in ubp1 appeared during 
the selection for the intermediate CQ resistance in AS-15CQ.  In fact only two 
genotypes present in the AS-15CQ could generate the observed genetic diversity (see 
Fig. 5.17).  Two of the progeny strains (AS-ATN and AS-30CQ would be generated 
by isolation of both original genotypes and the third (AS-15MF) would be a result of 





tm12   I102del








tm12   I102del
ubp1 V2728F




Figure 5.17 The possible order of occurrence of mutations on chr 3 and chr 2 in the AS lineage  
 
This model resolves all the contradictions presented.  It also allows for the 
possibility that the tm12 mutations occurred before the ubp1 mutations (in both 
cases), as predicted by the genomic data. 
However it also leaves another unanswered question.  If both ubp1 and tm12 
contribute to the intermediate phenotype, what would be the genetic factor 
 190 
responsible for further increase of CQ resistance between AS-15CQ and AS-30CQ?  
There are in fact two mutations specific for this strain: PCHAS_101550 Y162H on 
chr 10 and PCHAS_030200 T707N on chr 3.  The first mutation failed to generate a 
selection signature in any of the experiments described in chapters 3 and 4 (none of 
the markers on chromosome 10 showed the signs of selection) and therefore its 
involvement in CQ resistance is unlikely.  However PCHAS_030200 would be fit 
with obtained selection data.  It would explain both the lack of additional selection 
valley after chr 2 (the selection of this gene it would be masked by the effect of tm12 
gene present on the same chromosome) and the lack of definitive selection valley on 
chr 3 (the presence of the two selected genes would cause the whole chromosome to 
be selected as observed in chapter 4 (Fig 4.12-14)).  Therefore PCHAS_030200 is 
classified as a likely contributor to the resistance.  
5.5.3. The possible mechanism of CQ/ART resistance in 
P.chabaudi 
In this chapter I identified three (or possibly, four) novel genes potentially 
implicated in CQ resistance in P.chabaudi: aat1, ubp1, tm12 and possibly 
PCHAS_030200.  At least three of these genes (aat1, ubp1, tm12) contain coding 
mutations within highly conserved regions, affecting the residues that are conserved 
or semi-conserved in Plasmodium genus and likely to affect the function of the 
putative proteins. 
Aat1, the main gene associated with the CQ resistance in this study, is a 
potential amino acid transporter localized into the digestive vacuole membrane.  
Interestingly, the two main determinants of CQ resistance in P.falciparum are the 
potential DV transmembrane transporters: pfcrt and pfmdr1.  Additionally one of the 
possible functions of PFCRT is amino acid transport (Martin et al., 2005).  Also the 
A173E mutation in AAT1 bears some similarities to the crucial K76T mutation in 
PFCRT.  In both cases, these mutations are located at the entrance to the predicted 
transporter.  In the case of aat1, A173E is predicted to lie before the beginning of the 
1
st
 transmembrane domain on the digestive vacuole side.  In the case of pfcrt, K76T 
lies at the beginning of the first TMD.  Additionally, in both cases, the basic or 
neutral residue is replaced by a neutral or acidic one, respectively.  This change 
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(increasing negative charge) can possibly act to facilitate the transport of the 
positively charged CQ (a weak base).  It is therefore tempting to speculate that AAT1, 
similarly to PFCRT, either actively transports or allows the leak of CQ from the 
digestive vacuole.  
The role TM12 is more speculative.  This protein acts epistatically to att1 and 
is located in the same cellular compartment (DV).  It is therefore possible that it 
participates in the same mechanisms, modifying the CQ transport.  It may, for 
example, act as another transporter (similarly to PFMDR1 in P.falciparum) or affect 
the function of AAT1directly (by interacting with that protein) or indirectly 
(alternating the DV environment, compensating for the loss of function caused by 
A173E mutation etc.).   
The discovery of a third conserved gene (ubp1) connected with CQ resistance 
is of particular interest.  It contributes to high-level CQ resistance without being 
directly involved in the transport and, most importantly, it also confers the ART 
resistance to the parasites, without the previous exposure to this drug.  The fact that 
the same gene has an effect on two drugs of supposing different mode of action 
raises several questions.  Ubiquitination and de-ubiquitination may regulate the post-
translational state of many protein targets in many different ways e.g. affecting their 
function, targeting them to particular intracellular compartment or to degradation etc. 
(d'Azzo et al., 2005).  This plays a major role in cellular processes such as cell-cycle 
control, protein turnover, intracellular trafficking of membrane proteins and receptor-
mediated endocytosis.  Thus a number of intriguing possibilities present themselves.  
Does ubp1 change the ubiquitin state of any of the putative transporters connected 
with CQ resistance (AAT1?  TM12?, PFCRT and PFMDR1 homologues?)?  Does it 
regulate their function? Or does it take part in general stress responses, allowing the 
parasite to survive drug-induced oxidative stress more successfully, by globally 
regulating protein turnover?  Does it modify the cell cycle of the parasite allowing 
the temporary arrest in response to drug pressure (one of the main targets of HAUSP 
protein, a structural homologue of ubp1 in human, is p53, a well-known protein 
involved in cell cycle control and apoptosis (Sarkari et al., 2010)?  The identification 
of ubp1 mutations therefore opens up new directions to investigate antimalarial drugs 
and the molecular mechanisms of their action and resistance. 
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6. The fitness cost of high CQ resistance. 
6.1. Introduction 
Section 1.3.3 of Chapter 1 describes the concept of fitness cost of drug 
resistance and reviews the evidence indicating its existence in malaria parasites.  For 
example, the pfcrt-dependent chloroquine resistance in P.falciparum is thought to be 
a significant burden to the parasite.  However the study of this phenomenon in field 
isolates is often difficult due to ethical issues and the large number of additional 
factors affecting the performance of resistant and sensitive strains.   
The P.chabaudi lineage presented here offers a unique opportunity to study the 
fitness consequence of CQ resistance in vivo under laboratory conditions, because 
the behaviour (growth) of a resistant mutant and its isogenic sensitive progenitor can 
be studied in parallel.  In this study, it allows us to evaluate the effects of the 
mutations associated with a high level of resistance without the confounding effects 
of additional genetic variation.   
The first indication of fitness costs related to high CQ resistance were observed 
in the AS-30CQ v. AJ and AS-3CQ v. AJ competition experiments described in 
Chapter 2.  The highly resistant AS-30CQ strain grew slower than its low-resistant 
progenitor AS-CQ in both single and mixed infections.  However a clear 
interpretation of the results was not possible because the parasites were tested in 
separate experiments, a few months apart, using different batches of animals, and 
slightly different treatment protocols.  Moreover, in single infection controls only 
one mouse was used for each strain/treatment variation.  Therefore, it was impossible 
to distinguish between differences in the parasites themselves, and host variation.  
Finally, in those mixed infections, the parasites were competed with a genetically 
different strain, AJ.  The relative fitness of the two AS strains in such a situation may 
depend on many complex factors and interactions.   
Therefore in this chapter competition experiments directly comparing the two 
congenic strains was performed in order to investigate whether a measurable 




6.2. Experimental design 
Note: This experiment, competing the high CQ resistant clone AS-30CQ with the low 
CQ resistant clone AS-3CQ, was attempted before there was a full inventory of 
mutations arising in the AS lineage.  It was not possible to analyse the competition 
between AS-3CQ and AS-PYR1 because no discriminating genetic marker was 
available.  However, one mutation, ubp1 V2728F discriminating AS-3CQ and AS-
30CQ was known (Hunt et al. 2007). 
The general experimental design is presented on Fig.6.1. The mixture of two 
parasite strains – the highly resistant AS-30 CQ and low resistant AS-3CQ was 
grown in 4 groups of 4 mice treated for the first three days (d0-3) with following 
doses of chloroquine:  
 Untreated - where growth of both strain can be monitored without the drug 
pressure  
 1.5 mg of CQ kg-1 day-1- the very low subcurative drug treatment that would 
provide the moderate level of stress for both resistant strains,  
 3 mg of CQ kg-1 day-1 - the concentration that allows the growth of both 
strains, but proved to be restrictive for the sensitive strain, AS-sens 
 10 mg of CQ kg-1 day-1 - the concentration that should differentiate between 
the high-resistant strain, AS-30CQ and the lower-resistant strain AS-3CQ. 
In addition, in order to monitor the effect of the various drug doses, single 
infections were set up. AS- sens, AS-3CQ and AS-30CQ were grown in the presence 




Each treatment group contained 3 animals.  All 
infections and parasitaemia were monitored by daily blood smears.   
In order to monitor the proportion of the two strains in mixed infections, every 
second day a blood sample (tail bleed) was taken for quantitative genotype analysis.  
Mice 1 and 3 from each group were sampled on odd days (day 1, 3, 5 p.i etc.) and 
mice 2 and 4 on even (day 2, 4, 6 p.i. etc.) days.  The proportional sequencing of part 
of the ubp1 gene containing the previously identified mutation was used to estimate 

































Figure 6.1 The experimental design of AS-3CQ v. AS-30CQ competition experiment   
Each mouse represents a group of animals injected with the mixture of AS-3CQ and AS-30CQ strains 
(a), or the single AS-sens (b), AS-3CQ (c) or AS-30CQ (d) strain.  The number inside the mouse 








6.3. Materials and methods 
6.3.1. Experimental infections  
The AS-sens, AS-3 CQ and AS-30CQ strains were described in section 1.7.2 
of Chapter 1.  The inoculations, drugging, parasitaemia calculation, blood sampling 
and DNA isolation was performed as described in Chapter 2 Sections 2.3.2-2.3.5.   
6.3.2. Proportional sequencing of ubp1 gene 
The isolated DNA was amplified using a nested PCR.  The inner and outer 







Amplification was conducted as in Chapter 2, using an identical program to 
that used to amplify dhps. The products were purified using QIAquick PCR 
purification kit (Qiagen) and sequenced (using forward and reverse) using an ABI 
Prism0® BigDye™ Terminator dideoxy sequencing system (Applied Biosystems).  
All amplification reactions were performed in triplicate. 
The resulting electropherograms were analysed using Chromas 2.33 software 
(Technelysium Pty Ltd) and the heights of polymorphic peak on the position 237/176 
(forward/reverse chromatogram) was calculated as described in Chapter 2.  The 
assay was calibrated using parasite mixtures of known proportion (data not shown). 
 197 
6.3.3. Statistical analysis 
The influence of various factors on parasitaemia and parasite (allele) proportion 
was tested with general linear model using R 2.8.1 software (http://www.r-
project.org/) with lm4 package.  The parasitaemia or parasite proportions were used 
as response variables.  The combined results from all of the time-courses of infection 
were used with mouse number as a grouping factor.  All data was arcsin-transformed 
to meet the criteria of normal distribution. The explanatory variables included 1) 
drug treatment – to compare the behaviour of the same strain at various drug dosed, 
2) parasite strain – to compare the performance of different strains at similar drug 
concentration and 3) type of infection – to compare the behaviour of strain between 




6.4.1. Single clone infections   
The three strains, the sensitive AS-sens, the low resistant AS-3CQ and the 





The parasitaemia of all infections were monitored and presented (Fig 6.2).   
In untreated animals all three strains presented the growth pattern typical of 
rodent malaria, reaching peak parasitaemia after about 8-9 days followed by rapid 
clearance (Fig 6.2a).  The sensitive strain AS-sens reached a higher peak 
parasitaemia (51.6 ± 4.6%) than the low resistant AS-3CQ (36.01 ± 1.88%) and the 
difference between the growth of two strains was statistically significant (P = 0.037).  
However no difference was observed between the growth of the low resistant and 
highly resistant clone (peak of parasitaemia 38.6 ± 7.44%; P = 0.27)).  




 (Fig 6.2b) the growth of sensitive AS-sens was 
significantly suppressed – the parasites appeared only at day 12 and did not reach a 
peak of infection during the course of experiment.  The low resistant parasite 
appeared (day 7) and reached the peak of parasitaemia (15.8 ± 4.8%) on day 11.  
Interestingly the AS-30CQ parasite did not appear as early as AS-3CQ, appearing 
only on day 10 and reaching the peak of parasitaemia on day 13 with (21.1 ± 2.1%).  
The difference between AS-3CQ and AS-30CQ however was not statistically 
significant. 




 treatment resulted as expected in complete 
suppression of growth for both the sensitive and low resistant AS-3CQ parasites.  
The highly resistant AS-30CQ managed to develop parasitaemia whose peak 
appeared on the same day (day12) and was only minimally decreased (13 ± 3.5%) in 




infections.   
In summary no significant growth difference could be observed between AS-






































Figure 6.2 The single strain infections 
The growth of AS-sens (), AS-3CQ () and AS-30CQ() in untreated infections (a) and at 3 (b) 















































6.4.2. Mixed infections 
In order to directly compare the low resistant and highly resistant strain, mixed 
infections containing equal proportions of AS-3CQ and AS-30CQ were established 




Their parasitaemia and the 
proportions of the strains in the infection ware monitored and are presented in Fig 6.3 
6.4.2.1. Parasitaemia  
All animals developed infections.  The growth of the mixtures in the untreated 




animals (Fig.6.3 a-b) was comparable to the growth of 
both clones in untreated single infections – the parasitaemia appeared on day 4 and 
reached ~ 35% on day 8 before a gradual decrease.  No significant difference was 





In contrast, as expected from previous experiments, the higher treatments (3 




) (Fig.6.3c-d) significantly decreased parasite growth 
(P=0.037 and P= 0.001 respectively).  In those groups the peaks of parasitaemia 
appeared later (days 12 and 14 respectively) and were lower (19.4 ± 3.4% and 14.2 ± 
2.7%) than in either untreated population.  
6.4.2.2.Proportion of AS-3CQ and AS-30CQ 
An analysis of the blood sample used to inoculate mice with mixed infections 
showed that the percentage of the highly resistant strain AS-30CQ was 49.77 ± 0.2 in 
line with expectations.  
Thereafter in all experimental groups, the percentage of AS-30CQ deviated 
depending upon the dose of drug used (Fig 6.4).  The percentage of AS-30CQ 




but rose in 




during the first 3 days of infection.  
Interestingly however, in contrast to previous experiments using competition 
between pyrimethamine resistant and sensitive parasites, which reported the constant 
decrease of the proportion of resistant parasite throughout the infection (Walliker et 
al. 2005), there was little further change during the rest of the infection. 
Specifically, consistent with previous phenotyping data, at the highest CQ 
 201 




– after day 3 p.i. the infections were 
dominated by the more resistant strain (Fig. 6.3d).  In all animals, 100% AS-30CQ 
was observed during the course of the infection, except at days 5 to 7 when some 5-
20% of AS-3CQ was observed.  




 (Fig. 6.3c and 6.4) the proportion of the two strains 
was more equal, resulting in ~ 30% of AS-30CQ throughout the infection.  The 
variation between individual animals was greater here than in other treatment groups.  
For instance the average proportion of AJ alleles throughout the infection in mouse 1 
showed about 7.2% ± 0.02 of AS-30CQ while in mouse 3 it was 45.8% ± 0.6 (Fig 
6.4).  Within each animal, though, the proportion was still remarkably consistent, 
suggesting that the proportional sequencing technique was reliable and suggesting 
that there was consistent variation in clone proportion between individual mice. 
In untreated animals (Fig 6.3a) the proportion of the highly resistant AS-30CQ 
strain in the infection remained at ~10 – 20% from day 3 p.i. onward.  This shows 
that in a drug free environment AS-30CQ performs worse than AS-3CQ even if no 
significant difference of growth between the clones could be observed in single 
infections.  This is suggestive of a ‘fitness cost’ of the mutations identified in 
Chapter 5 





there was a stronger shift of proportion in favor of the low-resistant clone – 
on average only 6.4 ± 0.9% of infection consisted of the highly resistant AS-30CQ 
(Fig 6.3b).  This value was significantly (P=0.018) lower than in the untreated group, 
suggesting that the difference of growth between the two strains is stronger at low 



































Figure 6.3 AS-30CQ +AS-3CQ mixed infection 
The parasitaemia (red lines) and proportions of AS-30CQ strain (blue bars) in mixed AS-30CQ v.  




of CQ. Each graph is 
























6.4.2.3. Partial infections   
For each group of infections, we were able to calculate a clone-specific 
‘virtual’ parasitaemia by multiplying the total parasitaemia by the proportion of that 
clone.  It allowed us to compare directly the growth of a strain in mixed and single 
infection at the same drug concentrations (Fig 6.5) 
In untreated mixed infections, the growth of AS-3CQ is very slightly decreased 
relative to its growth in single infections (difference not significant) while AS-30CQ 
is significantly reduced in the presence AS-3CQ, achieving only around 1/6 of the 
parasitaemia obtained in single infections.  This effect was even stronger in the 1.5 












data were compared to untreated single infections because single infection data at 1.5 




was not available).  The low resistant AS-3CQ strain showed no 
differences in growth between mixed and single infections at these concentrations 









) compared to 





) that was eliminating its competitor, AS-30CQ, was the parasitaemia 
comparable to those in single infection.  Even there however, the presence of 
competitor delayed the peak of parasitaemia for two days.  
In summary, the low-resistant strain remains unaffected by the presence of 
competitor and the changes in proportion of parasites are due to various degrees of 































































































































Figure 6.5 Differences between single and mixed infections 
The comparison of behaviour of AS-30CQ and AS-3CQ strains in single (grey lines) and mixed (dark 





6.5.1. Do mutations underlying chloroquine resistance incur 
fitness costs? 
In this study I compared the growth in mixed infections of two isogenic clones 
of the malaria parasite, P. chabaudi in a rodent host, namely the low resistant AS-
3CQ and the highly resistant AS-30CQ.  As expected, AS-30CQ outgrows AS-3CQ 
at high CQ doses confirming the increase in CQ resistance in AS-30CQ relative to 
AS-3CQ.  In contrast, in the absence of drugs, it is the low resistant AS-3CQ that 
grows significantly better than highly resistant AS-30CQ.  At low, sub curative 
concentrations the AS-3CQ strain outgrows AS-30CQ even more than in the 
untreated infections; almost completely suppressing its competitor.  At an 
intermediate concentration, we observed a more equal growth of both strains 
although the low resistant one still achieves the higher parasitaemia.   
These data can be interpreted as follows.  The low-resistant clone AS-3CQ has 
increased ‘host-specific’ fitness relative to the highly resistant AS-30CQ at low and 
intermediate doses of chloroquine as well as in the absence of drug.  Only at the high 
doses does the advantage of the high CQ resistance outweigh the decreased ability to 
compete.  At intermediate concentration the two effects balance each other, possibly 
causing the final result to be more susceptible to random changes, slight variation in 
CQ availability within the host, or experimental error (hence the higher variation 
between the animals in this group).  Therefore these results taken together strongly 
suggest the existence of fitness cost associated with mutations conferring higher 
levels of CQ resistance in rodent malaria.   
Here it has to be noted however that these data concerns only the “rodent part” 
of the malaria life-cycle.  In order to fully assess the impact of resistance on 
reproductive success the other parts of the cycle including gametocyte production, 
mosquito transmission, sporozoite replication and mammalian transmission etc. must 
be taken into account.  Therefore further research is necessary in order to understand 
fully the impacts of high level of resistance on parasite fitness.  Nevertheless, it is 
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possible to see how a similar analysis is possible after parasite mixtures have been 
passed through both mammalian and mosquito hosts.  Indeed, because genetic 
recombination will occur between the high- and low-resistance strains, independent 
estimations of the changes in the proportions of all specific mutations is possible.  
6.5.2. What genetic changes account for the fitness costs? 
If a fitness cost is a stable feature of the highly resistant strain, it is conferred 
by the mutations that took place between AS-30CQ and its sensitive progenitor AS-
3CQ.  In Chapter 5 I described the use of Solexa whole-genome re-sequencing to 
define a complete inventory of SNPs arising in the AS drug-resistant lineage (Table 
5. 5 in that Chapter and Appendix D).   
In summary there are four point mutations which arise between AS-3CQ and 
AS-30CQ.  Three of them (point mutations in ubp1gene on chr 2, tm12 on chr 3 and 
non-syntenic PCHAS_030200 on chr 3) are non-synonymous mutations linked to 
high-level chloroquine resistance.  The others are a non-synonymous SNP in 
PCHAS_101550 gene on chr 10 and a large deletion including PCHAS_051920 gene 
on chr 5.  The roles (if any) of these two mutations in drug responses cannot be 
defined at present. 
One interpretation is that one or more of the mutations connected with 
resistance incur fitness costs and that the two remaining mutations are either neutral 
or partially compensate those costs.  Therefore a fitness cost observed in AS-30CQ 
would be a direct consequence and inherent feature of resistance.  Alternatively, the 
fitness costs may be incurred by one of unselected mutations.  In that case it would 
be random consequence of bottleneck that appeared in malaria population during the 
selection of resistant genotype (“a founder effect”).  The second hypothesis appears 
less likely as such a mutation (conferring a significant fitness cost without any 
advantages related to drug resistance) would be very likely to be lost during the 
passages.  However further research will be required to confidently assign the fitness 
cost of specific mutations.  For example the generation of recombinant parasites 
carrying different combinations of the five described mutations and a series of 
competition experiments between them could address this question.  Alternatively, 
parasites AS-3CQ and AS-30CQ could be cycled through mice and mosquitoes.  
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Recombination would allow ‘shuffling’ of the mutations and hence their fate in the 
absence of drugs could be monitored independently of each other. 
6.5.3. Additional observations 
6.5.3.1. The advantage of low resistant strain at low drug concentration. 
Because no treatment privileged the growth of the low resistant strain and the 
high treatment dose resulted in infection composed almost exclusively from the 
highly resistant one, I was expecting that the intermediate treatment doses would 
result in a gradual transition between these two states.  Instead, the proportion of the 





.  This suggested that the difference of fitness is stronger at low, sub-
curative concentration than in untreated animals. 
One of possible explanations of this phenomenon is that the low drug dose does 
not activate the resistance mechanism but induces a low level stress in both strains, 
so enhancing the competition between the two clones and putting the more “fragile” 
clone at greater disadvantage.  This would be consistent with recently published 
findings suggesting that between two sensitive clones the less virulent one is going to 
be less affected by drug (Schneider et al., 2008). 
6.5.3.2. The stability of parasite proportions over time. 
In previous competition experiments, including pyrimethamine-resistant v. 
pyrimethamine-sensitive clones described in (Walliker et al., 2005) and AS-30CQ v. 
AJ and AS-3CQ v. AJ experiments described in Chapter 2, the proportion between 
the two parasite strains changed steadily throughout the infection.  It suggests that 
the fitness cost is maintained constantly during the exponential growth of parasite 
and as the infection is controlled by host factors such as immunity, red blood cell 
availability etc.   
In contrast, during the current experiment, the proportion of both clones 
changed rapidly during the first three days before stabilising later in the infection, 
during days 4 - 18.  It implies the existence of some mechanism that maintains an 
equilibrium value, such as the existence of two opposing but balanced processes.  
Alternatively, it is possible that for first three days only, the strains are in exponential 
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growth phase and after that their growth is limited by the available resources (e.g. 
erythrocytes) rather than their intrinsic growth rate which may be genetically 
determined.  This might suggest that fitness costs only prevail while the growth rate 
is high, the parasitaemia is low, a cytokine storm is small or the immune response 
negligible etc.  Thereafter, it is possible that there are no differences in growth rates 
between the clones. 
 
 
In summary the generated data strongly suggest the existence of a fitness cost 
related to the high CQ resistance in AS lineage and reveals some previously 
unreported phenomena associated with mixed infection.  These processes can be 
further investigated, leading to an improved understanding of parasite ecology and 





7. General discussion and final remarks 
In this Chapter I wish to summarize the most important findings of this thesis 
and their relevance for malaria research as well as indicate some future research 
directions suggested by the findings from this study.  
7.1. Summary of results 
The main objective of this thesis was to identify the genetic basis of CQ and 
ART resistance in the AS lineage of rodent malaria parasite P.chabaudi.  The 
selection conditions allowing me to discriminate between the sensitive, low resistant 
and highly resistant parasites of the lineage were established in preliminary 
experiments (Chapter 2) and used for the drug-selection of genetic cross and 
backcrosses between the highly resistant (AS-30CQ) and sensitive (AJ) parasites 
(Chapter 3 and 4).  The genetic analysis of this material generated genome-wide 
scans of drug-selection, mapping three critical loci contributing one after another to 
increasing level of CQ resistance (on chr 11, chr 3 and chr 2) and one major locus on 
chr 2 responsible for ART resistance.   
Next Solexa genome re-sequencing was applied to identify a comprehensive 
inventory of mutations arising within the AS lineage (Chapter 5).  The main result 
was that the pre-dominant selection valleys for different levels of CQ resistance and 
for ART resistance contained only one or two mutations.  It was therefore possible to 
identify the A173E aat1 and V2728F ubp1 as the possible determinants of CQ- and 
ART-resistance, respectively.  Additionally two genes on chr 3 (PCHAS_31370 and 
PCHAS_030200) and the ubp1 mutation may contribute to higher levels of CQ 
resistance. 
Finally the effect of the high CQ resistance on parasite fitness was studied in 
Chapter 6, suggesting that the highly resistant parasites are at a competitive 
disadvantage in the absence of drugs and at the low CQ concentrations. 
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7.2. Combination of LGS and Solexa sequencing for the 
identification of genes involved in drug resistance 
The main scope of my work was to identify novel genes involved in drug 
resistance.  The strategy used in this thesis exploits two novel approaches.  Firstly, 
we adopted a QTL modification of LGS.  This applied different levels of selection to 
achieve an elegant dissection of the genetic determinants of different levels of CQ 
resistance.  Secondly, the massive power of new genomic sequencing technologies 
was applied to the drug-resistant AS lineage to generate a comprehensive inventory 
of mutations accumulating under selection by multiple drugs. 
These approaches represent a substantial improvement over previously used 
strategies.  Until this study, LGS was shown to be efficient in mapping only one 
dominant locus conferring the trait under investigation (Culleton et al., 2005; 
Martinelli et al., 2005; Hunt et al., 2007) and failed to supply the gene-candidates 
(unless a previously identified functionally relevant gene was present within the 
identified locus).  The study of chloroquine resistance described here is the first case 
of successful use of LGS to identify multiple loci contributing to a given trait and the 
candidate mutations within them.  Moreover, the use of different drug concentrations 
during LGS selection allowed not only the identification of all involved loci but also 
the evaluation of the strength of selection on each and the formulation of some 
hypotheses regarding the epistatic interaction between them; for example, the 
interaction between the chromosome 11 and 3 in case of higher level CQ resistance.  
, 
The chosen strategy proved to be a very efficient tool, allowing to pass from 
the characterisation of the phenotype (chapter 2 and 6), through the mapping of the 
involved loci (Chapters 3 and 4) to identification of candidate mutations (Chapter 5) 
within a relatively short amount of time.  The whole process could be optimised and 
completed within less than 6 months.  Additionally, once established, this strategy 
can be successfully used for identification of the genes involved in any phenotype 
that can be successfully selected in laboratory conditions.  For example, this 
approach was also used concurrently to investigate the genetic basis of mefloquine 
and artesunate resistance.  Although initially developed in malaria parasites, it can be 
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applied to other organisms provided that genetic recombination and selection of the 
desired phenotype is possible.  In fact a very similar strategy was recently used in 
budding yeast to map the genes involved in different traits including resistance to 
ethanol, 4-nitroquinoline neomycin etc. (Ehrenreich et al., 2010).  
7.3. Relevance for human malaria 
7.3.1. The new gene candidates involved in CQ/ART resistance. 
The first immediate consequence of the findings described in this thesis is the 
discovery of new gene candidates connected with CQ and ART resistance that may 
now be investigated in human parasites.  Previous work has shown that the genetic 
determinants of drug resistance are often shared by P.chabaudi and P.falciparum (as 
in the case of pyrimethamine (Cowman and Lew, 1990), mefloquine (Cravo et al., 
2003) and atovaquone (Afonso et al., 2010) resistance).  Therefore it is possible that 
also the genes identified here will play some role in CQ/ART responses in human 
malaria. 
In P.falciparum the main determinants of CQ responses were already identified 
( see section 1.4.2.) and no strong signatures of selection connected with CQ 
resistance could be detected on the chromosomes containing the homologues of  
aat1, tm12 and ubp1 genes (Mu et al., 2007; Patel et al., 2010).  However, the 
identified genes may still be the additional factors modifying the CQ responses 
whose presence was described in section 1.4.2.3.   In fact aat1 homologue in 
P.falciparum was one of the 35 genes differentially regulated in three pfcrt mutants 
characterized by different chloroquine responses (Jiang et al., 2008) indicating its 
involvement in the CQ resistance pathway.  More importantly however the 
discovered genes may be the main determinants of the CQ resistance in P.vivax, 
which is filogenetically closer to rodent parasites than P.falciparum (Silva et al., 
2010) and which is able to acquire the CQ resistance in pfcrt-independent way 
(Nomura et al., 2001).  The model of chloroquine resistance in P.vivax would have a 
great value, as despite the recent advances in culturing and genetic analysis, this 
parasite is still challenging to study in the laboratory conditions.   
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Additionally the involvement of ubp1 (and possibly aat1) in the emerging ART 
resistance in P.falciparum remains to be investigated.  Although this gene was not 
mutated in laboratory selected ART resistant P.falciparum (Chavchich et al., 2010) 
and the two mutations described in this study were not identified in field (Imwong et 
al., 2010) it is still possible it influences ART responses. 
7.3.2. The insights into the mechanism of CQ and ART resistance 
Despite the differences in the involved genes, parallels can be drawn between 
the putative mechanisms of CQ resistance in P.falciparum and P.chabaudi.  The 
similarities between the main determinant of CQ resistance in P.falciparum (pfcrt) 
and aat1 gene discovered here were already mentioned (see section 5.5.3).  Both 
genes are predicted to be putative amino acid transporters situated within the 
digestive vacuole membrane. The mutation connected to CQ resistance is located on 
the internal side of digestive vacuole, outside the first transmembrane domain, and at 
the entrance to the putative channel.  In both cases the CQ resistance seems to be 
connected with either removal of positive charge (P.falciparum) or introduction of 
the negative charge (P.chabaudi) that can facilitate the efflux of charged CQ from 
the vacuole.  Additionally, in both systems a supplementary protein with 12 
transmembrane domains, situated within digestive vacuole membrane, was identified 
– pfmdr1 (another potential CQ transporter) in P.falciparum and tm12 in P.chabaudi.  
In both cases this protein seems to act epistatically, increasing the level of resistance 
in parasites already carrying the crucial change within aat1 or pfcrt gene. Finally, in 
both parasites CQ resistance is connected with CQ accumulation in resistant parasites 
(Miki et al., 1992), changes in the morphology of digestive vacuoles (Ohsawa et al., 
1991) and reversal of resistance by calcium channel blockers like verapamil (Tanabe 
et al., 1990).  Therefore, although different proteins may be involved, it is tempting 
to speculate that the same general resistance mechanism, based on CQ transport by 
modified amino acid transporter, exists in both species.   
The involvement of ubp1 in CQ/ART resistance doesn’t have its direct 
equivalent in P.falciparum.  Interestingly however, the study of ART resistance in 
P.falciparum reveals that it may be connected with delayed recrudescence and cell 
cycle arrest at the ring stage (Teuscher et al., 2010; Witkowski et al., 2010).  As 
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mentioned previously (see section 5.5.3.), one of the possible functions of ubp1 
(based on the proteins it interacts with in yeast two-hybrid system) is cell-cycle 
control.  Additionally, its structural homologue in human (HAUSP) is regulating the 
function of P53 protein – a well-known mediator of cell cycle arrest in eukaryotic 
cells(Sarkari et al., 2010).  It raises the question, whether also in the case of 
artemisinin the same general mechanisms of resistance may exist in both parasites.  
In summary, regardless of their involvement in CQ/ART resistance in human 
malaria, the identity of the discovered genes supplies an interesting insight into the 
mechanisms of drug resistance in the Plasmodium genus that can be now further 
investigated in human parasites.   
7.3.3. The connection between chloroquine and artemisinin 
resistance 
In the light of the above similarities a connection between the CQ and ART 
resistance is of particular interests.  Our findings strongly suggest that ubp1 (and 
possibly aat1) is contributing to the resistance to both CQ and ART.  Additionally in 
AS lineage, despite repeated efforts, artemisinin resistance could not be selected 
from the sensitive AS-sens strain.  However it did appear spontaneously under CQ 
pressure after which this parasite could be further selected for increased ART 
resistance (see section 1.7.2).  It suggests ART resistance (most likely conferred by 
the ubp1 gene) can arise only on CQ resistant background.   
It is not the first case of cross-resistance between those two drugs observed in 
rodent model.  For example attempts of selecting ART resistant P.berghei (that was 
CQ-sensitive) failed.  However the parallel experiment was successful in naturally 
CQ resistant P.yoelii resulting not only in appearance of ART resistance but also in 
spontaneous 7-fold increase of CQ resistance in that parasite (cross resistance with 
other quinoline have also been observed) (Chawira et al., 1986).  Also the selection 
of P.vinckei for resistance to arteether (one of the artemisinin derivatives) resulted in 
spontaneous increase resistance to some of the quinoline drugs (CQ was not tested in 
this experiment) (Puri and Chandra, 2006). 
In human malaria the relationship between the two drugs is less obvious.  On 
one hand no connection can be observed between the main determinant of the CQ 
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resistance (pfcrt) and artemisinin responses.  In fact, if anything, the contrary can be 
observed – an introduction of resistant pfcrt allele into sensitive parasites seems to be 
associated with increased sensitivity to artemisinin in vitro (Sidhu et al., 2002). and 
in field the ART treatment often selects for the sensitive pfcrt allele (Sisowath et al., 
2009).  On the other hand however, the secondary CQ-resistance determinant 
(pfmdr1) has been connected to changes in ART responses both in vitro and in vivo 
(see section 1.5.3.1.), although is unlikely that this gene is a sole determinant of ART 
responses.  Additionally, the generation of artemisinin resistance in laboratory 
conditions does not seem to require the presence of CQ resistant background 
(Chavchich et al., 2010), however in field the resistance to artemisinin did arose in a 
region where the high CQ resistance reached nearly fixation (Lim et al., 2003; Saito-
Nakano et al., 2008; Rungsihirunrat et al., 2009) and the recent study of the progeny 
of the cross between CQ resistant and CQ sensitive parasite (Beez et al., 2010) 
indicates that some genotypes will influence the parasite ability to develop stable 
ART resistance.  
Are all these cases the correlation between quinolines and artemisinins due to a 
general “drug-response” phenotype mediated by pfmdr1 and/or ubp1?  Or some 
fundamental similarities between the two groups of drugs are still to be discovered?   
Is CQ resistance somehow priming the parasites to acquire the ART resistance?  The 
answer to these questions would have very significant implications for international 
treatment policies as the resistance to chloroquine is still widely spread throughout 
the P.falciparum population and artemisinin is currently the first line of treatment. 
7.3.4. A platform for identification of genes connected to drug 
resistance 
In addition to the findings related with the two particular drugs chosen in this 
study, the approach developed in this thesis is a useful tool for feature identification 
of gene-candidates connected to the new drugs.  As described previously the current 
strategies of gene identification in human malaria are ethically and technically 
difficult and often result in the identification of causative genes years after the 
resistance has been identified field. The rodent parasites, LGS and Solexa sequencing 
can be used for identifying candidate-genes involved in the resistance to new drugs 
as even before they are introduced.  The identified candidates could be immediately 
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tested in human malaria (using transfection studies) and the mechanisms by which 
they are causing the resistance could be investigated.   
The described approach could identify potential markers and mechanism of 
resistance before it actually arises in the field.  This would allow the prospective 
monitoring of the population for signs of resistance and reacting before it reaches 
significant levels in the population. 
7.4. Feature directions 
This section briefly outlines the feature work based on the data from this thesis. 
7.4.1. The use of Solexa SNPs quantification to improve the 
existing gene finding strategy. 
The LGS ‘read-out’ can be improved by replacing pyrosequencing markers 
with quantitative SNPs defined and measured by Solexa sequencing.  Previous work 
(Grech et al., 2002) suggests that may be ~100,000 SNPs differentiating the two 
parental parasite strains, AS and AJ.  Therefore if both parents (AS and AJ) are 
sequenced, SNPs between the two parental strains can be defined and their frequency 
in drug-selected and unselected cross-progeny populations tested.  Every SNP can be 
sequenced multiple times (20 - 60x) providing large amounts of LGS data which can 
be used to estimate errors in proportions and to define the limits of the base of the 
selection valley at greater resolution. 
Update: at the time of submission of the final version of this thesis, such sequencing 





As predicted ~100,000 SNPs were discovered and their frequency measured.  The 
data analysis confirmed the results obtained with pyrosequencing markers and 
supplied better resolution of identified selection valleys.  This data is being now 
subjected to further analysis. 
7.4.2. Further investigation of gene candidates 
The described work identified a number of genes potentially involved in CQ 
and ART response.  Molecular biology approaches can now be used to 
unambiguously confirm the causative role of the described mutations in drug 
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resistance and elucidate the mechanisms by which they influence CQ/ART 
responses.  Various P.chabaudi and/or P.falciparum parasites containing the mutated 
version of one or more of these genes can be generated using transfection technology 
and studied using a range of techniques involving growth inhibition tests, protein 
expression analysis, CQ/ART accumulation assays etc.  
7.4.3. Exploration of fitness cost and its consequences 
In order to explore the idea of fitness cost, a series of experiments can be 
designed during which mixtures of various parasites can be grown repeatedly 
through the full life-cycle of natural mice/mosquito passages and the parameters of 
the infection (strain proportion, anaemia, parasitaemia, number of oocysts etc.) 
recorded.  This would enable us to estimate overall fitness costs (through the full life-
cycle) and to establish where these costs have maximum effect.  Alternatively 
genetic crosses can be used for the same purpose: in these cases the fitness 
implication of single mutations could be studied. 
 
In summary, the described work offers multiple possibilities for further 
investigation.  They offer exciting new options for malaria studies and can be of the 
utmost importance in understanding and limiting the evolution of drug resistance and 




Appendix A – Buffers and Solutions 
 
Citrate Saline 
0.85 % w/v NaCl 
1.5% w/v Tri-Sodium Citrate  
Ph buffered to 7.2 
 
PBS 
0.8% w/v NaCl 
0.02% w/v KCl 
0.115% w/v  Na 2 HPO 4 
0.02% w/v KH 2 PO 4 
Ph buffered to 7.4 
 
Deep-freeze solution 
:28%w/v glycerol,  
3%w/v sorbitol,  
0.65%w/v NaCl 
sterilized by filtration 
 
Mammalian Ringer Solution. 
27mM KCl  
0.15M NaCl 
0.2mM CaCl 2   
 
Ringer/FCS solution 
50% heat inactivated foetal calf serum 
50% mammalian Ringer Solution 
20U/ml heparin 
 
TBE buffer  
100 nM TRIS 
100 mM Boric Acid 
2 mM EDTA 
 
Parasite Lysis Buffer 
150mM NaCl 





Appendix B – General PCR protocol. 
 
The following PCR protocol was using for DNA amplifiation : 
 
The reaction was set in 100 l tube as follws: 
 
Ingredient Concentrationt Volume [l] 
DNA template ~40ng/l 1 
PCR Buffer (Promega) 5X 10 
Mg Cl
2
 25 mM 3 
dNTP (Promega) 10 mM each 1 
Primer 1 (forward) 10 pmol/l 1 






O  32.75 
 




96°C 1 min 
  
96°C 1 min 
52°C 1 min 
65°C 1 min 
  




10 l of generated product was used for electrophoresis in 1% agarose gel in TBE 
buffer with the addition of 1 l od Safeview© stain.  The gel was visualised using 







Appendix C – The list of pyrosequencing 
assays used in LGS analysis 
The list of the assays used in LGS experiments described in Chapters 3 and 4.   
The markers were designed as described in section xxx.  For each selection, 
initially 2-4 markers on each chromosome were chosen in order to assess the overall 
shape of the genome scan.  Later additional assays were added starting with the 
regions of particular interests (e.g. potential selection valleys).  The addition of new 
markers was stopped after the analysis of initial data indicated that it is unlikely to 
result in substantial data improvement.  Only in case of selection 2 of the backcross 
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Appendix D – The alignment of the three 
conserved genes connected to CQ/ART 
resistance. 
 
All alignments according to Clustal W2 software.  The symbols indicate: 
*- a identical position 
: - a conserved position 





P.falciparum_PFF1430c        --------------------------MN-KKYGTSSNNHDN--KKDKKNN 21 
P.vivax_PVX_114575           --------------------------MNENGVGENKNNFKKGEKRSKKGN 24 
P.knowlesi_PKH_111940        MLILTAQHAPPPTPWCNPLQFSYFYKMNENGIIENKNNSKKGEKRSKKGN 50 
P.chabaudi_PCHAS_112780      ---------------------------MVNNIDTLDYCHSANDVVSNIVN 23 
P.berghei_PBANKA_112830      ---------------------------MANNIDILDYCHSTNDVVQNIVN 23 
P.yoelii_PY04168             ---------------------------MVNNIDILDYCHSTNDVVPNIVN 23 
                                                          :     .   .      :  * 
 
P.falciparum_PFF1430c        ADKNKNKKNTTTGEENKDSNKSLVNNDSKKNDSSK--NKYNIVKANIKNI 69 
P.vivax_PVX_114575           PKKAGSKDDHAKSDPAGAPSGEVNSGNAREGDEAKENSAHPPSKNNMSNL 74 
P.knowlesi_PKH_111940        PKKVDSKEDHTNSDPAGTPSGNVNNGNTPQVEEKKENNTEASNKNSVTNL 100 
P.chabaudi_PCHAS_112780      YKK--NNDNYNYRGKYDDGNTGISKNNMG-------------ANSNYNNA 58 
P.berghei_PBANKA_112830      YKK--NNDNYNYLEKHDDENAGISKNNIG-------------VNSNYNRV 58 
P.yoelii_PY04168             YKK--NNDSYNYLEKHDDVNAGISKNNMG-------------ANSNYNGV 58 
                              .*  .:..          .  : ..:                : . .   
 
P.falciparum_PFF1430c        FASDKKNEKSDK------NEKN-ESSKSSKNTETYTNVNDKKSNNLITKG 112 
P.vivax_PVX_114575           FSSNKKKNKQKKKYESNMGENNADMNGNNLKTSPYVNLGDDDMNEG-AEG 123 
P.knowlesi_PKH_111940        FSWKKKKNKQKK-CENKMEENNSDIHGNSLKTSPYVNLGDDDINEVGEEG 149 
P.chabaudi_PCHAS_112780      FMFNNKIGNEAKQIDTNMENITPYINIDSLENTTKINLIDGSDKNDNMRD 108 
P.berghei_PBANKA_112830      FVFNNKRGDETKQIDTNMESITPYININSLESTKKINLVDESSKNYNMGN 108 
P.yoelii_PY04168             FVFNNKIGDETKQIDTNMENTTPYININSLENTSKIDLIDESSKNYNMGN 108 
                             *  .:*  .. *       . .     .. :.    :: * . ::    . 
 
P.falciparum_PFF1430c        SN----DKKKKKKDSKK-------------------NSSNNNNNNTIVDI 139 
P.vivax_PVX_114575           DGYYGEDNNNGAKDVQKNCQEGN----------ENENCDCDNQNSTIVDV 163 
P.knowlesi_PKH_111940        DGYYDQDNNNDVNDTQENYQESN----------ATENYDNENENIAIVDV 189 
P.chabaudi_PCHAS_112780      HWYHQNKNDNKKKNNKNSKNNKN---------ISNQYVSLAHVNDNDQEI 149 
P.berghei_PBANKA_112830      NWYHQNKYNNKMNNSKNSKN------------SHNKHISIAHIKYDDQEI 146 
P.yoelii_PY04168             NWYHQNKYNNKMHNSKNSKNSKNSKSSKNSKHSHNKHISIDHIKDDDQEI 158 
                                   . .:  :: ::                     .  : :    :: 
  
P.falciparum_PFF1430c        SDGD-YTNDEEGTNKPKRNWKGRTFSRFTPGGVRSSTVLFICTAIGVGFL 188 
P.vivax_PVX_114575           GENEKNPEDEEAEKS-KKNWQRRTFSRFTPGGVRSSTVLFICTAIGVGFL 212 
P.knowlesi_PKH_111940        GGNEKNAQDKEEEKKRKKNWKRRTFSRFTPGGVRSSTVLFICTAIGVGFL 239 
P.chabaudi_PCHAS_112780      NENGKNKLCEENETNTKKTWQKRAFGPFTPGGVRSSTVLFLCTAIGVGLL 199 
P.berghei_PBANKA_112830      NEKGKNKLYEENQTNTKKTWKRRAFSPFTPGGVRSSTVLFLCTAIGVGLL 196 
P.yoelii_PY04168             NEKEKNKIYEENQTNKKKTWKKRTFSPFTPGGVRSSTVLFLCTAIGVGLL 208 
                             .        :*  .. *:.*: *:*. *************:*******:* 
 
P.falciparum_PFF1430c        SIPYVFSKLGIILSIILIILNAFESYVTTNILCTSSLEHNTFVYGNLLKK 238 
P.vivax_PVX_114575           SIPYVFSKLGIILSLLLILLNAVESYVTTNILCLSSLEHNTFVYGNLLKK 262 
P.knowlesi_PKH_111940        SIPYVFLKLGIILSLLLILLNGMESYVTTNILCMTSLEHNTFVYGNLLKK 289 
P.chabaudi_PCHAS_112780      SIPYVFSQLGIILSIILILLNALESYITTNILCMSALEHNIFVYGNLLEK 249 
P.berghei_PBANKA_112830      SIPYVFSELGIILSIILILLNSLESYITTNILCMSSLEHNIFVYGNLLEK 246 
P.yoelii_PY04168             SIPYVFSELGIILSIILILLNSLESYITTNILCMSSLEHNIFVYGNLLEK 258 






P.falciparum_PFF1430c        IGNKYYKTIIDFGLSFGFVSSYILILILISNFLSTIFYVFNFPTLFTNNV 288 
P.vivax_PVX_114575           IGHKYHKTIIDIGLTFGFLSSYILILILISNFLSSILYVFDFPSFLYNHT 312 
P.knowlesi_PKH_111940        IGHKYHKTIIDIGLTFGFLSSYILVLILISNFLSSILYVFNFPSFLYNHN 339 
P.chabaudi_PCHAS_112780      IGNKYYKTLIDLGLTFSFLSGYVLILILMNDYLSNVLHTFNFPSFICNRV 299 
P.berghei_PBANKA_112830      IGNKYYKTLIDFGLTFSFLSGYVLVLILVNDYLSNILYTFNFPSFISNRI 296 
P.yoelii_PY04168             IGNKYYKTLIDFGLTFSFLSGYVLVLILVNDYLSNILYAFNFPSFISNRI 308 
                             **:**:**:**:**:*.*:*.*:*:***:.::**.:::.*:**::: *.  
 
P.falciparum_PFF1430c        FLVILICLLILPITFRNKVGSLNHFLIFSLFSLSITVLTIGLQTKSYNNL 338 
P.vivax_PVX_114575           FLIILVCVLIVPITFRDQVGSLNSFLIFSLCSLTITVLTIGWQARDYYTI 362 
P.knowlesi_PKH_111940        VLIIIVCSLIVPITLRDQVGSLDSFLIFSLCSLMITVLTIGWQARGYYTV 389 
P.chabaudi_PCHAS_112780      FITIVICLLVLPLTFREHIGSINYFLIFSLFSITLTVLTVGYQSKYYMSL 349 
P.berghei_PBANKA_112830      FITIVICLLVLPLTFREHIGSINCFLVFSLFSITLTVLAVGYQSKYYMSL 346 
P.yoelii_PY04168             FITIVICLLVLPLTFREHIGSINCFLIFSLFSITLTVLTVGYQSKYYMSL 358 
                             .: *::* *::*:*:*:::**:: **:*** *: :***::* *:: * .: 
 
P.falciparum_PFF1430c        LINKEVNLFKMDKHFFKCFNILLFSFSQQPNACFITGQFNQPTHRRLNKS 388 
P.vivax_PVX_114575           LINKEIVLFNMDKHFFKCFNILLFSFSQQPNACFIAGQFNQPTHRRLTKS 412 
P.knowlesi_PKH_111940        LINKDIVLFNMDRHFFKCFNILLFSFSQQPNACFITGQFNQPTHRRLTKS 439 
P.chabaudi_PCHAS_112780      LPEKNISLFKINKHFFKCFNILLFSFSQQSNACFITGQFNQPTQRRITKS 399 
P.berghei_PBANKA_112830      LPEKNISLFKINKHFFKCFNILLFSFSQQSNACFITGQFNQPTQRRVTKS 396 
P.yoelii_PY04168             LPEKNISLFKINKHFFKCFNILLFSFSQQSNACFITGQFNQPTQRRITKS 408 
                             * :*:: **::::****************.*****:*******:**:.** 
 
P.falciparum_PFF1430c        TFRSVILQVIFYTLFGILGYFSFLNTAKDNIVLNYENSNVSILLCKFLLS 438 
P.vivax_PVX_114575           AYRSVLLQIIFYTLFGLLGYLSFLTTTKDNIILNYEDTNVSILLCKFLLS 462 
P.knowlesi_PKH_111940        AYRSVVLQIIFYSLFGLLGYLSFLTTTKDNIILNYEDTNISILLCKFLLS 489 
P.chabaudi_PCHAS_112780      ESRSILIQLIFYTLFGLLGYLSFLNTTKDNIILNYEETNMSILLCKFFLC 449 
P.berghei_PBANKA_112830      ESRSILIQVIFYTLFGLLGYLSFLNTTKDNIILNYEETNMSILLCKFFLC 446 
P.yoelii_PY04168             ESRSILIQVIFYTLFGLLGYLSFLNTTKDNIILNYEETNMSILLCKFFLC 458 
                               **:::*:***:***:***:***.*:****:****::*:*******:*. 
 
P.falciparum_PFF1430c        LTFFFSVPLNFMGSYQSMLALGITTRDALYKLYTYIFRRTGYSANLSLLL 488 
P.vivax_PVX_114575           ITFFFSVPLNFMGSYSSLLSLYLSARNMFLKFYVFVTRRNRYMANLSTFL 512 
P.knowlesi_PKH_111940        ITFFFSVPLNFMGSYSSLLSLYLSARNMFLKFYVFVSRRNRYMANLSTFL 539 
P.chabaudi_PCHAS_112780      ISFFFSIPLNFIATYPSMMSLYTTIHNNIQKLYSALFTRNEYLPSLSNIL 499 
P.berghei_PBANKA_112830      ISFFFSIPLNFIATYPSMISLYTSIRNKIQKLYSVLFTRNEYLPSFSNIL 496 
P.yoelii_PY04168             ISFFFSIPLNFIATYPSMISLYTSIRNNIQKLYSVVFTRNEYLPSLSNIL 508 
                             ::****:****:.:* *:::*  : :: : *:*  :  *. * ..:* :* 
 
P.falciparum_PFF1430c        SEYTND-----PYQETHADNITEHSSVSESQTDDQNQRMWISVIVTIFCA 533 
P.vivax_PVX_114575           REDEANPFEAPPFEENALDNLTENSSTTESQAEDKTQRKLISISVTILCA 562 
P.knowlesi_PKH_111940        REDEDN-----IFEDNALDNLTENSSTTESQAEDRKQRRLISICVTILCA 584 
P.chabaudi_PCHAS_112780      RYDTEN-----PFGEYAQDGNTENSRVAESQGDDMFQRKFVAIFVTCLCA 544 
P.berghei_PBANKA_112830      RYDTEN-----PFDEYTLDENTENSSTSESQGDDMFQRKCAAIFVTCLCA 541 
P.yoelii_PY04168             RYDTEN-----PFGEYIQDENTENSSASESQGDDMFQRKCAAIFVTCLCA 553 
                                  :      : :   *  **:* .:*** :*  **   :: ** :** 
 
P.falciparum_PFF1430c        LIACKVKKLSNVIGIGGGITSTLISCLLPNLIYYKNRHNVSNKLKRYSTL 583 
P.vivax_PVX_114575           LIAFNVKKLSNVIGIGGGITSTLISW------------------------ 588 
P.knowlesi_PKH_111940        FIAFNVKKLSNVIGIGGGITSTLISCLLPNLIYFKNRHNVKNKLERYSTL 634 
P.chabaudi_PCHAS_112780      FVEFNVSKLSNFIGIFGGFTSSIISCLLPNLIYYKNMHTFKNKTERYATL 594 
P.berghei_PBANKA_112830      FVEFNVSKLSNFIGIFGGFTSSIISCILPNLIYYKNMHTFKNKIERYATL 591 
P.yoelii_PY04168             FVEFNVRKLSNFIGIFGGFTSSIISCILPNLIYYKNMHTFKNKTERYATL 603 
                             ::  :* ****.*** **:**::**                          
 
P.falciparum_PFF1430c        FMLCFFSFMGFLSVVVTTLNLIL------------------- 606 
P.vivax_PVX_114575           ------------------------------------------ 
P.knowlesi_PKH_111940        CMLCFFSFMGFFSVITTALILIF------------------- 657 
P.chabaudi_PCHAS_112780      ALLCFFSAMGLISSIVTAFIIIR------------------- 617 
P.berghei_PBANKA_112830      ALLCFFSVIGLISSIVTAFIIIY------------------- 614 








P.falciparum_PFB0675w        MLELLRNAYNKCKEYILGLSKKSQIYKINILNYCLLFSFFLFYASYFFFI 50 
P.vivax_PVX_002795           MMPFLSNTYSKCREQIARKLTISSKRQIYIINNSLFLSFILFYISYFFFI 50 
P.knowlesi_PKH_040510        -MASLNNIYSKCREHIARKFTISNKRKIYIINNSLFLSFILFYISYFFFI 49 
P.chabaudi_PCHAS_031370      -MVFFYSIYSALMKYMTNKLSYSRKQKIFVINNCLFFSFILFYISYYFFF 49 
P.berghei_PBANKA_031160      -MVFFYSIYSALMKYITNKLSYSRKQKIFVINNCLFFSFILFYISYYFFF 49 
P.yoelii_PY05194             -------------------------------------------------- 
                                                                                
 
P.falciparum_PFB0675w        NGIINPAVKIVFHGSIIEDKTKVYENSIIESIWLLFTKGSYFNMAMLLFF 100 
P.vivax_PVX_002795           NGIINPAVKIVFHGNIIADNTQVYENSILESIWLLFTSKSYFNMAMLLLF 100 
P.knowlesi_PKH_040510        NGIINPAVKIVFHGNIIADTTQVYENSILESIWLLFTSKSYFNMGMLLFF 99 
P.chabaudi_PCHAS_031370      NGLIYPAVKIVFHGSVIANQTIVYKNSILESIWLLYTSGSYFNMGVLLIF 99 
P.berghei_PBANKA_031160      NGLIYPAVKIVFHGSVIANQTIVYKNSILESIWLLYASGSYFNMGVLLIF 99 
P.yoelii_PY05194             -------------------------------------------MGVLLIF 7 
                                                                        *.:**:* 
 
P.falciparum_PFB0675w        SIIIPFLKLLMVSDNFYSFIVLYKMNKKREEEKRRRRRRIRAREYNNAKY 150 
P.vivax_PVX_002795           SIIIPILKLIMVSDNFYCFFKLYNLSLQHEEEEKEEE------------- 137 
P.knowlesi_PKH_040510        SIIIPILKFIMVSDNFYCFFKLYNLSLQHEEEEKEEE------------- 136 
P.chabaudi_PCHAS_031370      SVIIPILKFVMVTDNFYSFFKLYNLGLKFNENDKDD-------------- 135 
P.berghei_PBANKA_031160      SVIIPVLKFVMVSDNFYSFFKLYNLSLNFNENDKDD-------------- 135 
P.yoelii_PY05194             SVIIPVLKFIMVSDNFYSFFKLYNLSLNINENDKDD-------------- 43 
                             *:***.**::**:****.*: **::. : :*:.:                 
 
P.falciparum_PFB0675w        NKNRYKMNKYNRNKNINDIYKDDIYYSENIFKNDEINYINTINENEEFIL 200 
P.vivax_PVX_002795           --------------------------------EDDIFFINTVNENEQFIL 155 
P.knowlesi_PKH_040510        --------------------------------EDDIFFINTVNENEQFIL 154 
P.chabaudi_PCHAS_031370      --------------------------------AKLIYYINIVNENEEFAL 153 
P.berghei_PBANKA_031160      --------------------------------AKLIYYINIVNVNGEFAL 153 
P.yoelii_PY05194             --------------------------------AKLIYYINIINENEEFAL 61 
                                                              . * :** :* * :* * 
 
P.falciparum_PFB0675w        KKFKILNFISRFQFVDVFISLFIVSSLNLYLLEARMLNGAYYFLNYCMLS 250 
P.vivax_PVX_002795           KKFSILSSISRFQFVDVLISLFIVSSLNLYLLEAKILSGAYHFLNYCLLS 205 
P.knowlesi_PKH_040510        KKFSILSSISRFQFVDVLISLFIVSSLNLYLLEAKILSGAYHFLNYCLLS 204 
P.chabaudi_PCHAS_031370      KKFSILSSISRFQFVDVFISLFIVSSLNLYLLEAKILIGAYHFLNYCVLS 203 
P.berghei_PBANKA_031160      KKFSILSSISRFQFVDVFISLFIVSSLNLYLLEAKILIGAYHFLNYCVLS 203 
P.yoelii_PY05194             KKFSILSSISRFQFVDVFISLFIVSSLNLYLLEAKILIGAYHFLNYCILS 111 
                             ***.**. *********:****************::* ***:*****:** 
 
P.falciparum_PFB0675w        TISSFLLFSFTSLKIHIFKNGNIKISACLNESNLEVTTSGPLSTKDLVEE 300 
P.vivax_PVX_002795           TISSFFLLTLTSLKIRIFKRGNIKIYSLPAERRLSVRTSLQQENTRESR- 254 
P.knowlesi_PKH_040510        TISSFFLLTLTSLKIRIFKRSNIKIYALPTERCLSVRNSLQ-EDARDNR- 252 
P.chabaudi_PCHAS_031370      TISSYLLLTFMKIKINIFKEGNIKIFSSRNENSVAGKNSDSMLCNGKRD- 252 
P.berghei_PBANKA_031160      TISSYLLLTFMKIKINIFKDGNIRIFSSRGENILTGKNSGTIIYNENK-- 251 
P.yoelii_PY05194             TISSYLLLTFIKIKINIFKDGNIRIFSSRDENIANGKNTDXIIYNDNK-- 159 
                             ****::*::: .:**.*** .**:* :   *      .:            
 
P.falciparum_PFB0675w        EGHAQINNLIINDKNMTSGVVNDFSGNGNNVELTDDLKSGEPQNRDDIQT 350 
P.vivax_PVX_002795           ------------DLDCTNGEGVALPGQLRNGEENDDTLTGEANKMSVTRG 292 
P.knowlesi_PKH_040510        ------------MLDCVKGEGVEFHGKLKNGK--NDSPVVEVNKIDLKRG 288 
P.chabaudi_PCHAS_031370      ------------ILKKESSK-----IEFNKIY--DSNNTKESHQWNKKN- 282 
P.berghei_PBANKA_031160      --------------------------EFNNIYDNNNNNTKDNHKWNKKN- 274 
P.yoelii_PY05194             --------------------------ELNNIX--NNNNTKENHKWNKKNK 181 
                                                       : .:    :.    : :: .  .  
 
P.falciparum_PFB0675w        EETKKEKMNTR--------------THNDEDNTKKKNIKDKKKANGDDKV 386 
P.vivax_PVX_002795           GGDDPEEGEE--------------HNRNGANHSEHLNSALRKGAELPGNA 328 
P.knowlesi_PKH_040510        GGKNLDEGEEDDDDNNNNNNNYNNNNNNGGNNPEQLDSILRKGVEWMGLA 338 
P.chabaudi_PCHAS_031370      -KKKSNKE---------------------DLNSDNMNVTHKKKMTSEKDD 310 
P.berghei_PBANKA_031160      IKTKNSKENL------------------GGLNSDNTNVAHKINNESENED 306 
P.yoelii_PY05194             KKKKNSKENF------------------DGLNSEN------INNESENED 207 




P.falciparum_PFB0675w        IQKCIDNERKKKQNGMIQSVNDGDKNSNFNNNNNNNINGDSNNNNINGDS 436 
P.vivax_PVX_002795           KNIRRGGKKRVSHEGRPPREDPHQAGVTGMIDNRGVYHRDFPRASMHHMH 378 
P.knowlesi_PKH_040510        KKNRKGGKKKVFHEEGSMQGD-YTSGTTGIITHRGVYHLDPSIPRVNQRG 387 
P.chabaudi_PCHAS_031370      KIGHINSKYKMNDNEIKSLEEDTSAGKT---------------------- 338 
P.berghei_PBANKA_031160      KIGHMNSKYKIDSNGNKSLEEDTSAGKT---------------------- 334 
P.yoelii_PY05194             KIGNINNKYKIDGNENKSLEEDTSAGKT---------------------- 235 
                                  ..: :   :      :    . .                       
 
P.falciparum_PFB0675w        NNNNINGDSNNNNINGDSNNNNINGDSNNN--------NINGDSNNNNYH 478 
P.vivax_PVX_002795           HMHHMHHRGGALPRGSGSWKGEAEMMPHDKMPHLREELNDCNPNERGALG 428 
P.knowlesi_PKH_040510        IHSREIHFSGAMQRGSGSWKGETELITYD-----HEDLNNS-VNERGRHS 431 
P.chabaudi_PCHAS_031370      -------------------TGDENMSPNKQ--------NDC--------- 352 
P.berghei_PBANKA_031160      -------------------TGDEHMTSNKE--------NGR--------- 348 
P.yoelii_PY05194             -------------------TGDEHMTSNKE--------NEC--------- 249 
                                                ..: .  . .         *            
 
P.falciparum_PFB0675w        NNYHNNYRNNYHNNYRNNNCRNNILEQNKCDKNVLCYNNIYNTMKDNDTY 528 
P.vivax_PVX_002795           QKSGNTEPSQFPPHERYERYEKHLLCYNKLQT-LSNINYLYKVMKNNDAY 477 
P.knowlesi_PKH_040510        KKKVNLESTQLQPHER---YEKQLLCYNKLQT-LNNINYQYKVMKNNDAY 477 
P.chabaudi_PCHAS_031370      EDIDSIDGENVIEHNS---YENNILCYNKLQS-LNSVSYLYKVMKNNDAY 398 
P.berghei_PBANKA_031160      EEIDSIDGENVAENNS---YENNIMCYNKLQS-LNSVSYLYKVMKNNDAY 394 
P.yoelii_PY05194             EEIDSIDCENIAEKNS---YENNILCYNKLQS-LNSVSYLYKIMKNNDAY 295 
                             :.  .    :   :      .::::  ** :. :   .  *: **:**:* 
 
P.falciparum_PFB0675w        IYLKKNKFNSLLKSNCIKTNFNMIKIGYVIFLFVLLCLCIYLITGVECSL 578 
P.vivax_PVX_002795           IYLKKKKFNSLLKTNFHHCRLNKIKIGYACFLFVFLCLCVYLITAVECSM 527 
P.knowlesi_PKH_040510        IYLKKKKFNSLLKMNFHQCRLNKIKIWYACFLFLFLCLCVYLITAVECSM 527 
P.chabaudi_PCHAS_031370      IYLKKKKFNLLLRESFQKTRFNTIKVAHTFILLFLLCISIYFITSVETDM 448 
P.berghei_PBANKA_031160      IYLKKKKFNLLLRTNFQKTRFNTIKLAHAFILLFLLCLSIYFITLVETDM 444 
P.yoelii_PY05194             IYLKKKKFNLLLKTSFQKTRYNTIKIAHAFVLLFLLCLSIYFITIVETDM 345 
                             *****:*** **: .  : . * **: :. .*:.:**:.:*:** ** .: 
 
P.falciparum_PFB0675w        FGIYIYLSYFNFNIEGILIDYMDMLNILKLKIKKGYIYPFFVMLPFIFPV 628 
P.vivax_PVX_002795           VGIYIYLSYFNFNVEGILIDFIDMLNILKLKINRSYIYPFFVMLPFIFPV 577 
P.knowlesi_PKH_040510        VGIYIYLSYFNFNVEGILIDFIDMLNILKLKINRSYIYPFFVMLPFIFPV 577 
P.chabaudi_PCHAS_031370      LGIYIYLNFFNFNIESVMIDYIDMLNILKLKVNQNYVFPFFFMFPFIFPL 498 
P.berghei_PBANKA_031160      LGIYIYLNFFNFNIESVMIDYIDMLNILKLKVNKNYVFPFFFMFPFIFPL 494 
P.yoelii_PY05194             LGIYIYLNFFNFNIESVMIDYIDMLNILELKVNRNYVFPFFFMFPFIFPL 395 
                             .******.:****:*.::**::******:**:::.*::***.*:*****: 
 
P.falciparum_PFB0675w        IISMCFFLSVFFLNMYYESFSKLYKKISELKNEFINSSENDNVNERILVS 678 
P.vivax_PVX_002795           IIGLSFFMSVLFMNLYYVNFSRGYKKMCALNDELVFSPEVED-NQKMMVS 626 
P.knowlesi_PKH_040510        IIGISFFLSVLFMNLYYVNFSRGYKKMCAMNDELVFSPEVEE-NQKMMVS 626 
P.chabaudi_PCHAS_031370      IIAVSFMLSVFFMNLYYVNFSVWYKKITAFSDELVFDPEVQN-NQKITIS 547 
P.berghei_PBANKA_031160      IIAISFFLSIFFMNLYYVNFSIWYKKITAFSDELVFDPEVPN-NQKITIS 543 
P.yoelii_PY05194             IIAISFILSVFFMNLYYVNFSIWYKKITELNDELVFDSEVPN-NQKITIS 444 
                             **.:.*::*::*:*:** .**  ***:  :.:*:: ..*  : *::: :* 
 
P.falciparum_PFB0675w        ETSNHLCLN---ESNDKVSNTSDDFLSRNNSNISSSKSEMINSNFVFNKL 725 
P.vivax_PVX_002795           ERYNYLYIKKEIEKNDRLSNTSDDLTSPNNSTISSSKSEDINTSFISNRM 676 
P.knowlesi_PKH_040510        ERYNYLYIKKEIEKNDRLSNTSDDLTSPNNSTVSSSKSEDINTSFIFSRM 676 
P.chabaudi_PCHAS_031370      ERHNYLCIKKEIEKNDKLSNTSDELSSHNNSTITSSKSEDINTEFVYSGL 597 
P.berghei_PBANKA_031160      ERHNYLCIKKEIEKNDKLSNTSDELSSHNNSTITSSKSEDINTEFVYNGL 593 
P.yoelii_PY05194             ERHNYLCIKKEIEKNDKLSNTSDELSSHNNSTITSSKSEDINTEFVYNGL 494 
                             *  *:* ::   *.**::*****:: * ***.::***** **:.*: . : 
 
P.falciparum_PFB0675w        LNFYFSFAVFFSYLGSAFLHISLGEIICIALLTFYQIVKHTNNLNITILL 775 
P.vivax_PVX_002795           LNFYFSLSVFFTSICSFCMHISLGEIISISLLTFYQIVKHTHNLNILVLY 726 
P.knowlesi_PKH_040510        LNFYFSLSVFFTSICSFCMHISLGEIISISLLTFYQIVKHTHNLNILVLY 726 
P.chabaudi_PCHAS_031370      LNFYFLMSSFFASICSILLHMSLGEIIAIAIIIFYQIVKHTYNLNILVLY 647 
P.berghei_PBANKA_031160      LNFYFLMSSFFASLCSILLHISLGEIISIAILIFYQIVKHTYNLNILVLY 643 
P.yoelii_PY05194             LNFYFLMSSFFASLCSILLHISLGEIISIAILIFYQIVKHTYNLNILVLY 544 
                             ***** :: **: : *  :*:******.*::: ******** **** :*  
 
P.falciparum_PFB0675w        KSEKIKFCKFLLFILYGLLCFSINLYVNQWEEYITKLKRLKRRILLFEKN 825 
P.vivax_PVX_002795           KSNTVKFCKFLLFVVYGLLCLSINLYVSQWELYVKKLKKTKKRIALFQNN 776 
P.knowlesi_PKH_040510        KSSTVKFCKFFLFVVYGLLCLSINLYVSQWELYVKKLKKTKKRIALFQNN 776 
P.chabaudi_PCHAS_031370      KTDKIHFSKFILFIAFGLICFSINMYVAQWEKLVKKLQKIRKQIYLFEAN 697 
P.berghei_PBANKA_031160      KTDKIHFSKFILFISFGLICFSINMYVTQWEKIIKKLQKIRKQIFLFESN 693 
P.yoelii_PY05194             KTDKIHFSKFILFISFGLICFSINMYVAQWEKLIKKLQKIRKQIFLFESN 594 




P.falciparum_PFB0675w        KFSEIVDLNTQKGDGDHFDETQIFSIFFSFLIKKNE--GSKMRDNDMNSD 873 
P.vivax_PVX_002795           RYSEIVDLNIQK---HEHWHVPIYSYFFQFLLKKEHFFSSSLKHNHITK- 822 
P.knowlesi_PKH_040510        RYSEIVDLNIQK---HEHWHVPIYSYFFQFLLKKEHFFSPSIKHNQITK- 822 
P.chabaudi_PCHAS_031370      RCSEIVDLNIQK---NKNWTIPIYTYFFKSLIKPNQIVFKKNKKIDISE- 743 
P.berghei_PBANKA_031160      RCSEIVDLNIQK---NKNWNIPIYTYFFKFLIKQNQNILKKKKKIDISQN 740 
P.yoelii_PY05194             RCSEIVDLNIQK---NKNWNIPIYTYFFKFLIKQNQNIFKKKNKINISQD 641 
                             : ******* **   ..     *:: **. *:* :.    . .. .:..  
 
P.falciparum_PFB0675w        SEDSIYDAYEQQIQLHHGDNMVNGMLMMRRISMQNLEDDETQ-------- 915 
P.vivax_PVX_002795           --EHTDTVQTMMMHRVYENDTSLGYQNTRVDNDELNDFNEFN-------- 862 
P.knowlesi_PKH_040510        --EHTDTVQTMMMYRVYENDTSLGYQNTRVDND---EMVEFN-------- 859 
P.chabaudi_PCHAS_031370      --DNNTHIIRTQSSNMYDYDENR--------------------------- 764 
P.berghei_PBANKA_031160      INNN--HIIRTQSSTMYDNDENK--------------------------- 761 
P.yoelii_PY05194             INNNNNHIIRTQTSTTYDCDANQNYQNCQNYQNYQNCQNYQNCQNYQNCQ 691 
                               :             :  :                               
 
P.falciparum_PFB0675w        --------------------------VEYINREIHTQGDLHVRRTNQGIL 939 
P.vivax_PVX_002795           -------------------------LVSDRDSQLSDPDAQVDRAALPG-L 886 
P.knowlesi_PKH_040510        -------------------------LVSERDSQMSAEEGQAQPAETIAPT 884 
P.chabaudi_PCHAS_031370      ---------------------------MYQNMQSSIDEETLSYLNSSSIT 787 
P.berghei_PBANKA_031160      ---------------------------NYQNMQSPNDEETLNYLDSSSIT 784 
P.yoelii_PY05194             NYQNCQNYQNCQNYQNCQNYQNCQTYQNYQNTQSSNDEEALNYLNSSSIS 741 
                                                           : :              .   
 
P.falciparum_PFB0675w        RFNMRRGKKGSNENMGVHHESGNVDDANG-MNNVDDTNNMNNVDGTNNMN 988 
P.vivax_PVX_002795           AAVRADLRTDLRNDLRTDLPGELPTELRTEVRTPGQDECFVNG---STAR 933 
P.knowlesi_PKH_040510        IAGNTEMPTGVPREVGTDAPEEVPTGE----RSVDQDECFVNSGTTHTGR 930 
P.chabaudi_PCHAS_031370      NIRNKKKNSSKKNKNSTEDPAGVINKYNI--QSKGNNDRLINSG-MRKEQ 834 
P.berghei_PBANKA_031160      NIKNKKKNSNKKKKNSIDDTVGMINKCTN--QSKGNNDCLINSG-MRKEQ 831 
P.yoelii_PY05194             NIKNKK-NNNKKNKNPIEDTNGMLNKYNN--QNKGDNDYLINSG-MRKEQ 787 
                                     ..  ..   .             .. .: : : *     . . 
 
P.falciparum_PFB0675w        NVDGTNNMNNMDGRNNMNNINSVDNMNNLNNNDGEEEEE----------C 1028 
P.vivax_PVX_002795           SAPSDGLGGTGRGQNPGEAEQAEKQTEKQTEKQTEKQTEKQGEKLVEGDQ 983 
P.knowlesi_PKH_040510        NAPNDGLG--------------DGEKQRSSSAEVEKQEE--------GDS 958 
P.chabaudi_PCHAS_031370      CGPVSFLFS---------------EVKKRSTKLGKSNYN----------- 858 
P.berghei_PBANKA_031160      CGPVSFLFS---------------EVKKRSTKLGKTHHYV---------- 856 
P.yoelii_PY05194             CGPVSFLFS---------------EVKKRSTKLGKTHR------------ 810 
                                                     : :. .    : .              
 
P.falciparum_PFB0675w        VNDVLNYDNNNYAINEDAEEYIKNTSGER--------AVIICSEKRIYEK 1070 
P.vivax_PVX_002795           PNALPPAAASESSDAPGRAENANAGGVTS------------PGGENQVDE 1021 
P.knowlesi_PKH_040510        PRGGAVVVASESSTPSGKGENGNEEGVIT------------SGGENQVEE 996 
P.chabaudi_PCHAS_031370      -KKNRISVQSYEQIRDGEDDNIDDDEDGIYEEDKNENEDTESRENDPIEG 907 
P.berghei_PBANKA_031160      -KKNRISGQNYEQIKDGEHDNIDDECK----------NEDEEIENVQIEE 895 
P.yoelii_PY05194             ----IIIGQNYEQIKDGEDDNINDKN-----------------EHAQIEE 839 
                                      .      .  :  .                     .   :  
 
P.falciparum_PFB0675w        NGNGDIITRN-YKNEERYIYLKKWIPFKSMILSKLEKRKRNRKEAY---- 1115 
P.vivax_PVX_002795           AESGEASKKGPTFKSDPRGYLKNFMPIKSILLFHLEKRKKKKNKGGGGGG 1071 
P.knowlesi_PKH_040510        TESGDISKKGISFKNDPKGYLKNFMPIKSILLFHLEKRRKKKSKGGGDG- 1045 
P.chabaudi_PCHAS_031370      GHNNSLEKSN----SQNIPYIKSFVPIKSILLIQLEKLKAKKKKDR--GH 951 
P.berghei_PBANKA_031160      IHS-SLEKSN----SQNIPYIKNLMPIKSILLIQLEKLKAKKKKDR--GV 938 
P.yoelii_PY05194             GHN-SLEKSN----SQNIPYIKNLIPIKSILLIQLEKLKAKKKKDRGGGF 884 
                               . .  . .    .:   *:*. :*:**::* :*** : ::.:       
 
P.falciparum_PFB0675w        --------------------------NTPRVLILIHSFLFILIVFIFLMV 1139 
P.vivax_PVX_002795           GGGGGKGLGGLVGRLLRKLLGVGSSERISRVFILLHGFLFLLIFVTTVMV 1121 
P.knowlesi_PKH_040510        ---GGKGFGAFIERLLRKVLGVGSSEKISRMYILLHGFLFLLIFITTFMV 1092 
P.chabaudi_PCHAS_031370      GSKYGDKS---------------EPIDVTKLFYYFHILLFILIISTTLMG 986 
P.berghei_PBANKA_031160      GNKFGEKS---------------EPINIAKLFYYFHIILFILIITSIFMG 973 
P.yoelii_PY05194             GNKFGEKS---------------EPINIANLFYYFHIILFILITISILMG 919 
                                                         ..:   :* :**:**    .*  
 
P.falciparum_PFB0675w        FFKKEPIFRFNMPSVNKRLNNFFKSTSFHEIIPNSVGKCKTKKYIAKEPC 1189 
P.vivax_PVX_002795           FFKREGIFRFNMNAVNKRLNSFFKSSHFHSLIPNSIGKCKTKKYLAKEPC 1171 
P.knowlesi_PKH_040510        FFKREDVFRFDMNAVNRRLNSFFKSAHFHSLIPNSIGKCKTKKYLAKEPC 1142 
P.chabaudi_PCHAS_031370      FFKNESVLKFNMNSVNKRLNDYFTSPNFYAFIPTSVGKCKTKKYLAKEPC 1036 
P.berghei_PBANKA_031160      FLKNEQVLKFNMNSVNKRLNDYFTSPNFYAFIPASIGKCKTQKYLAKEPC 1023 
P.yoelii_PY05194             FFKNEQVLRFNMNSVNKRLNDYFTSPNFYAFIPTSIGKCRTQKYLAKEPC 969 





P.falciparum_PFB0675w        FNVGHIYHEEKTFYHATLLFLQGLRSVKIMNMNFYYEKGIYYLSLDGYFK 1239 
P.vivax_PVX_002795           YNVGHIYHEEKTFYHATLLFLQGISSIKIANVHFYYDKGKYNLILDGYFK 1221 
P.knowlesi_PKH_040510        YNIGHIYHEEKTFYHATLLFLQGISSIKIANIHFYYEKGKYNLILDGYFK 1192 
P.chabaudi_PCHAS_031370      YEVGRIYHEEKTFYHATLLFLQGISSINIDNIYFYYDQGKYYLTFNGYFK 1086 
P.berghei_PBANKA_031160      YEIGRIYHEEKTFYRATLLFLQGISSINIDNIYFYYDQGNYYLTFNGYFK 1073 
P.yoelii_PY05194             YEVGRIYHEEKTFYHATLLFLQGISSKKLIQ------------------- 1000 
                             :::*:*********:********: * :: :                    
 
P.falciparum_PFB0675w        HIIGPLFLKLCLGTNFCPISTYAFLVGSKPTFSVNVAVQCNNKKPPYYMT 1289 
P.vivax_PVX_002795           HIIGPLFLKLCIGTNFCPISTYAFLIGSKPTFSITMSAHCNDRKPPNYIT 1271 
P.knowlesi_PKH_040510        HIIGPLFLKLCIGTNFCPISTYAFLIGSKPTFSITMSAHCNDKTPPNYIS 1242 
P.chabaudi_PCHAS_031370      HIIGPLFLKLCLGSNFCPISTYAYLIGNKPTFSITIEAQCDDYAAPNYIS 1136 
P.berghei_PBANKA_031160      HIIGPLFLKLCIGSNFCPISTYAYLVGNKPTFSITIEAQCDDYASPDYIS 1123 
P.yoelii_PY05194             -------------------------------------------------- 
                                                                                
 
P.falciparum_PFB0675w        DIIVKDLKITKIEIVKHSDVIDNVDIKLDDVQDRVQEKVNAMLEAKKKII 1339 
P.vivax_PVX_002795           DIVVKDLKITKIEVIKHNDIIENVDIQLDDVQERVQEKVNSMLAERKRFI 1321 
P.knowlesi_PKH_040510        DIVVKDLKITKIEVIKHNDIIENVDIQLDDIQERVQEKVNSMLAERKRFI 1292 
P.chabaudi_PCHAS_031370      NLVVSDLQITKIEVIKHSDIIDNVDIKLDDIQERVQEKVNAMLADHLQII 1186 
P.berghei_PBANKA_031160      NLVVSDLKITKIEVIKHSDIIENVDIQLDDIQERVQEKVNAILADHLEII 1173 
P.yoelii_PY05194             -------------------------------------------------- 
                                                                                
 
P.falciparum_PFB0675w        VWKNQKYHLEGFLNYLISKNALSGFSCEPINY--- 1371 
P.vivax_PVX_002795           LWKSHKYNLEGFINYLISKNALAGFSCRPMNYHDV 1356 
P.knowlesi_PKH_040510        LWKRHKYNLEGFINYLISKNALAGFSCKPMNYQDL 1327 
P.chabaudi_PCHAS_031370      IWKNQKYDLESFVNYLISRNSLYGFSCEPYNY--- 1218 
P.berghei_PBANKA_031160      IWKNKKYNLESFINYLISRNSLFGFSCEPYNY--- 1205 
P.yoelii_PY05194             ----------------------------------- 





Note: In P.vivax two neighbouring proteins (PVX_081445 and PVX_081440) are identified as ubp1 
homologues (probably as an effect of annotation error).  They are most likely two fragments of the 
same protein.  Both are shown on the alignment. 
 
P.falciparum_PFA0220w        -------------------------------------MSHINYNVEKRKS 13 
P.vivax_PVX_081545           MRERIRVEADKPLPKDESDN---LFNPIWLSHFEKEKKAKLSSTCSTLQS 47 
P.knowlesi_PKH_020900        MRERILTRTDKPLPHDDADDGNKLCNLIWLSHIENEKKKDLGITCSRQKC 50 
P.chabaudi_PCHAS_020720      ------------------------------------------MDKNKKKN 8 
P.berghei_PBANKA_020880      ------------------------------------------MEKKKKKH 8 
P.yoelii_PY01242             -------------------------------------------------- 
                                                                                
 
P.falciparum_PFA0220w        LKKHNNNNNNNNNIYNNKIDTPNIKNYDDSSKHINTNPQVLDSILLSNME 63 
P.vivax_PVX_081545           KRSGNHHEYSSSYDRGDSHRCNRGDGLGHWRDDANECDDATFFILHNLKE 97 
P.knowlesi_PKH_020900        KKSGKHHDYSSRYDSRNEHRCKYGDPMSHRGGDADECDEAASFMLHKLKE 100 
P.chabaudi_PCHAS_020720      KKLEIRDPSDEINNCEGEKGGTQFDESFPFD-----NPEPNHINENHNVN 53 
P.berghei_PBANKA_020880      KKREISESDNNMNNCGKEKGSIQHDELYNIEQYLSDNLESNNIIENQNID 58 
P.yoelii_PY01242             -------------------------------------------------- 
                                                                                
 
P.falciparum_PFA0220w        KDKKLRLLNNYINMFDKNKNDKVTTNHPSHNIYNRKNNDTYDDQDKDEQY 113 
P.vivax_PVX_081545           NTRKGCTLAKGSEKGKRISRREEDTLFPAQFGSTDDENFLFGKQVRGDPQ 147 
P.knowlesi_PKH_020900        NIRKGCSLTHGSENGKRSSRRE-DALFPSHLGVADDVNLLLRKKVKGDHQ 149 
P.chabaudi_PCHAS_020720      NDDQNHVNIKKKN--------TSNSFENDILEFLPPNVDNNSDIFHANEV 95 
P.berghei_PBANKA_020880      NDYQKHITIKKKNCNEKRGKNLSNSFEDNTLEFLPQNVDDNSNNFQKTEI 108 
P.yoelii_PY01242             -------------------------------------------------- 
                                                                                
 
P.falciparum_PFA0220w        VDTDDSFSLSNTKKKINKRDIISYDNYIFEDEDKVSSKYLEYKNDSTSHM 163 
P.vivax_PVX_081545           KVVHTLRGPSQRQERTRTKAKGTTKENDTSWGEGACLLSGKRRKDRQEDG 197 
P.knowlesi_PKH_020900        KFIRTVRDPSLRKGSTRIKVNEATKRNDISGGKGACLLIGKSRKDRHGDG 199 
P.chabaudi_PCHAS_020720      NKIEETNLNDNEQNTMNIKNKDPNNRLDPKGND-------DNIVKNVESD 138 
P.berghei_PBANKA_020880      NKIEENNLNSTEAIKMNKKKKDINNRSDSKDNDCKCYDNDNADVKHTEND 158 
P.yoelii_PY01242             -------------------------------------------------- 
                                                                                
 231 
 
P.falciparum_PFA0220w        KKKKDEGSNRKGNI-------------------------NMDSNNNDDNN 188 
P.vivax_PVX_081545           ALRGDRHDRRRHQTNGHHEELYLSDVYHSDMHVSDMYSGDGDFLRADGES 247 
P.knowlesi_PKH_020900        AVRRDRHGCGHHQK---------TNEYDEELYMNYGDSCDGEILEVDGVN 240 
P.chabaudi_PCHAS_020720      FEKNNN------------------------------------LLVTDENV 152 
P.berghei_PBANKA_020880      FEKNGNHSTNENDK-------------------------NKDLLAIEENI 183 
P.yoelii_PY01242             -------------------------------------------------- 
                                                                                
 
P.falciparum_PFA0220w        NNINMKS----------------------------------NTNNNNNNN 204 
P.vivax_PVX_081545           ADGGRAQRMGEWGGRSKRGAKQSAGGDPDKPHKSHKPGKMRKMSKMKKVR 297 
P.knowlesi_PKH_020900        AEEVKAEGMGEWGGHSKRGGKHSS--------------RRGDSSKAHKPR 276 
P.chabaudi_PCHAS_020720      NDHFENT----------------------------------NEQLNKNQD 168 
P.berghei_PBANKA_020880      NDHFESS----------------------------------DGYENEHSN 199 
P.yoelii_PY01242             -------------------------------------------------- 
                                                                                
 
P.falciparum_PFA0220w        NNNNKDDDYYDDNNYYHKNHSDSINNSINYNDIHRKEKKNKKNTHNEKKY 254 
P.vivax_PVX_081545           KMQSMRKSRGGENGKSGLIGCRSGSVTTQSSSPDQDCYQAEEERGKAKKK 347 
P.knowlesi_PKH_020900        KVEKMRKSRREKNWKNCLIGCRSGSVMTQFSSPDHDCYQAEEEKRKEKKK 326 
P.chabaudi_PCHAS_020720      KDENIGK-------------------PNKREDSDEHESGRKKRSVKDN-- 197 
P.berghei_PBANKA_020880      KSEKGDEYENEHSNKSEKGDKPENEHSNKSTEMNEHGNDGKKRSVKDN-- 247 
P.yoelii_PY01242             -------------------------------------------------- 
                                                                                
 
P.falciparum_PFA0220w        ISNMYNFQYDDYDKKKKKKNTLETYDSDTKNSDIFINTGFLPYSLNKKKN 304 
P.vivax_PVX_081545           KKKK--SDINSTDGVPNQIASLFFNLSDMRKNNLSKADGVTVKKSCRHHC 395 
P.knowlesi_PKH_020900        KKKKKKSDMKSTEEMTNYISSLLFNLSDMRKNNLSKADGVMVKKSCSHYC 376 
P.chabaudi_PCHAS_020720      -------VYEDFIREYKNLQSLFSYNQTMIKESFNP----MPTILEDDNN 236 
P.berghei_PBANKA_020880      -------VYEDFIREYKNLQSLFAYNKTIIKENFNP----MPTISEENKN 286 
P.yoelii_PY01242             -------------------------------------------------- 
                                                                                
 
P.falciparum_PFA0220w        NKKRKGKKKNEQEENRHNVNYDDNMDDDDDDNNDNNNDDDSNNNNNDDDS 354 
P.vivax_PVX_081545           KGERTRGADGPSGRGGQLEGASPPDRKNGSPANGAARGSAKISSKYS--A 443 
P.knowlesi_PKH_020900        RVERTR--DG-ADVEGQRRGGDECGDECGGECDGASPRHGKNGSTADGAA 423 
P.chabaudi_PCHAS_020720      YSDKNGSERNEDMKIPFDENVDKNATPRNHINPDYSAAYNLNDDAVISDV 286 
P.berghei_PBANKA_020880      GSDIK--------------------------------------------- 291 
P.yoelii_PY01242             -------------------------------------------------- 
                                                                                
 
P.falciparum_PFA0220w        NNNNNDDDSNNNNNDDDSNNNNNDDDSNNNNNDDSNNNNNDDSNNNN--- 401 
P.vivax_PVX_081545           KNYGKNSAKICGKYSAKNCAQNSGKNIRKKIGKHIGKYIADDEDEDGEEV 493 
P.knowlesi_PKH_020900        GRSGKFSRKFCVKRSAKNCAQNEGKNICKKISKHMNKYIAEDEDGDE--- 470 
P.chabaudi_PCHAS_020720      NKTSEKVSEEVHETMDNKVDETDHPHFSNQLNYPTNNDVQEDENKSL--- 333 
P.berghei_PBANKA_020880      ----------MDKKMNKTEERNNHSDFSNQLNYPTNNNLKDDENKSR--- 328 
P.yoelii_PY01242             -------------------------------------------------- 
                                                                                
 
P.falciparum_PFA0220w        ------------------NDDSNNTGSFFKNKMIQSHVINNKYDNTNDYL 433 
P.vivax_PVX_081545           LSEGEILSEGEVLGEGEVLGETQGERHSKGKKKSGKNSSGREKDTAERDD 543 
P.knowlesi_PKH_020900        -------------GKEEILGETQGERQKKKKKKNVKNTN-RKKDTAE--- 503 
P.chabaudi_PCHAS_020720      ------------------LRERGNENDKENGVETQNNDTN---------- 355 
P.berghei_PBANKA_020880      ------------------LSEQDDE------IEEKSSDNN---------- 344 
P.yoelii_PY01242             -------------------------------------------------- 
                                                                                
 
P.falciparum_PFA0220w        DDLESFEYNKTKKKKKKKNDTIDDVFKNKRNDNTKIKYNYNNNNNNNNNV 483 
P.vivax_PVX_081545           RSGNCSSREAGTKNFAQGRRGTLHDDSRAPAPEWHFVRYGRGDEASGQSA 593 
P.knowlesi_PKH_020900        -----------TKNYAQGRRETLHDDSRTPAPEWHFVRNGRGEEISSESA 542 
P.chabaudi_PCHAS_020720      ------------LGEEKEHMELKKEIKHKEFENQE-RKQNKEKEMNDASA 392 
P.berghei_PBANKA_020880      ------------FGEGKEHEELKKEIKNKESENRENKKINKQKETSDINA 382 
P.yoelii_PY01242             -------------------------------------------------- 
                                                                                
 
P.falciparum_PFA0220w        LEYELNYVHNSFDTHPKKWSHHSLPDNYEGEKKKKKNKTKKKRHDMNFYS 533 
P.vivax_PVX_081545           GGNQRGSHRGGSSGGSGSNRSCDSGSHRSRDNGSSSGCKRDSRRCSHRRS 643 
P.knowlesi_PKH_020900        GRNHR-------------------RRYRSVDSGNSSGCERGSRRR-RSSS 572 
P.chabaudi_PCHAS_020720      PENE--------------------------KNIDEISKKKENHYIQKKNT 416 
P.berghei_PBANKA_020880      PESEENIIL------------------EKEKDSDSISKKKENLYMQKKNT 414 
P.yoelii_PY01242             -------------------------------------------------- 




P.falciparum_PFA0220w        IDKNNLDEQDLFSNQEALTILKNFAKENNVSHPYKEKKINKNKKTS---- 579 
P.vivax_PVX_081545           RRRSRRDGGPLFGGNVFLASETEGEGSPSISPKRNARVVVNSRRALTPSG 693 
P.knowlesi_PKH_020900        ISVNLPEGGPLLGGNVFSADETEGEGAASVSPKRDARVVAKLGRAEPPSD 622 
P.chabaudi_PCHAS_020720      --ITQLQEKKSSSNTSIASIINDNYDDHKISKKNNIEHVGKTQFSN---- 460 
P.berghei_PBANKA_020880      NKLQKGKEQNSSSNISVASIINDNFDNYNISKNNSISKIDKTKTYN---- 460 
P.yoelii_PY01242             -------------------------------------------------- 
                                                                                
 
P.falciparum_PFA0220w        -------SNSMYKDYSNNINNYNNNNDENNN-YKDIVSNYDNNYEYDKKN 621 
P.vivax_PVX_081545           SLIGSEVSTTSRSDCADRDAPFKKNSKQSQPWGERTMNS-NSYSLHDAEG 742 
P.knowlesi_PKH_020900        SHSVSEVRKAARCDSVDRDAPFKNHSKQSEFLYERTMKSSNSYSLRDGED 672 
P.chabaudi_PCHAS_020720      -------DSIKKKHHPIDRNEYKSSSPKNNRTNTEIKKGITESDNLKIKK 503 
P.berghei_PBANKA_020880      -------DLTKKKDGSIDNNEYKNDASKNYRPSIEINKSKNESDNIKIKK 503 
P.yoelii_PY01242             -------------------------------------------------- 
                                                                                
 
P.falciparum_PFA0220w        KNKIDVEQNVHMINYINVNNKQTNINNHNDNNFNVNKELSINDNVYENFI 671 
P.vivax_PVX_081545           FADAHQQRYAEEDSHPQKESEQRGKKNKKKNSKGIDLDTSLPERGSIGEV 792 
P.knowlesi_PKH_020900        FEEAQQERYGEEERHPQRELEQREKKNKKKNSKEIDVDGTLPERGIIAQV 722 
P.chabaudi_PCHAS_020720      IEKETD----DPNLYINILDENSKDNKKKDLYLNNSFYLSKQD------- 542 
P.berghei_PBANKA_020880      AEKQEGNKMNDHNFNINFLDESIKDNSKTDLFLNISSDFSKHD------- 546 
P.yoelii_PY01242             -------------------------------------------------- 
                                                                                
 
P.falciparum_PFA0220w        REYKNLQSLFSYNKNKIEDHFNPLTRIIEKNKEDNIVLENNINKFILNAH 721 
P.vivax_PVX_081545           DRRGHRQSITHEKEHKESTSKYTHVIASQKKKKKNSSEIHDEGSIHDEKK 842 
P.knowlesi_PKH_020900        DQRGRHPNSTYEKETKVSTSKYAHTIASPQKKKRNSSEIQDDGSVNDEKK 772 
P.chabaudi_PCHAS_020720      -RSSKIQSAKNVE--EVNGKIKKVKKHQASSDESSEVNEM--------DH 581 
P.berghei_PBANKA_020880      -NNDNDNKLKGVKNIEVNSQIKKTSKHRVIYDDNSEVDEMNQIDINLNDH 595 
P.yoelii_PY01242             -------------------------------------------------- 
                                                                                
 
P.falciparum_PFA0220w        EGLSKKMLSYHMDEQEDVQGMKSIEDDNKGGDNKGGDNKGGDKKGGDNKG 771 
P.vivax_PVX_081545           TSVKDNVYENFIREYQNLQSLFSFNKDKIGEEKGEE---------EEERK 883 
P.knowlesi_PKH_020900        TSVKDNVYENFIREYQNLQSLFSFNKDKMEDDNDNDNDNDNDNGDEDDDD 822 
P.chabaudi_PCHAS_020720      ENYSKINKSLTEQHRKKDTKKKKVEKKKKNNNNNTENTFDSKHLNDDNFS 631 
P.berghei_PBANKA_020880      ENYNKINNNMNEQNRKGDIKKKKVEKKKKNSN---KNTFISNHLNDDNIS 642 
P.yoelii_PY01242             -------------------------------------------------- 
                                                                                
 
P.falciparum_PFA0220w        GDKKGDDKKGDDNKDDDNDDDDDDDDNDDDDDDESTISYSKSDLSKIVEY 821 
P.vivax_PVX_081545           KERKKEGGEKDDRKDDPFGGSLSRALDKDVEENLREDAPSKNHLSTMLTT 933 
P.knowlesi_PKH_020900        DDEEEEDKKKKKKGDDSYGESRSRVLDRDGNESLCEDVLSKNHRSRMLAN 872 
P.chabaudi_PCHAS_020720      LS------------------YFTED-KKEGYDSIHEAKEVLQEYVNGKVK 662 
P.berghei_PBANKA_020880      LS------------------YFTEENKKEDYDSIHEIEKSSNEYIHVNNK 674 
P.yoelii_PY01242             -------------------------------------------------- 
                                                                                
 
P.falciparum_PFA0220w        INNDDME------EMTRFSNNNSVLQKKKQNKKKKNEQNKDNILTKNSKH 865 
P.vivax_PVX_081545           DGYTNSKGEAPPVDAKRGKSSDPNRSDKRVESLEELSYNFGHYNFNESID 983 
P.knowlesi_PKH_020900        DGYANSKGEKSPRGAERGKPSEPNQSDQGVDSLEQLSYNIGQYDNTESVG 922 
P.chabaudi_PCHAS_020720      KHIRENK------ETNKYKNVDPTLVKKIKNITKHTDFNINNLDDQLCKL 706 
P.berghei_PBANKA_020880      KDIRDNK------ETNKYKNIDPTIMKKIKNINKGTGLNINNRVCKLNSP 718 
P.yoelii_PY01242             -------------------------------------------------- 
                                                                                
 
P.falciparum_PFA0220w        NSTHTINCKNKKDLKNLSTSTNIMDESIHKNNNDNNMNSNKNNNDNNMNS 915 
P.vivax_PVX_081545           KEEIGVVPRKDSLRSRDKGLGGNDDAGSSGVVPMGDNRRGKTHSSGKENA 1033 
P.knowlesi_PKH_020900        NIEVGVVVRDNSPPSRGKGLCGNDDTDSSGVVPIGDNQQDKSHSDGKENE 972 
P.chabaudi_PCHAS_020720      -DPPIKHSKHHKETTKKKSVRQSSS-SVKKKHTKHSSKKNKKEDDPNDSD 754 
P.berghei_PBANKA_020880      -IKEIKQVRNHKEIAKKKTLSPNSSFIKKKKHIKHSTKKNKKEDDANDSK 767 
P.yoelii_PY01242             -------------------------------------------------- 
                                                                                
 
P.falciparum_PFA0220w        NNNNNDNNMNSNNNNNDNNMNSNNNNNNNYNSSSDMKIIESNNIPYSPNN 965 
P.vivax_PVX_081545           SGMNEAVTHEHGVEKNRRGQKSADVDPSEGVGGKKNKTEGSSRQGRRESS 1083 
P.knowlesi_PKH_020900        SGTNEGVTHAHGVGK-----ESEDMDASEEGTVKKNRTGGSTRHVRRESS 1017 
P.chabaudi_PCHAS_020720      IKEWESKFIEEDE-------------------------------EEDEEY 773 
P.berghei_PBANKA_020880      IKKWESKFVEENEEMEEENEEMEEENEEMEEENEEMEEENEEIEEEKEED 817 
P.yoelii_PY01242             -------------------------------------------------- 





P.falciparum_PFA0220w        NMKKKKKKKKKNLKEKLNNNIKYNEIITK--------------------- 994 
P.vivax_PVX_081545           GGSVQRMRQIGSLHSGAKGNSQDGEADMNGVRGENADLLVRDDLLGSGDV 1133 
P.knowlesi_PKH_020900        GGNVHRIKEAANLESSTKVKSQDEDTHMNRVRSKNSDLLIWNEQVQPG-- 1065 
P.chabaudi_PCHAS_020720      NDPYLTIINEKQKKKESKHSKKKKIYMTN--------------------- 802 
P.berghei_PBANKA_020880      NELYWETINEKKKKKK-KYSKKKKSQIMN--------------------- 845 
P.yoelii_PY01242             -------------------------------------------------- 
                                                                                
 
P.falciparum_PFA0220w        ---------------------------------------THIFPTNKIIQ 1005 
P.vivax_PVX_081545           VGRGDIVGRGDVVGRGDIVGRSDVVGRDNPLARADSLGKVSLSSNKTAPN 1183 
P.knowlesi_PKH_020900        ----------------------------DMLLFPDSLRKGSLSKNKTVPD 1087 
P.chabaudi_PCHAS_020720      ---------------------------------------ESFKNSISTVD 813 
P.berghei_PBANKA_020880      ---------------------------------------ESFNNSISSVD 856 
P.yoelii_PY01242             -------------------------------------------------- 
                                                                                
 
P.falciparum_PFA0220w        HDKGVEYETTNSKHLLHKNINNIYNQSEQNWSLHEDLLKEVLTKEEYNEK 1055 
P.vivax_PVX_081545           ENNYFEYEANNSKKLLHKNMSNLYSMNGSNLTFHQDFFKDILSLNEEKKK 1233 
P.knowlesi_PKH_020900        ENNYFEYGAKNSKKLLHKNMSSMYSMNGSNLSFHQDFFKDILLLNDEKKK 1137 
P.chabaudi_PCHAS_020720      DTQSGQEDDENDQAMQLSFFNFFDKQKNNQHIVNLQKEDNEIEKDELNYK 863 
P.berghei_PBANKA_020880      DIQSEQEEDENDKAMQLSFFNFFDK------------------------- 881 
P.yoelii_PY01242             -------------------------------------------------- 
                                                                                
 
P.falciparum_PFA0220w        LIKKNKNKNSKINKKTVDNKETHLHKQIAEKYDNIHTYIVETR------- 1098 
P.vivax_PVX_081545           EKKKKKSSKQHSFDQFDELSYFADVKSGKHSKHRNNCTPQEDEFAKGFDF 1283 
P.knowlesi_PKH_020900        EKKKKKSSKQHSFDNIQHLPYFEETKKGKQNKEN-----RKD-------- 1174 
P.chabaudi_PCHAS_020720      KKKKKKKDNRKTNDILKDD------VKFEHNINNFFSSFWDNE------- 900 
P.berghei_PBANKA_020880      KKKKKKKHSQKSNDILKEN------LKLENDINNFFISFWDNK------- 918 
P.yoelii_PY01242             -------------------------------------------------- 
                                                                                
 
P.falciparum_PFA0220w        KDKYSPSDHEKQNSFIKERVLHSKKKIKGKKNSKRNIKMVSRNKENKKER 1148 
P.vivax_PVX_081545           KREKGGDRKGSSGGKSAAGGRRSLRGEEENDEEGDDEEENDDDGEVERGK 1333 
P.knowlesi_PKH_020900        -KKKGNDDDDKHGED----------DEYNDDEDGDVVDDVGDDDEVHREE 1213 
P.chabaudi_PCHAS_020720      NLKKKNKDDLYN---------------LNNENN-KDIYSVNKIEKKINKP 934 
P.berghei_PBANKA_020880      NLKKNNKEDLYN---------------FNNENNTKDIHSINKIEKKMSKQ 953 
P.yoelii_PY01242             ----------------------------------------------MSKQ 4 
                                                                                
 
P.falciparum_PFA0220w        TMKSQNDNHLNNHESDDNNSIENSYEESAMYDENNSSIHDDNSKKEKFSD 1198 
P.vivax_PVX_081545           AAAEDSDDYGDCDDHGDHGDHGDYDGEGSEGDGD-SYGHEDLRDGDHLEG 1382 
P.knowlesi_PKH_020900        AAGEDIYKE-------ESDDYGNYDAEGVEGRGDDSYDQEELHNGDHLER 1256 
P.chabaudi_PCHAS_020720      YLHISKEDNIN---------------------EQIDRLRREIAQNNILTE 963 
P.berghei_PBANKA_020880      YIHTPKEDNLN---------------------EQIDILRKKNSQNNILQN 982 
P.yoelii_PY01242             YVHISKEDNLN---------------------DQIDVIRTNYSQNNILRN 33 
                                    .                         : .  : .  . : :   
 
P.falciparum_PFA0220w        NEKYHERAEEEIVSDDLYQEDDNSDHSNKKIKMNMKSMTSFDKDKRRYTI 1248 
P.vivax_PVX_081545           SQRPSGSHKERRKKKKSQGEPTRKSKSGKLEKVKIVE------------- 1419 
P.knowlesi_PKH_020900        PHGQTESHKERKKKKKLQGELTKKSKSGKMEKVKIVE------------- 1293 
P.chabaudi_PCHAS_020720      HDKHIDERKGDIRKFLHWDDGKKGKHNGKDDKK----------------- 996 
P.berghei_PBANKA_020880      QDKYIDE--------------KKGKHSGKD-------------------- 998 
P.yoelii_PY01242             RDKYIDE--------------KRGRHNGKD-------------------- 49 
                              .                    .  :..*                      
 
P.falciparum_PFA0220w        QNLEEIKKKSKKSINKNENDKYGYNSDYMNDSGDFAVEKKDKKKKTQQEN 1298 
P.vivax_PVX_081545           ---------EKNKPHKRRSVREKRNSNRTHNNSICSLGEDHLYDDAGDFL 1460 
P.knowlesi_PKH_020900        ---------EKNRTHKRRSTKEKRKCSRTHNNSICSLEDDDFNDDAIDYP 1334 
P.chabaudi_PCHAS_020720      ---------EKDKLKEKDKIKYKEKMDYPNYEHNRNYDEDKRKHKKNHME 1037 
P.berghei_PBANKA_020880      ----------KDKFREKDKMKYRDKISYINYEHNRSYIDNKHKYKKNYLE 1038 
P.yoelii_PY01242             ----------KDKFREKDRMKYRDKISYTN------YIDNKHKYKKNYLE 83 
                                       *.  .:.   :   : .  :        ...   .      
 
P.falciparum_PFA0220w        CDNKYGNKYNKCDKDK--------------------------DKDNYNNK 1322 
P.vivax_PVX_081545           YNEGRGHHHDGAIGDDPPGDNLHIDVLEEFRRDDSHKGIVGYSDEVHYQE 1510 
P.knowlesi_PKH_020900        YHEKRVLLDDAVIGDD----NLDIDMLDDLPKG----GILAYPDEVPNQE 1376 
P.chabaudi_PCHAS_020720      NYDESYNPYSIEEYN-------------------------------NYSS 1056 
P.berghei_PBANKA_020880      NYDELYN-YSIEEYN------------------------------NNYSS 1057 
P.yoelii_PY01242             NHDQVYNNYPIEEYDD--------------------------DDDNNNYS 107 





P.falciparum_PFA0220w        DKFLPSDQAFHYDNRKAKKKNKEDILKDQYNDEHIKEYFYSLIEGQVSKN 1372 
P.vivax_PVX_081545           EGANSEKAKRKRKNSRRKKEDSRDEYMKGFFSSVMDNQMYKKNLNSKDFG 1560 
P.knowlesi_PKH_020900        EGPNVEKAKRKRKGSRRKKEDLREEYMKEFFSSVLDNQIYKKNLNSKDFC 1426 
P.chabaudi_PCHAS_020720      SENE-----LKRIYNKNEKKYMDGILLNKNYDEPINNSLKKKHHKHEDKE 1101 
P.berghei_PBANKA_020880      SEHEKRENELKKIYNKNERKYLDGIILNKNYDESINNVLKKKDHKNEEKE 1107 
P.yoelii_PY01242             SEDEKREKGFKKIYNKNEKKYLDGIILNKNYDEPINNVLKKKNHKNEEKE 157 
                             .         :    : :::       .   .. :.: : .      .   
 
P.falciparum_PFA0220w        NKNKKKKNSQRDYSLNKSTKE---------------------KGVKKERL 1401 
P.vivax_PVX_081545           HSFGPEGEEDADEEGEDERDDRNGRDAREKHMLRNISKVIRTENLNTEIE 1610 
P.knowlesi_PKH_020900        RNFALEGEEDMADAIEGEEG--------EKYMLKNISKVIRAENIDTEIE 1468 
P.chabaudi_PCHAS_020720      NNYFLENNNDN-STAHNNNG-----------------------YTTKGLG 1127 
P.berghei_PBANKA_020880      NNYFFQKNNDN-STVHNNSG-----------------------YATKSLG 1133 
P.yoelii_PY01242             NNNFFQKNNDNNSTVNNNSG-----------------------YATKGLG 184 
                             ..   : :.:     . .                            .    
 
P.falciparum_PFA0220w        LHNKHFKETDSEED--------QNNKKNKNNIYLKKNYDQENEKDNEYEN 1443 
P.vivax_PVX_081545           LLRNEILQTKMSKESLPSVEKKKGAHKIDNSVEATHRKKKSYDKEEEKRA 1660 
P.knowlesi_PKH_020900        LLRNEILQTKMSKESVSHVEKKKSAHKISNPLEMTHRKKKSNDKEEEKRN 1518 
P.chabaudi_PCHAS_020720      FFSSNFFHLKKLIE--------KKNVENNDSLKRENGVDKFYEKNENNAK 1169 
P.berghei_PBANKA_020880      FFSSNFFHLKRLLE--------KKNVETNDPLKRENELDKFYEKNE---- 1171 
P.yoelii_PY01242             FFSSNFFHLKRLLE--------KKNVETNDSLKRENELDKFYEKNE---- 222 
                             :  ..: . .   :        :   : .: :   :  .:  :*::     
 
P.falciparum_PFA0220w        EKS------------------------YKKSTRPYYEEDHTPYRKQNIQD 1469 
P.vivax_PVX_081545           SFMGGPRVDPSEDRGVDPRTAKAGSHHNAIPSTYAKEEDDYYAFHHEKKK 1710 
P.knowlesi_PKH_020900        SFK------------LDFKTGKDGTHHNAFTSHYAKDEDDYYTIHHEKKK 1556 
P.chabaudi_PCHAS_020720      NE-------------------------KKKLSSFDILQKFINNKG-DTKY 1193 
P.berghei_PBANKA_020880      ---------------------------KKKSSSFDIFQKFINNKGHDMKC 1194 
P.yoelii_PY01242             ---------------------------KKKSSSFDIFQKLINNKTHDMKC 245 
                                                            :     :.       : :  
 
P.falciparum_PFA0220w        WSSYTKDKENKLNMDDDINMNKGNDQDVNRTYKNEKNKEEDKYGKNEKNE 1519 
P.vivax_PVX_081545           RESHVKLRDVSFEEDDRLRRPKGRSRIAGRDTVHSFNDEGSGIPPTHGNS 1760 
P.knowlesi_PKH_020900        RESHVRMRDINFEEDERFKKSKGRNKLAGRDRVHSFNEEGRGIPPTHGNN 1606 
P.chabaudi_PCHAS_020720      GKIDDSYKRGNNDVAELYHISRRKGSINEYGDPHETAQISDGYSEKAGHN 1243 
P.berghei_PBANKA_020880      GKISNFYKRESHDYSDIYYTSRGKESFKECIDPNDTEQISDAYSEYIEHF 1244 
P.yoelii_PY01242             EKMSNSYKRESNDYSDMYYTSREKENLKKYIYPNDTPQISDAYNDYIEHF 295 
                              .     :  . :  :     : .         :.  .          :  
 
P.falciparum_PFA0220w        K---------YDKYDKYEKYEKYDKYKKDNKNQHDDPLYDNINKNYDNDN 1560 
P.vivax_PVX_081545           SSIGGG--LHLNKSLEFFSNNFLSLKRLIERKSGDPHYDAKREDDYVDRA 1808 
P.knowlesi_PKH_020900        NSAGGGGGLHLNRSLEFFSSNFLSLKKLIERKNVDTNYDAKREDDYVEKG 1656 
P.chabaudi_PCHAS_020720      D---------IDEYTNFQTYRR-------NPDERDRRYYKDKREYHEN-- 1275 
P.berghei_PBANKA_020880      D---------IDKYGNFRKYKR-------NKDDKNRKYYKDRHEYHEN-- 1276 
P.yoelii_PY01242             G---------IDKYEKFQTYKG-------NKSDKDRTYYKDRCESHENGK 329 
                                        :.  :: . .        : .. :     .  . : :   
 
P.falciparum_PFA0220w        KGLEFFSNNFFHIKKFIEKKENENVHMSKIENSQKEEELNHKRNNLNSSG 1610 
P.vivax_PVX_081545           D-----EEVNFDVKKKKKNSYDDYEHPQMVHKNSHKNSRGLRFDNFFGIN 1853 
P.knowlesi_PKH_020900        E-----EEVDIDVRRKKRNSYDDYEHPQMMNKSSHKISRGLRFDNLFGIN 1701 
P.chabaudi_PCHAS_020720      -----------------EKHEKNSKHKKHAEYKWKKINKELINDHTDHIE 1308 
P.berghei_PBANKA_020880      -----------------EKHEKNSKHKKPAEYKCKKINKELLNDRIHNIE 1309 
P.yoelii_PY01242             NGKNEKNE-KNEKNEKSEKNSKNSKNKKRAECKSKKINKELLNDRIQNIE 378 
                                              .:  .:  : .  . . :: .     :.      
 
P.falciparum_PFA0220w        K-TEKLEKFLGLYKENNEAMDFYKSVLIEENNSMNISKNKINKNNIIDDR 1659 
P.vivax_PVX_081545           KRSSDSLSFYRSFIKQEG------KSGKGD-HRKKGRGRRDSGERFDSGF 1896 
P.knowlesi_PKH_020900        KRNSESLNFYRSFIKEDG------KSGKGDHHRKKGRGRRDSEERFDSGF 1745 
P.chabaudi_PCHAS_020720      D-DEKSVKFRKKFNYN--------------------LTRTGSNESMINEF 1337 
P.berghei_PBANKA_020880      Y-DDKSLNFQKKYISN--------------------LTRTDSNETMVNEF 1338 
P.yoelii_PY01242             Y-DDKSLKFQKKYISN--------------------LTRTYSNEMLLNNF 407 
                                ..  .*   :  :                      .  . : : .   
 
P.falciparum_PFA0220w        MKDNIS------------------KINRYNSDDTYIKVENNYDNKKEMNN 1691 
P.vivax_PVX_081545           GAGFGSGFGAGFGG----GYVTGFGSDSGGEHTGAARRAPRGEDAENADD 1942 
P.knowlesi_PKH_020900        GTWFGTGLGSDLVGERRGAARRAQRSEDYMEDVEEVGSVANGQDTHNVDD 1795 
P.chabaudi_PCHAS_020720      GINKLN------------------PQFSDEEKN----------ENNNINK 1359 
P.berghei_PBANKA_020880      SMDKLN------------------HQSNNEDKNENNNDFNKYENNNGFNK 1370 
P.yoelii_PY01242             SVDKLD------------------HQFNNGDEN--------YENCENYEN 431 





P.falciparum_PFA0220w        SDELNGNNNNNNNKNNNNNNNNNNNNNNNNNNNNNINNGGDKNRRNNFNN 1741 
P.vivax_PVX_081545           MEDVEDADDAEDADGVTDGEHDDDLEHADSVADDPVRSARRRKGEKAFSA 1992 
P.knowlesi_PKH_020900        EGDDNDKDDDNDRGDDNDKGDDHEAAYGEDYADDRIRSIRRRKGEKVFST 1845 
P.chabaudi_PCHAS_020720      YDE-------------------------KDD-------EIYENSENFLYS 1377 
P.berghei_PBANKA_020880      YENNNEFNKYENNNGFNKYENNNEFNKYENNNDLKKYDEFYENSESFLYS 1420 
P.yoelii_PY01242             YEN------YEN------YENN------ENN----------ENSESFLYS 453 
                               :                         ..           .: .. :   
 
P.falciparum_PFA0220w        NN------------------------------------------------ 1743 
P.vivax_PVX_081545           GRAADGVAGRAAGRSAKGAARGRAKRGEQLHSGEQLHSGEPLHSEDPLHS 2042 
P.knowlesi_PKH_020900        GREEDVVAGRAGSRSEKGTLRDRAKR------------------------ 1871 
P.chabaudi_PCHAS_020720      -------------------------------------------------- 
P.berghei_PBANKA_020880      -------------------------------------------------- 
P.yoelii_PY01242             -------------------------------------------------- 
                                                                                
 
P.falciparum_PFA0220w        -------------------------------------------------- 
P.vivax_PVX_081545           EDPLHSEDPLHSEDPLHSEDPLHSEDPFHSEDHLHSEDHLHSEDHLHSED 2092 
P.knowlesi_PKH_020900        -------DAVHG----------------QSTEDLHSGEKLADGEKLQNEE 1898 
P.chabaudi_PCHAS_020720      -------------------------------------------------- 
P.berghei_PBANKA_020880      -------------------------------------------------- 
P.yoelii_PY01242             -------------------------------------------------- 
                                                                                
 
P.falciparum_PFA0220w        ------------------------IYMCKNVKNIILSLELSNEEKINEVR 1769 
P.vivax_PVX_081545           HLHSEDHLHSEEPLPSEDHLRCGPGKSHKNVKNILLSLELSNEDKIHKVR 2142 
P.knowlesi_PKH_020900        QSVNVEELH-------------GSGRNHKNVKNILLSLELSNEDKIYKVR 1935 
P.chabaudi_PCHAS_020720      ------------------------VDNFKIVKNILLSLELTNDNKINKIR 1403 
P.berghei_PBANKA_020880      ------------------------VDNFKIVKNILLSLELTNDDKISKIR 1446 
P.yoelii_PY01242             ------------------------VDNFKIVKNILLSLELTNDNKISKIR 479 
                                                         * ****:*****:*::** ::* 
 
P.falciparum_PFA0220w        KILFYSSSDEKKYIMNEILNILYIYPQLYVSCIISLFYLFILDNEIFEKY 1819 
P.vivax_PVX_081545           KILYYSSSDEKKLMINEILNTLYVYPQLYVACIICLFYLFILDNELFERN 2192 
P.knowlesi_PKH_020900        KILYYSCSEEKKLMINEILNTLYVYPQLYVACIISLFYLFILDNELFERN 1985 
P.chabaudi_PCHAS_020720      KILFYSSSEEKKKIMDEILNTLYIYPQLYVSCIICLFYLFILDNDLFERK 1453 
P.berghei_PBANKA_020880      KILFYSPSEEKKKIMDEILNTLYMYPQLYVSCIICLFYLFILDNDLFERN 1496 
P.yoelii_PY01242             KILFYSPSEEKKKIMDEILNTLYMYPQLYVSCIISLFYLFILDNDLFERN 529 
                             ***:** *:*** :::**** **:******:***.*********::**:  
 
P.falciparum_PFA0220w        FNADDLVYLFNEKIDFRYAEWFLKTYLFYKYKYSDNTHTKGSIYYIKKGS 1869 
P.vivax_PVX_081545           FNSDDLVYLFNEKIDFRYAEWFLKTYIFYKFKFSGGTHSSEYYKNCVRSA 2242 
P.knowlesi_PKH_020900        FKPDDLVYLFNDKIDFRYAEWFLKTYIFYKFKFSSGTHSSEYYKNCVRSA 2035 
P.chabaudi_PCHAS_020720      FSPEDLVYLFNDKIDFRYAEWFLKTYLFYKYKFSNSSNSDDEHKSYTCDD 1503 
P.berghei_PBANKA_020880      FSSENLIYLFNPKIDFRYAEWFLKTYLFYKFKFSNSSNSDDGYNSYICE- 1545 
P.yoelii_PY01242             FSSKDLVYLFNPKIDFRYAEWFLKTYLFYKFKFSNYSNSDDEHNSYICE- 578 
                             *...:*:**** **************:***:*:*. :::.           
 
P.falciparum_PFA0220w        PRNSIKREDSNMYADQSVMAENIKKNYLNEGNQKDD---DNKNNYDDKEN 1916 
P.vivax_PVX_081545           VGSDGKQGSVDLEEVESPPGGEAGRAAG-EATDKAAGEATDKAAGEEADR 2291 
P.knowlesi_PKH_020900        VGSEGKRASVDVKEGENSLEGAHAFSGGNSHRDMSADRAVDRAVDRTADK 2085 
P.chabaudi_PCHAS_020720      ELFDEPLKFKDASIGKDKAEKLKN---EQLKNEKLK---SEKN--GDINS 1545 
P.berghei_PBANKA_020880      ----------NDSIGKEKVA----------KIEKGR---IEKG--GDINS 1570 
P.yoelii_PY01242             ----------NSSVGKENVANTEKGRIEKDRIEKGR---IERG--EEANS 613 
                                       :    :.               :       ::      :  
 
P.falciparum_PFA0220w        NYDDKENNYDDKENNYDDNKNNYDDNKNN--------------------- 1945 
P.vivax_PVX_081545           AVGEEADRDPDNVADRAPDRASDRAPDRVSDRGG---------------- 2325 
P.knowlesi_PKH_020900        TADKTADKTTDRVADRVADRVADKTVDKVGEREGDGVTASTADGICDRAS 2135 
P.chabaudi_PCHAS_020720      LISEKDDTRGNSTLDGIEGNEKTKRKNKA--------------------- 1574 
P.berghei_PBANKA_020880      LVSEKDDIEGN------------KKIQKI--------------------- 1587 
P.yoelii_PY01242             LVSEKDDIEEN------------EKKQKI--------------------- 630 
                               ..  :   :               ..                       
 
P.falciparum_PFA0220w        --------YDDKKNNYDDKKNNYDDNKNNYDYNNNKNDDDDSINVSSSLK 1987 
P.vivax_PVX_081545           --LRERHIQDKMFDVFFEGYHSSVDPADNYFCERRSHMARGER------- 2366 
P.knowlesi_PKH_020900        DSARERHIKHKMFDIFFEGYHSSVDSTDNYFCERKRHMARGERD------ 2179 
P.chabaudi_PCHAS_020720      --------KNIICDNFFESYNSSGDSMDNYVYCPNEKIEE--RNKNNESD 1614 
P.berghei_PBANKA_020880      --------KNTIYDNFFESYNSSGDSMDNYLYYQNDKIEE--QNKINESN 1627 
P.yoelii_PY01242             --------KNTIYDKFFESYSSSGDSMDNYIYYKNGKNGKNCNDKNYEPN 672 





P.falciparum_PFA0220w        GIHKNTFDPFFEKHSNNSLMDSGDDYLCDMNNLSNNKKDIYILWTYFESS 2037 
P.vivax_PVX_081545           --------------------------------------DAHDLWKSIEKL 2378 
P.knowlesi_PKH_020900        ---------------------------------ARTGNDSSDLWKSIEKL 2196 
P.chabaudi_PCHAS_020720      ---------------------------------KQSERKIDEIWNKIESN 1631 
P.berghei_PBANKA_020880      ---------------------------------KKLERKIDKTWNKIETN 1644 
P.yoelii_PY01242             ---------------------------------KELEKKIDKTWNKIEIN 689 
                                                                   .    *. :*   
 
P.falciparum_PFA0220w        KCVGYNECKTLLSLCLKNENETCINNISASKLRSLVISIWSNIPSSKPKR 2087 
P.vivax_PVX_081545           KCVGYKECKTLLKLCLKNEKQKNINQLKASKIRNLVISIWSNIYTSRPKK 2428 
P.knowlesi_PKH_020900        KCVGYKECKTLLKLCLKNEKEKNINHLKASKIRSLVISIWSNIYTSRPKK 2246 
P.chabaudi_PCHAS_020720      KYVGYNECKMLLKICLTNENIQNIKMLSESKIRSLVISIWLNIRCSRPKK 1681 
P.berghei_PBANKA_020880      EYVGYNECKMLLKICLSNEQVQNIKLLSESKIRSLVISIWLNIRCSRPQK 1694 
P.yoelii_PY01242             EYVGYNECKMLLKICLSNEKVQNIKLLSESKIRSLVISIWLNIRCSRPKK 739 
                             : ***:*** **.:**.**:   *: :. **:*.****** **  *:*:: 
 
P.falciparum_PFA0220w        SFIKLIFNWINNKKDDLHKKKNLFYLLKSEKKNNKNLSKICFNYFLNYLI 2137 
P.vivax_PVX_081545           SFLKIIFNWLNCKKDDLNKKKNLLYLLQAEKKKNVHLQKICFSYFLMYII 2478 
P.knowlesi_PKH_020900        SFLKIIFNWLNSRKDDLSRKKNLLYLLQEEKKKNIHLQRICFTYFLNHII 2296 
P.chabaudi_PCHAS_020720      YFLKLIYNWINNKNDDFNKKKNLFNLLKAEKKHNKNITKACFNYFLKFLI 1731 
P.berghei_PBANKA_020880      YFLKLIYNWINNKNDDFNKKKNLFNLLKAEKKYNKNITKACFNYFLKFLI 1744 
P.yoelii_PY01242             YFFKLIYNWINNKNDNFNKKKNLFNLLKEEKKYNKNITKVCFSYFLQFLI 789 
                              *:*:*:**:* ::*:: :****: **: *** * :: : **.*** .:* 
 
P.falciparum_PFA0220w        KYKDNCSNDIIYILYLIDENELKIYSKNFIQNHKINFNQFISIWNIMCIL 2187 
P.vivax_PVX_081545           KHKEECSNDLIYSLYLIEEGELKKYSRDFFQMNRIDVNQFISIWNVMCIL 2528 
P.knowlesi_PKH_020900        KHKEECSNDLIYSLYLIEEDKLKKYSKEYFEMNRIDVNQFISIWNVMCIL 2346 
P.chabaudi_PCHAS_020720      KYKENCSNDIIYTLYLIDEHELKLYSKKFIEKNQININQFISIWNIMCIL 1781 
P.berghei_PBANKA_020880      KYKENCSNDIIYTLYLIDENELKLYSKKFIEKNQININQFISIWNIMCIL 1794 
P.yoelii_PY01242             KYKENCSNDIIYTLYLIDENELKLHSKKFIEKNKININKFISIWNIMCIL 839 
                             *:*::****:** ****:* :** :*:.::: ::*:.*:******:**** 
 
P.falciparum_PFA0220w        FWDTDEINNFTFLQKN-KYYYYDFMLIFLKTFYDYINVNRDMREIMKMKL 2236 
P.vivax_PVX_081545           FWDTKKINDFAFLHKS-KFYYYDFMLIFFRAFYEYACVNKGVERGALYLR 2577 
P.knowlesi_PKH_020900        FWDTKKINDFAFLHKS-KFYYYDFMLIFFRAFYEYVCVNKGIERGALYLK 2395 
P.chabaudi_PCHAS_020720      FWDTKKIHNFTLSNKNTNNYYYDFMLIFLKTFYEYIFT-ANSQFGQNIYL 1830 
P.berghei_PBANKA_020880      FWDTKKIHNFTFFKKNNNNYYYDFMLIFLKNFYEYIFP-ANSQIVQNIYL 1843 
P.yoelii_PY01242             FWDTKKIHNFTFFKKNNNNYYYDFMLIFLKNFYEYIFP-ANAQIFQNAYL 888 
                             ****.:*::*:: :*. : *********:: **:*     . .        
 
P.falciparum_PFA0220w        KRTFLTGYHHDVEEPSQEHMSLYQE-------------KNNIHNQDNRLS 2273 
P.vivax_PVX_081545           RAGAAAASAASAAATAAT--ATAGAD-----------------AADG-AL 2607 
P.knowlesi_PKH_020900        RVVPGDGGTGTVISGVVTGGVNGGVN-----------------GAEGTDG 2428 
P.chabaudi_PCHAS_020720      KRMSNTSGVSAISFPNRNYN------------------------------ 1850 
P.berghei_PBANKA_020880      KKTININSISTINLTNQTHN------------------------------ 1863 
P.yoelii_PY01242             KKTINFNSISTTNLINQPHNKPSSKISSKLSSKMSSKMSSKLSSKLSSKL 938 
                             :                                                  
 
P.falciparum_PFA0220w        FTYMKKMSLSNSSINNKQDKHEDQNEYLNLFDIENIINNFNFTDFVNNEI 2323 
P.vivax_PVX_081545           APPRRSHSLSNCSSNKDDTQEDEGDGYLNLFDVENIINNFNFDDFVSSEL 2657 
P.knowlesi_PKH_020900        VSPRRSISLSNCSSNKDDTQEDEGDGYLNLFDVENIINNFNFDDFVNSEM 2478 
P.chabaudi_PCHAS_020720      --KLSSKASSTYAESQNKGNYNDESDDFNLFDVENIIKEFNFNDIVNAEV 1898 
P.berghei_PBANKA_020880      --QFSSKLSSSYPESKNKENYNDESDYFNLFDVENIIKDFNFNDISNIEV 1911 
P.yoelii_PY01242             SSKMSSKLSSSYPEP---QNYNDESDNFDLFDVENIIKYFDFNDVSNIDI 985 
                                  .   *. .      : :: .  ::***:****: *:* *. . :: 
 
P.falciparum_PFA0220w        SRDNYFDSFFGATNMPIPS------------------------------- 2342 
P.vivax_PVX_081545           RSSSYFDAFLGGGPAARRP------------------------------- 2676 
P.knowlesi_PKH_020900        RSSSYFDAFLGGGPAARRSGVRETSSVGKQKLNSSALQSARDSEAGQTGE 2528 
P.chabaudi_PCHAS_020720      SSKNLMH-SPRDHNHDS--------------------------------- 1914 
P.berghei_PBANKA_020880      NTKNFTS-QFRDNNQDF--------------------------------- 1927 
P.yoelii_PY01242             NTKNFTSSQSRDNNPDS--------------------------------- 1002 
                               ..                                               
 
P.falciparum_PFA0220w        ------MSNISLAGNHTTQYEKNTRHNYNSPLTHPLWRNRQEKERDLQRI 2386 
P.vivax_PVX_081545           ----------------------------------EPFPADKPGEPASQGG 2692 
P.knowlesi_PKH_020900        PYRGVVTGSSHRPCSTDGVESPTLQTAHYGTHFAEPFPADKAAEPSTQGG 2578 
P.chabaudi_PCHAS_020720      -----------HGTHPSESIESAENREE----IEQAKENTIGIKNMLKFI 1949 
P.berghei_PBANKA_020880      -----------IGTNHSETMESETREVEQSVHAKENTENTNGIKNMLKFI 1966 
P.yoelii_PY01242             -----------LGTNHSETIESE---------------NANGIKNMLKFI 1026 





P.falciparum_PFA0220w        KDEEERLKRRGGVPLTEAYDIENLIFLGICIKIVICRISNLLNAKSCLQQ 2436 
P.vivax_PVX_081545           PQPAFAPSAQRSAYPNDSSEMENLLLLGICIKIVICRISNLLNAKSCLEQ 2742 
P.knowlesi_PKH_020900        TQSTFSPITQRSVFPSDNSEMENLLLLGICIKIVICRISNLLNAKSCLEQ 2628 
P.chabaudi_PCHAS_020720      IQKSK--KEKNMICCSDANELKLLVFLGICIKIVICRISNLLNAKACLEQ 1997 
P.berghei_PBANKA_020880      IQKIK--KEKNIISCVDINEIKMLIFLGICIKIVICRISNLLNSKTCLEQ 2014 
P.yoelii_PY01242             IQKIK--KEKNIISCVDINEIIMLVFLGICIKIVICRISNLLNSKTCLEQ 1074 
                              :       :      :  ::  *::*****************:*:**:* 
 
P.falciparum_PFA0220w        FHYFLNHKRLGLKIFKYSHIILVYFIPFFKKYYFLWKFIEHEIDKDIMNL 2486 
P.vivax_PVX_081545           FNYFLNNQKLGFRTFKNAHMVLVYFIPFFKRYFFLWKFIEHEIDVEIMTL 2792 
P.knowlesi_PKH_020900        FNYFLNNQKLGFRTFKNAHMVLVYFIPFFKRYYFLWKFIEHEIDVEIMSL 2678 
P.chabaudi_PCHAS_020720      FYYFINHKILGLKIFRHSHIVLVYFIPFFKKYYFLWKFIEHEIDPEIIKL 2047 
P.berghei_PBANKA_020880      FYYFINHKILGLRIFKHSHIILIYFIPFFKKYYFLWKFIEHEIDPEIIKL 2064 
P.yoelii_PY01242             FYYFINHKILGLRKFKYSHIVLIYFIPFFKKYYFLWKFIEHEIDPEIIKL 1124 
                             * **:*:: **:: *: :*::*:*******:*:*********** :*:.* 
 
P.falciparum_PFA0220w        IKYIMDHLENMQVENIPLSLCNINNTSNQMLPGVSNQNMNERTYAENLHN 2536 
P.vivax_PVX_081545           LQDILNDLEHIQAT----------------------------SSS----- 2809 
P.knowlesi_PKH_020900        LQNILNDLEQLQAS----------------------------SSVGRMYL 2700 
P.chabaudi_PCHAS_020720      INAIINNLENLQNN----------------------KNINNIGSNPMLHP 2075 
P.berghei_PBANKA_020880      INAIINNLESLQIN----------------------KNINNIENSPKFHP 2092 
P.yoelii_PY01242             INAIINNLENLQIN----------------------KNINNIENNSKLHP 1152 
                             :: *::.** :*                                       
 
P.falciparum_PFA0220w        MNNIHNNKFCPSSYRHTQNILNMNSTHNNSSVNNNFNKMNHSISEKMGKN 2586 
P.vivax_PVX_081545           -------------------------------------------------- 
P.knowlesi_PKH_020900        GVGGTHQVCGVSNPLHVREMSQSRNVCDRLPQENLQERFTSPFGERPFVR 2750 
P.chabaudi_PCHAS_020720      YTRSNTSLPEVDHFSFPSKDKNLNHTFNNFSTQYNPHDYKTSFSHSISIE 2125 
P.berghei_PBANKA_020880      YIRSNTSLPKVDHLFFPSKDNKLNNIFSNFNMQSKPHNYKTSFSHSTSIE 2142 
P.yoelii_PY01242             YIRSNTSLPEIDHLSFPLKNNKLNNRFTNLNIQSNPHYYKTNFSHTPSIE 1202 
                                                                                
 
P.falciparum_PFA0220w        KNDNIFSFLKSTKNNMSFDQNGRLVNSNINYMKNKNLLLCKEEQEKHTSF 2636 
P.vivax_PVX_081545           -------------------------------------------------- 
P.knowlesi_PKH_020900        SSTCNSQNRGAFPTGGEKK-----------------ISSLEHFYANGKFN 2783 
P.chabaudi_PCHAS_020720      NNNSKQNFFKHKQNDLSLD---------------SDLPTPDLFNPKNKKK 2160 
P.berghei_PBANKA_020880      SNNNNNN---FKQNNISLS---------------FDMLISDSFNVKNNKK 2174 
P.yoelii_PY01242             SNNNNNNN--LKQNNISFS---------------SDMLISDPFNVKNKKN 1235 
                                                                                
 
P.falciparum_PFA0220w        QSLNCNRTKNNSIQERVVYGKEINNNHNLKDINVFKYKKHEHKHGEFFNL 2686 
P.vivax_PVX_081545           ---------------------------------------ASTDASHPPSE 2820 
P.knowlesi_PKH_020900        LY---------------------SNEIRRMGRSGPNGEGAEEDDVYFASG 2812 
P.chabaudi_PCHAS_020720      KK---------------------KNSEKFEDSH-NKNQQHPHDYSEFDSH 2188 
P.berghei_PBANKA_020880      ------------------------NSEKFGDTHSNENQRYFHDYSELGCS 2200 
P.yoelii_PY01242             XKIKKKNSENSKNSENSENSKNSENSEKIGDTHSNVTHGYSNGYFELGCQ 1285 
                                                                                
 
P.falciparum_PFA0220w        NNMKYPLYGKNKNIMDDDNLGNNIFHPKKKNKDEFIGSFKNNSSYVINDE 2736 
P.vivax_PVX_081545           RDPT---------------------------------------------- 2824 
P.knowlesi_PKH_020900        RGPSPMG---------------------AMNTVSMSVAPLKGALCRSEED 2841 
P.chabaudi_PCHAS_020720      NN----------------------FHKNIINNINNINYFRPSSLFNTN-E 2215 
P.berghei_PBANKA_020880      NK---------------------SFHANLTNNIN---YLQPNSIFKLN-E 2225 
P.yoelii_PY01242             NKNVH-----------------KNVHKNVNNNIN---YLQSNSLFKLN-E 1314 
                             .                                                  
 
P.falciparum_PFA0220w        FIGSFKNNSSYVINDEDDEHYISYDDMF 2748 
P.vivax_PVX_081540           -------------EEDTDENCITYDDMF 26 
P.knowlesi_PKH_020900        -------------EEDTDENCITYDDMF 2853 
P.chabaudi_PCHAS_020720      ---NYFRPSSLFNTNENCDHGITYDDMF 2227 
P.berghei_PBANKA_020880      ----YLQPNSIFKLNEKCDQVITYDDMF 2237 
P.yoelii_PY01242             ----YLQSNSLFKLNENCDQGITYDDMF 1326 
                                           ::  :: *:***** 
 
P.falciparum_PFA0220w        RNYDSDDDSN-------------ISNSKNTSENFNVKDFITNLHFANLDD 2785 
P.vivax_PVX_081540           RNYDSENNS---------------EGRGSPEENCNVKDFITSLHFN---- 57 
P.knowlesi_PKH_020900        RNYDSEDNS---------------EGRDCLDESCNVKDYITSLHFN---- 2884 
P.chabaudi_PCHAS_020720      RDNDNSSDD--------------NYFDKGKNKICNVKEYITNLHFNN--- 2260 
P.berghei_PBANKA_020880      RDDDDDYDYDHDYEN--------NYFDKNKSKIHNVKEYITNLHFNN--- 2276 
P.yoelii_PY01242             RNEDENDEDENENDENENDENDGNYFDKNKNKTRNVKEYITNLHFNN--- 1373 





P.falciparum_PFA0220w        DNNIISKNFFSTSKKLNDQKGEQKGEQNGEQK---CEQKYEQKYEHQGSS 2832 
P.vivax_PVX_081540           --NPLEERILSRRKASASQCGEKKAGRDNDDNDDGEAATHGDNGEE-ETS 104 
P.knowlesi_PKH_020900        --NPLEEKILSKRKGAKSVGGEKKGKVNNDGE---EVAKNGDNVEEKENS 2929 
P.chabaudi_PCHAS_020720      ----LPDYPTSLKNSDENKKSEDKKKKKKKIK---NENQNSKEEQDNGEE 2303 
P.berghei_PBANKA_020880      ----LPNYLTSLKNENDNKKIEDKKKKKKKLK---DHDQSQNKNKNSKEQ 2319 
P.yoelii_PY01242             ----LPDYLTCLKSGNANK-----KKKKKKIK---DQYQSQSQSQSQGQS 1411 
                                 : .   .  .   .         . . :         .: :    . 
 
P.falciparum_PFA0220w        VKIQNNKIINKMKYDPFLSSSESSNYNEDKNIMYMYPNEPNYKDSKKVLS 2882 
P.vivax_PVX_081540           PNKEAGATVGEANGSACHQESKEDLFGSNPTRVGVFP-----------ME 143 
P.knowlesi_PKH_020900        YIKEGGTIMGEGNGSTCPHESKEDIFGSKPTRVGIFP-----------ME 2968 
P.chabaudi_PCHAS_020720      ENHSNK-----TQHKENNNISKVNEQNENILLYNIQDN-----------E 2337 
P.berghei_PBANKA_020880      ENGKEENRNSKTQLKEYNNISKLIGKNENIPFYNIPDN-----------E 2358 
P.yoelii_PY01242             KNSKEQ----ENEEGENKNTSKLIGQNEDIPFYYISDN-----------E 1446 
                                .        :       *:    ...     :              . 
 
P.falciparum_PFA0220w        QKKKKKKSTINNFHRINSNGPHTNEEFIEKDQSTSIIGSLGQDDSFDKIS 2932 
P.vivax_PVX_081540           SSTPKQSLLGQNYHFTSRAYKNGGT--------SASAGAVGVGTLTAMMM 185 
P.knowlesi_PKH_020900        SSTVRQNSSGQNYHMNSKDYKSGGAKDLPYGKKSSGGGAPGGANSTSMMM 3018 
P.chabaudi_PCHAS_020720      NAENKISKNSNTTRKYMIDENLNEYKIENKKDVSNNYNNKEGSPTFEEDK 2387 
P.berghei_PBANKA_020880      NSENKISKIGNSDRKYLFDNHFDEYKNGNKKCLKNNYNHKEGSANFEEYK 2408 
P.yoelii_PY01242             NSGNKISKTGNPARKYLLN-------------------------NFEENK 1471 
                             .   : .   :  :                                     
 
P.falciparum_PFA0220w        HKNTHFDHHKNNPSDLTNNHMMKNVKHMKNIKQHCSN---DDYSTSKYEE 2979 
P.vivax_PVX_081540           PP----------DPFANENSVMKKFPSLGVLESEDEK---VEKAEKRAEN 222 
P.knowlesi_PKH_020900        PP----------DPFASENNVMKKFPSLGLPESDDEK---GENGE---VN 3052 
P.chabaudi_PCHAS_020720      YR-------HNNRSSTPQNNGIKKFPTVSYEDADNSNNMVDKKSQKNYIN 2430 
P.berghei_PBANKA_020880      YK-------ENSKSNIHQNNGINKFPTISYENVDNLNHIIDKKTQKEYLN 2451 
P.yoelii_PY01242             YK-------QNNKLNIHKNNGISKFPTISYEDVENSNNMIDTKTQNNYLD 1514 
                                              :*  :.:.  :   . .  :            : 
 
P.falciparum_PFA0220w        LVNEHTIRKNTNRRNSLYAYPTQNRISDQ----------MENQKIRKNTS 3019 
P.vivax_PVX_081540           PEATKGLPPTNDNRR------RAKKKDSL----------KSNATAKRDGS 256 
P.knowlesi_PKH_020900        FKSGKALPLNTENRK------KEKKNDSL----------KNNTTGKGDGS 3086 
P.chabaudi_PCHAS_020720      LELDREKKENFGSSKKLTNIESAKGMNND--------DNYNSNNEILNNR 2472 
P.berghei_PBANKA_020880      LEMNRKKKESFSSSKRLTNIESVKDLNSG-----------ENNNEIINDR 2490 
P.yoelii_PY01242             LEMNRRKKESFSSSKRLTNIESVKGFNSDNGGDNNDDDNDENDGEAINSR 1564 
                                 :    .    .        :  ..            ..     :   
 
P.falciparum_PFA0220w        LEKNVHHMNDNYDEINFTEKYFEQEYGSDQHDQRNNSMDAVNSVNHVNRM 3069 
P.vivax_PVX_081540           DPNVVPSQTEQTGNHSMNGPLNEFPYDNPMQTTTTPGSTPLSRSICIKKN 306 
P.knowlesi_PKH_020900        NLNIVGHQTEQIGNHTINGQLNEFPYETPMQNTTPGG--ALNKNICIKKN 3134 
P.chabaudi_PCHAS_020720      RTIQTNGHTVNYNRNNNNMRPDEYENFVKD--KKNDLDIIQRKGISLVNA 2520 
P.berghei_PBANKA_020880      KSIQTNVHITNYIRNHNNIKSNEYEQFLREKNKNKKLEISQRNGISIVNS 2540 
P.yoelii_PY01242             KRGQASEHIGNYIRNHNNIKSKECEQFLREQNKKKELEISQKKGIYIVNS 1614 
                                 .     :  .   .    *                       : .  
 
P.falciparum_PFA0220w        DGVNHVNRMDGVNHVNRMDGVNRVNRMNHANRVSRMNHANRVSRMNHANR 3119 
P.vivax_PVX_081540           PLNDNYQEVDFTTSALRRK-----TKSGEGNKLKRRGAAP---------- 341 
P.knowlesi_PKH_020900        ALNDNYQEVDFTTSSLRTK-----NRPGEGNKTKKGGVAP---------- 3169 
P.chabaudi_PCHAS_020720      TTNNNYEEINIVNNPIEKN--------KHVSSDKLIQKRP---------- 2552 
P.berghei_PBANKA_020880      TTNNNYEEINIINSHIEKK--------KQDSSDKLIQKRP---------- 2572 
P.yoelii_PY01242             TTNNNYEEINIINNNTEKK--------KQINSDLLVQKRP---------- 1646 
                                :: :.::  .   . .         . .                    
 
P.falciparum_PFA0220w        VSRMNHANRVSPNNIEDIRMGGVKIKKYLMLPINKFTFENMSKRNYPHPP 3169 
P.vivax_PVX_081540           --------------------------KYLMLKVDTFELNKMTKSKLKHPP 365 
P.knowlesi_PKH_020900        --------------------------KYLMLKVDTCELKRMTRSKLKHPP 3193 
P.chabaudi_PCHAS_020720      --------------------------KYLMLPIDTTELKKMQKGKLRHPP 2576 
P.berghei_PBANKA_020880      --------------------------KYLMLPIDMIELKKMQKGKLRHPP 2596 
P.yoelii_PY01242             --------------------------KYLMLPINMIELKKMQKGKLRHPP 1670 
                                                       ***** ::   ::.* : :  *** 
 
P.falciparum_PFA0220w        VGLMNLGNTCYLNSLLQALYSTVSFIVNLFLFKINETNNKVRTVPNYEIY 3219 
P.vivax_PVX_081540           VGLVNLGNTCYLNSLLQALYSTVSFVVNLYLFNIREEPKEGGGEPCSNPF 415 
P.knowlesi_PKH_020900        VGLVNLGNTCYLNSLLQALYSTVSFVVNLYLFNIRQNVKEGG-EESSNPF 3242 
P.chabaudi_PCHAS_020720      VGLINLGNTCYLNSLLQALYSTVSFVVNLYIFNIDDNKELKHINNKNISN 2626 
P.berghei_PBANKA_020880      VGLINLGNTCYLNSLLQALYSTVSFVVNLYIFNIDDNEKIMNLNHQSSSN 2646 
P.yoelii_PY01242             VGLMNLGNTCYLNSLLQALYSTVSFVVNLYIFNIDDNEKIMYSNHQNVSN 1720 
                             ***:*********************:***::*:* :  :            
 
P.falciparum_PFA0220w        KSQMHQEN------------------------------------------ 3227 
P.vivax_PVX_081540           AEKESPASSPQGGAAQGG----GSKMNTLS-KQNTLSRQNTLSRLNTLNG 460 
 239 
P.knowlesi_PKH_020900        VEKQKHTLGPNGTNTLKGPVHRLSNVDGLNNIMNSIGKMNTLTRLNTLNG 3292 
P.chabaudi_PCHAS_020720      EMPIKNKLSFNLNN----------------------------------TN 2642 
P.berghei_PBANKA_020880      IISIKNKLLFNSNNLNNP------------------------------NN 2666 
P.yoelii_PY01242             KMSIKNKLFFSSN------------------------------------- 1733 
                                                                                
 
P.falciparum_PFA0220w        -------TNSELDYFLEEIKSFFKNMLTTDKSYISADRVLNMLPVELNNR 3270 
P.vivax_PVX_081540           TTPTNQVATAESERFLQELKNLYIIMTTTKKTYVSPDCILGLLPHELNNR 510 
P.knowlesi_PKH_020900        IPPMNHIGTVESERFLQELKNLYIIMTTTNKMYVSPDSILGLLPYELNNR 3342 
P.chabaudi_PCHAS_020720      MNNNNNNANLLSKRFLYELKILFKLMTTTNKKYVSPDNILGILPQELNNR 2692 
P.berghei_PBANKA_020880      PNINDSYTNLLSKRFLYELKILFKLMSTTNKKYVSPYSILSILPQELNNR 2716 
P.yoelii_PY01242             --INDSHKNLLSKRFLYELKILFKLMSKTNKKYISPDNILNILPQELNNK 1781 
                                     .   . ** *:* ::  * .*.* *:*.  :*.:** ****: 
 
P.falciparum_PFA0220w        NQQDVTEVFRYIFDKLGGSEKEFLRLIFSGVVIQKVQCQKCLFISKKKEI 3320 
P.vivax_PVX_081540           NQQDVTELLRYIFDKLGGSSREFLRLIFSGVLVQKVQCQKCFFVSKKEEV 560 
P.knowlesi_PKH_020900        NQQDVTELLRYIFDKLGGSSREFLRLIFSGVLVQKVQCQKCFFVSKKEEV 3392 
P.chabaudi_PCHAS_020720      NQQDVTELFRYTFEQLGGSEKKFLRLIFSGVVIQKVQCQKCFFISKKEEI 2742 
P.berghei_PBANKA_020880      NQQDVTELFRYTFEQLGGSEKRFLRLIFSGVVIQKVQCQKCFFISKKEEI 2766 
P.yoelii_PY01242             NQQDVTELFRYTFEQLGGSEKKFLRLIFSGVVIQKVQCQKCFFISKKEEI 1831 
                             *******::** *::****.:.*********::********:*:***:*: 
 
P.falciparum_PFA0220w        IHDLSFPVPISTNEKLSIQRFFDTFIQKEKIYGNNKYKCSRCNKKRNALK 3370 
P.vivax_PVX_081540           IHDLSFPVPVKASERLSIQKFFDTFVQKEKIHGSNKYRCSKCNKKRNALK 610 
P.knowlesi_PKH_020900        IHDLSFPIPVRASEKLSIQKYFDSFVQKEKIHGSNKYRCSKCNKRRNALK 3442 
P.chabaudi_PCHAS_020720      IHDLSFHVPAKSSKKQSIQKFFDTYIQKEKIYGNNKYKCSKCNKRRNALK 2792 
P.berghei_PBANKA_020880      IHDLSFHVPAKSTKKESIQKFFDTYIQKEKIYGNNKYKCSKCNKRRNALK 2816 
P.yoelii_PY01242             IHDLSFHVPAKSTKKESIQKFFDTYIQKEKIYGNNKYKCSKCNKRRNALK 1881 
                             ****** :*  :.:: ***::**:::*****:*.***:**:***:***** 
 
P.falciparum_PFA0220w        WNEIISPPCHLILILNRYNWSFSSNEKKKIKTHVKINSKIVVNNFDYKLY 3420 
P.vivax_PVX_081540           WNEIISPPCHLILILNRYNWSFSSNEKKKVKTHVKVNSKIVVNNFDYKLY 660 
P.knowlesi_PKH_020900        WNEIISPPCHLILILNRYNWSFSSNEKKKVKTHVKINSKIVVNSFDYKLY 3492 
P.chabaudi_PCHAS_020720      WNEIISPPCHLILILNRYNWSFSSNEKKKIKTHVKINKKIVVNNFDYRLY 2842 
P.berghei_PBANKA_020880      WNEIISPPCHLILILNRYNWSFTSNEKKKIKTHVKINKKIVVNNFDYKLY 2866 
P.yoelii_PY01242             WNEIISPPCHLILILNRYNWSFSSNEKKKIKTHVKINKKIVVNNFDYRLY 1931 
                             **********************:******:*****:*.*****.***:** 
 
P.falciparum_PFA0220w        GAIIHGGISASSGHYYFIGKKSERQNKKKS-SWYQMNDSVVTKANSKMIN 3469 
P.vivax_PVX_081540           GGIIHGGTSASSGHYYFIGKKSERDPQDEANDWYQMDDSVVSKTSSKSIN 710 
P.knowlesi_PKH_020900        GAIIHGGSSASSGHYYFIGKKSERDQEDETNDWYQMNDSVITKVSSKLIN 3542 
P.chabaudi_PCHAS_020720      GGIIHSGVSASSGHYYFIGKKSEK-GDNSKNEWYQMDDSAITKVSSKSIN 2891 
P.berghei_PBANKA_020880      GGIIHSGVSASSGHYYFIGKKSEK-CDNSKNEWYQMDDSVITKVSSKSIN 2915 
P.yoelii_PY01242             GGIIHSGVSASSGHYYFIGKKSEK-CDNFKNEWYQMDDSVITKVSSKSIN 1980 
                             *.***.* ***************:  ..   .****:**.::*..** ** 
 
P.falciparum_PFA0220w        KISKDLSNDHTPYVLFYRCKQAPISPDLYF-------------------- 3499 
P.vivax_PVX_081540           RISKDPSNDHTPYVLFYRCKQAPLSPALHF-------------------- 740 
P.knowlesi_PKH_020900        KISKDPSNDHTPYVLFYRCKQAPPSPALHF-------------------- 3572 
P.chabaudi_PCHAS_020720      RISKDPSNDHTPYVLFYRCKQAPDSPSLYF-------------------- 2921 
P.berghei_PBANKA_020880      RISKDLSNDHTPYVLFYRCKQAPVSPSLYF-------------------- 2945 
P.yoelii_PY01242             RISKDLSNDHTPYVLFYRCKQAPVAASFAEVAVSFAKVLTNFISSIFLNP 2030 
                             :**** ***************** :. :                       
 
P.falciparum_PFA0220w        --- 
P.vivax_PVX_081540           --- 
P.knowlesi_PKH_020900        --- 
P.chabaudi_PCHAS_020720      --- 
P.berghei_PBANKA_020880      --- 




Appendix E – Talks, posters and publications 
arising from this thesis 
 
Oral presentations: 
Fitness cost of chloroquine resistance in Plasmodium chabaudi, Katarzyna 
Modrzynska, British Society for Parasitology Spring/Malaria meeting, 
Edinburgh (UK), 2009 
Genetics of chloroquine resistance in rodent malaria parasite Plasmodium chabaudi, 
Katarzyna Modrzynska, British Society for Parasitology Spring/Malaria 
meeting, Newcastle (UK), 2008 
Posters: 
Genetics of chloroquine resistance in Plasmodium chabaudi. Katarzyna Modrzyska, 
British Society for Parasitology Spring/Malaria meeting, Edinburgh (UK), 
2009  
Identifying the loci of chloroquine (CQ) resistance in rodent parasite Plasmodium 
chabaudi, Katarzyna Modrzynska, Molecular Approaches to Malaria, Lorne 
(Australia), 2008 
Publications 
Paul Hunt, Axel Martinelli, Katarzyna Modrzynska, Sofia Borges, Alison Creasey, 
Louise Rodrigues, Dario Beraldi, Laurence Loewe, Richard Fawcett, Sujai 
Kumar, Marian Thomson, Urmi Trivedi, Thomas Otto, Arnab Pain, Mark 
Blaxter, Pedro Cravo  Experimental evolution, genetic analysis and genome 
re-sequencing reveals the mutation conferring artemisinin resistance in an 
isogenic lineage of malaria parasites –In press (BMC Genomics).  
 
Sofia Borges, Paul Hunt, Alison Creasey, Kasia Modrzynska, Richard Fawcett, 
Louise Rodrigues, Urmi Trivedi, Axel Martinelli and Pedro Cravo Genome-
wide scans of selection - malaria parasites with mdr1 duplication are 




Katarzyna Modrzynska, Alison Creasey, Laurence Loewe, Timothee Cezard, Axel 
Martinelli, Sofia Borges, Pedro Cravo, Mark Blaxter, Richard Carter, Paul 
Hunt Quantitative genome-wide Solexa re-sequencing reveals multiple 
mutations conferring complex chloroquine resistance phenotype in malaria 
parasite. – ready to be submitted (Nature Genetics) 
Katarzyna Modrzynska, Natalia Bednarska, Sabrina Reignoux Paul Hunt Fitness cost 
of chloroquine resistance in the rodent malaria parasite Plasmodium chabaudi 
– in preparation 
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